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Abstract 
 
Background/ Aim: The purpose of this study is to describe the prevalence of macro and 
microvascular (heart disease, retinopathy, nephropathy and neuropathy) and acute diabetic 
complications, and to assess the nature of their treatment protocol by PHC, and the 
metabolic control status, in patients with type 1 diabetes mellitus at Ramallah district. 
Material/Methods: We performed a cross-sectional population study evaluating all Type 
1 diabetic patients (n=142) consecutively attending clinics for review of both MOH and 
UNRWA PHC in Ramallah district at the year 2006. Only 116 registered patients 
participated in the survey. However, 9 of the 116 patients did not have the objective 
testing, in particular the HbA1c, therefore, not included in the analysis. Therefore, 107 
patients (92.2%) were included in the analysis. Of the approached patients, 80 patients 
(69%) have done the objective testing, i.e. HbA1c, fasting blood sugar (FBS), lipid 
profiling, and kidney functions testing, and blood pressure testing. Patients were referred to 
see an ophthalmologist, but only 63.8% did go (n=74 patients). Also, all these patients 
(n=107) were referred to consult with a diabetes specialist, but only 58.6 % (n=68) 
attended the consultations. 
Results: The results of this study showed that the mean age at onset of disease was 15.5 
(SD±7.4) years, the mean age of the patients was 23.5 (SD±10.4) years, and the mean 
duration of disease was 8.4 (SD±7.2). From our results we observed that 47.7% of patients 
were males, 66.4% were singles, and 53.3% were living in villages. 82.2% had less than 12 
years of education, and 41.1% were students.  
The mean HbA1c was 7.8 (SE±0.16), and 35.3% of the patients had a measurment >8.5%. 
The results of objective testing means were as follow: total cholesterol 191 (SE±5.1), 
triglyceride 146 (SE±11), FBS 203 (SE±9), LDL 123 (SE±4.7), urea was 28.2 (SE±1.4), 
creatinine was 0.9± (SE ±0.05), and HDL was 42 (SE±0.8). 
Although complications associated with diabetes mellitus were under reported, 48.6% of 
the sample suffers from one or more of the common complications. Reported frequencies 
of chronic diabetic complications associated symptoms by patient themselves were as 
follows: diabetic retinopathy 36.4%, neuropathy 26.2%, nephropathy 7.5%, heart disease 
3.7%, amputation 0.9% and diabetic foot syndrome 10.3% of the study patients. 
The prevalence of diagnosed retinopathy was 33.8%, nephropathy was found in 7.4%, 
neuropathy was present in 16.2%.  
iii 
Significant associations were found between diagnosed microvascular complications 
(retinopathy and clinical neuropathy) and HbA1c (p<0.05), disease duration (p<0.05), and 
sex (p<0.05) were observed. 
The majority of patients were treated with insulin mixture with two daily insulin injections. 
Reported screening rates at primary health care in this study by the patients themselves 
were as follows: 24.3% had at least one HbA1c measurement per a year and 91.6% fasting 
blood glucose, 16.8% had a foot exam, 5.6% had electrocardiography test, 53.9% had a 
protein urine test, 43% had plasma urea test and 37.4% had creatinine test, 11.2% had an 
eye exam, 84.1% had a blood pressure reading and 51.1% received a fasting lipid profile. 
85% had weight measured. Body mass index was greater than 25 kg/m2 in 36.4% of 
patients. 
The association of risk factors with diabetic complication (reported and evaluated) was 
also investigated.  The basis of the risk estimation was control of blood glucose, lipid, 
pressure, and socio demographic data. Diabetes duration and age were the only common 
significant risk factors for development of both evaluated and reported retinopathy. For 
neuropathy, disease duration was the only common significant risk factors for the 
development of both evaluated and reported complications.  However, when trying to 
develop the study multivariate models for the major complications (i.e. retinopathy, 
neuropathy and nephropathy) or glycemic control measurement, none of the above 
determinants were significantly associated with these outcome variables.   
Conclusions: This is the first study in which the prevalence of diabetic type 1 
complications is reported in a Palestinian community for patients registered in MOH and 
UNRWA. This cross-sectional study confirms that complications were common and 
mostly undiagnosed in a non-negligible percentage of patients. Treatment and control of 
diabetes by primary health care in this community is not optimal, and not achieving the 
level of complications intervention. Better continuing care and better education is needed 
for diabetic patients in these primary health care centers and for the health care 
professional to get a better care for these patients. 
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 ﺍﻝﺩﺭﺍﺴﺔﻤﻠﺨﺹ 
 ﺍﻝﻭﻀﻊ ﺍﻝﺼﺤﻲ ﻝﺩﻯ ﻤﺭﻀﻰ ﺍﻝﺴﻜﺭﻱ ﻤﻥ  ﻭﻭﺼﻑﻤﻌﺭﻓﺔ  ﺇﻝﻰ ﻫﺫﻩ ﺍﻝﺩﺭﺍﺴﺔ ﺕﻫﺩﻓ: ﺨﻠﻔﻴﺔ ﺍﻝﺩﺭﺍﺴـﺔ 
 ﺍﻝﻤﺯﻤﻨﺔ ﻭﺍﻝﺘﻲ ﺘﺘﻤﺜل ﻓﻲ ﻤﺸﺎﻜل ﺍﻷﻭﻋﻴـﺔ ﺍﻝﻘﻠﺒﻴـﺔ، ﺍﻝﻨﻭﻉ ﺍﻷﻭل ﻤﻥ ﺨﻼل ﻤﻌﺭﻓﺔ ﻨﺴﺒﺔ ﺍﻝﻤﻀﺎﻋﻔﺎﺕ 
ﻤﺭﺽ،  ﻋﻥ ﺍﻝ ﺍﻝﻨﺎﺘﺠﺔﺍﻋﺘﻼل ﺍﻝﺸﺒﻜﻴﺔ، ﺍﻋﺘﻼل ﺍﻝﻜﻠﻰ، ﻭ ﺍﻋﺘﻼل ﺍﻷﻋﺼﺎﺏ ﻭﻜﺫﻝﻙ ﺍﻝﻤﻀﺎﻋﻔﺎﺕ ﺍﻝﺤﺎﺩﺓ 
 ﺍﻷﻭﻝﻴﺔ ﺍﻝﺘﺎﺒﻌﺔ  ﺍﻝﺼﺤﻴﺔﺍﻝﺨﺩﻤﺎﺕ ﺍﻝﺘﻲ ﻴﺘﻠﻘﺎﻫﺎ ﺍﻝﻤﺭﻴﺽ ﻤﻥ ﺨﻼل ﻤﺭﺍﻜﺯ ﺍﻝﺭﻋﺎﻴﺔ ﺇﻝﻰ ﻤﻌﺭﻓﺔ ﺔﺒﺎﻹﻀﺎﻓ
  .  ﻓﻲ ﻤﺤﺎﻓﻅﺔ ﺭﺍﻡ ﺍﷲ ﺍﻝﺩﻭﻝﻴﺔﻝﻭﺯﺍﺭﺓ ﺍﻝﺼﺤﺔ ﻭﻭﻜﺎﻝﺔ ﺍﻝﻐﻭﺙ
ﻤﺭﺍﻜـﺯ ﺍﻝﺭﻋﺎﻴـﺔ ﺍﻝـﺼﺤﻴﺔ  ﻓﻲ 6002 ﻓﻲ ﺍﻝﻌﺎﻡ ﺃﺠﺭﻴﺕ ﺩﺭﺍﺴﺔ ﻭﺼﻔﻴﺔ ﻤﻘﻁﻌﻴﺔ : ﻤﻨﻬﺠﻴﺔ ﺍﻝﺩﺭﺍﺴﺔ 
 ﺸﻤﻠﺕ ﺠﻤﻴﻊ ﻤﺭﻀﻰ ﺍﻝﻨﻭﻉ ﺍﻷﻭل ﻤـﻥ ﻭﺯﺍﺭﺓ ﺍﻝﺼﺤﺔ ﻓﻲ ﻤﺤﺎﻓﻅﺔ ﺭﺍﻡ ﺍﷲ ﺍﻷﻭﻝﻴﺔ ﺍﻝﺘﺎﺒﻌﺔ ﻝﻸﻨﺭﻭﺍ ﻭ 
 ﻤﺭﻴﺽ ﺃﻱ  701 ﻤﺭﻴﺽ ﺘﻡ ﺍﻋﺘﻤﺎﺩ  611 ﺤﻴﺙ ﺸﺎﺭﻙ ﻓﻲ ﺍﻝﺩﺭﺍﺴﺔ. 241  ﺍﻝﺴﻜﺭﻱ ﻭﺍﻝﺒﺎﻝﻎ ﻋﺩﺩﻫﻡ 
 ﻝـﺸﺭﻭﻁ ﻡﻤﺭﻀﻰ  ﻝﻌﺩﻡ ﺍﺴـﺘﻴﻔﺎﺌﻬ  9 ، ﺒﻴﻨﻤﺎ ﺘﻡ ﺭﻓﺽ  ﻓﻲ  ﺍﻝﺘﺤﻠﻴل ﺍﻹﺤﺼﺎﺌﻲ%  2.29ﻤﺎ ﻨﺴﺒﺘﻪ
 ﻤﺨﺒﺭﻴـﺔ  ﺩﻡ، ﻜﺫﻝﻙ ﺘﻡ ﻋﻤل ﻓﺤﻭﺼـﺎﺕ ﻜﺭ ﺍﻝﺘﺭﺍﻜﻤﻲ ﻝﺩﻴﻬﻡ  ﻭﺠﻭﺩ ﻨﺘﻴﺠﺔ ﻝﻠﺴ ﻋﺩﻡﺍﻝﺩﺭﺍﺴﺔ ﻤﻥ ﺤﻴﺙ 
 ﺘـﻡ ﻜﺫﻝﻙ،96 %(  )   ﻤﺭﻴﺽ08ﻤﺜل ﻓﺤﺹ ﺍﻝﺴﻜﺭ ﺍﻝﺘﺭﺍﻜﻤﻲ، ﺴﻜﺭ ﺍﻝﺼﻴﺎﻡ، ﻓﺤﺹ ﺍﻝﺸﺤﻤﻴﺎﺕ ل 
( 6.85%) ﻤﺭﻴﺽ86 ﻓﻲ ﺤﻴﻥ ﻗﺎﻡ 8.36%()ﻤﺭﻴﺽ   47ﻋﻤل ﻓﺤﺹ ﻋﻴﻭﻥ ﻤﻥ ﻗﺒل ﺃﺨﺼﺎﺌﻲ ل 
  . ﺒﺎﻝﻤﻌﺎﻴﻨﺔ ﻤﻥ ﻗﺒل ﺃﺨﺼﺎﺌﻲ ﺍﻝﺴﻜﺭﻱ
 ﻋﺎﻤﺎﹰ 5.51ﺃﻥ ﻤﺘﻭﺴﻁ ﺃﻋﻤﺎﺭ ﺍﻝﻤﺭﻀﻰ ﻭﻗﺕ ﺍﻝﺘﺸﺨﻴﺹ  ﺎﺌﺞ ﻫﺫﻩ ﺍﻝﺩﺭﺍﺴﺔﺃﻅﻬﺭﺕ ﻨﺘ: ﺍﻝﺭﺌﻴﺴﻴﺔﺍﻝﻨﺘﺎﺌﺞ
 ,(4.01= ﺍﻨﺤﺭﺍﻑ ﻤﻌﻴﺎﺭﻱ )  ًﻋﺎﻤﺎ 5.32 ﻤﺘﻭﺴﻁ ﻋﻤﺭ ﺍﻝﻤﺭﻀﻰ ﻜﺎﻥ ﻭ، (4.7= ﺍﻨﺤﺭﺍﻑ ﻤﻌﻴﺎﺭﻱ )
  .(2.7= ﺍﻨﺤﺭﺍﻑ ﻤﻌﻴﺎﺭﻱ ) ﻋﺎﻤﺎﹰ 4.8 ﻫﻲ ﻝﻠﻤﺭﺽ  ﺍﻝﺯﻤﻨﻴﺔﺍﻝﻤﺩﺓﻤﺘﻭﺴﻁ ﻭ
 ﻓﻲ ﺤـﻴﻥ ، ﻤﻥ ﺍﻝﻤﺭﻀﻰ ﺫﻜﻭﺭ % 7.74  ﻨﺴﺒﺔ  ﺃﻥ ﺘﺒﻴﻥ  ﻝﻠﻤﺭﻀﻰ ﻌﺎﻤﺔﺍﻝﺍﻝﺼﻭﺭﺓ   ﻋﻥ ﻤﻥ ﻨﺘﺎﺌﺠﻨﺎ ﻭ
ﺍﻷﺭﻴﺎﻑ، ﻓـﻲ ﺤـﻴﻥ  ﻴﺴﻜﻨﻭﻥ ﻓﻲ ﺒﺄﻨﻬﻡ %3.35ﺃﻓﺎﺩ  ﻭ,ﻤﺘﺯﻭﺠﻴﻥ ﻏﻴﺭ  ﺍﻝﻤﺭﻀﻰﻤﻥ 4.66% ﻜﺎﻥ 
ﻤﻥ ﺍﻝﻤﺭﻀﻰ % 1.14 ﺔﻓﻴﻤﺎ ﻜﺎﻨﺕ ﻨﺴﺒ ، % 2.28 ﺴﻨﺔ ﻫﻲ 21ﻨﺴﺒﺔ ﻤﻤﻥ ﻝﺩﻴﻬﻡ ﺘﻌﻠﻴﻡ ﺃﻗل ﻤﻥ  ﻜﺎﻨﺕ
  .ﻤﻥ ﺍﻝﻁﻼﺏ
      3.53% ﻤﻨﻬﻡ،8.7±61.0 %ﻭ  ﻫ ﻝﻠﻤﺭﻀﻰ ﻨﺴﺒﺔ ﺍﻝﺴﻜﺭ ﺍﻝﺘﺭﺍﻜﻤﻲ ﻤﻌﺩلﺃﻥﻜﻤﺎ ﺒﻴﻨﺕ ﺍﻝﻨﺘﺎﺌﺞ 
  .5.8%ﻝﺩﻴﻬﻡ ﻨﺴﺒﺔ ﺍﻝﺴﻜﺭ ﺍﻝﺘﺭﺍﻜﻤﻲ ﺃﻋﻠﻰ ﻤﻥ 
  ﻫﻭ (ﺍﻝﺭﻴﻕ) ﺃﻥ ﻤﻌﺩل ﺴﻜﺭ ﺍﻝﺼﻴﺎﻡ  ﺍﻝﺘﻲ ﺃﺠﺭﻴﺕ ﻝﻠﻤﺭﻀﻰ  ﺍﻝﻤﺨﺒﺭﻴﺔ  ﺍﻝﺩﻡ ﻜﻤﺎ ﺃﻅﻬﺭﺕ ﻨﺘﺎﺌﺞ ﻓﺤﻭﺼﺎﺕ 
ﻭﻴﻭﺭﻴـﺎ ﺍﻝـﺩﻡ ,، 191±1.5 ﺍﻝﻜﻭﻝـﺴﺘﺭﻭل ﻫـﻭ ل ،ﻭﻤﻌﺩ 641±1.11، ﻭﻤﻌﺩل ﺍﻝﺩﻫﻭﻥ ﻫﻭ 302±9
 )LDL( 321 ﺍﻝﺩﻫﻥ ﻤﻨﺨﻔﺽ ﺍﻝﻜﺜﺎﻓـﺔ ، ﻭﻤﻌﺩل9.0±50. ،ﻭﻤﻌﺩل ﻓﺤﺹ ﺍﻝﻜﺭﻴﺎﺘﻨﻴﻥ ﻫﻭ2.82±4.1
  .24±8.0 ﻫﻭ)LDH( ﺍﻝﺩﻫﻥ ﻋﺎﻝﻲ ﺍﻝﻜﺜﺎﻓﺔ،ﻭﻤﻌﺩل ﻓﺤﺹ±7.4
 
 v
  ﻤﻥ ﻋﻴﻨﺔ ﺍﻝﺩﺍﺭﺴﺔ ﻴﻌﺎﻨﻭﻥ ﻋﻠﻰ ﺍﻷﻗل ﻤﻥ ﻭﺍﺤﺩ ﺃﻭ ﺃﻜﺜـﺭ ﻤـﻥ % 6.84ﻭﺃﺒﺭﺯﺕ ﻫﺫﻩ ﺍﻝﺩﺭﺍﺴﺔ ﻨﺴﺒﺔ 
 ﻨﺴﺒﺔ ﻭﺠﻭﺩ ﺍﻝﻤﻀﺎﻋﻔﺎﺕﻤﻀﺎﻋﻔﺎﺕ ﻫﺫﺍ ﺍﻝﻤﺭﺽ ﻭﻫﺫﻩ ﺍﻝﻨﺴﺒﺔ ﺃﻗل ﻤﻥ ﺍﻝﻭﺍﻗﻊ، ﺤﻴﺙ ﻜﺎﻨﺕ 
 ﺍﻋﺘﻼل ، )4.63%(   ﺍﻝﻤﺭﻁﺒﺔ ﺒﺎﻝﺴﻜﺭﻱ ﻤﺸﺎﻜل ﺍﻝﻌﻴﻭﻥ:ﻫﻲ ﻜﺎﻷﺘﻲﻴﻥ ﺍﻝﻤﺭﺽ ﺒﻨﺎﺀ ﻋﻠﻰ ﺇﺠﺎﺒﺘﻬﻡ  ﺒ
 ،ﺒﺘـﺭ ﺍﻝﻘـﺩﻡ  )5.7%( ﺍﻝﻤﺭﻁﺒﺔ ﺒﺎﻝـﺴﻜﺭﻱ  ،ﻤﺸﺎﻜل ﺍﻝﻜﻠﻰ( 2.62% ) ﺍﻝﻤﺭﻁﺏ ﺒﺎﻝﺴﻜﺭﻱﺍﻷﻋﺼﺎﺏ
  .4.01%() ،ﺍﻝﻘﺩﻡ ﺍﻝﺴﻜﺭﻱ )9.0%( ﺍﻝﻤﺭﻁﺏ ﺒﺎﻝﺴﻜﺭﻱ
ل ﺇﺠﺭﺍﺀ ﺍﻝﻔﺤﻭﺼﺎﺕ ﻭﺘﻘﻴﻴﻤﻬﺎ ﻤﻥ ﻗﺒـل  ﻤﻥ ﺨﻼ (ﺍﻝﻤﺸﺨﺼﺔ) ﺒﻴﻨﻤﺎ ﻜﺎﻨﺕ ﻨﺴﺒﺔ ﺍﻝﻤﻀﺎﻋﻔﺎﺕ ﺍﻝﻤﺭﻀﻴﺔ 
( 2.61%) ﺍﻋﺘﻼل ﺍﻷﻋﺼﺎﺏ ، )8.33%( ﻤﺸﺎﻜل ﺍﻝﻌﻴﻭﻥ :  ﻜﺎﻷﺘﻲ ﺨﻼل ﺍﻝﺩﺭﺍﺴﺔﺃﺨﺼﺎﺌﻲ ﺍﻝﺴﻜﺭﻱ
  .(   )4.7%،ﻤﺸﺎﻜل ﺍﻝﻜﻠﻰ 
 ﺍﻋـﺘﻼل  ﻭ ﻤـﺸﺎﻜل ﺍﻝﻌﻴـﻭﻥ   ﺍﻝﻨﺘﺎﺌﺞ ﻭﺠﻭﺩ ﻋﻼﻗﺔ ﺍﻴﺠﺎﺒﻴﺔ ﻭﺫﺍﺕ ﺩﻻﻝﺔ ﺇﺤﺼﺎﺌﻴﺔ ﺒـﻴﻥ ﺕ ﺃﻅﻬﺭ ﻜﻤﺎ
 ﺔ ﻭﻨـﺴﺒ ، ﺍﻝﺠﻨﺱ ،ﻝﻠﻤﺭﺽﺍﻝﻤﺩﺓ ﺍﻝﻤﻌﺭﻭﻓﺔ  ﻝﻁﺒﻴﺏ ﻭﻜل ﻤﻥ  ﻤﻥ ﻗﺒل ﺍ ﺎ ﺍﻝﺘﻲ ﺘﻡ ﺘﺸﺨﻴﺼﻴﻬﻤ ﺍﻷﻋﺼﺎﺏ
  .% 5 ﺤﻴﺙ ﻜﺎﻨﺕ ﻗﻴﻤﺔ ﺍﻝﺩﺍﻝﺔ ﺍﻹﺤﺼﺎﺌﻴﺔ ﺃﻗل ﻤﻥﺍﻝﺴﻜﺭ ﺍﻝﺘﺭﺍﻜﻤﻲ
.  ﺒﻤﻌﺩل ﻤﺭﺘﻴﻥ ﻓﻲ ﺍﻝﻴـﻭﻡ  ﻋﻥ ﻁﺭﻴﻕ ﺍﻝﺤﻘﻥ  ﻴﻌﺎﻝﺠﻭﻥ ﺒﺎﻷﻨﺴﻭﻝﻴﻥ ﺍﻝﻤﺨﻠﻭﻁ  ﺃﻨﻬﻡ  ﻤﻌﻅﻡ ﺍﻝﻤﺭﻀﻰ ﻓﺎﺩﺃ
 ﻤﻥ ﺨﻼل  ﻭﺫﻝﻙ  ﺍﻷﻭﻝﻴﺔ ﺔ ﺍﻝﺼﺤﻴ  ﺍﻝﺭﻋﺎﻴﺔ ﺨﺩﻤﺎﺕﺍﻝﺒﺭﻭﺘﻭﻜﻭل ﺍﻝﻌﻼﺠﻲ ﺍﻝﻤﻘﺩﻡ ﻤﻥ ﻗﺒل ﺘﻡ ﺘﻘﻴـﻴﻡ ﻜﻤﺎ 
  ﺤﻴﺙ ﻭﺠﺩ ﺃﻥ ﻤﻌﺩل ﺇﺠﺭﺍﺀ ﻓﺤﺹ ﺍﻝﺴﻜﺭ ﺍﻝﺘﺭﺍﻜﻤـﻲ  ﻝﻠﻤﺭﻀﻰ  ﺍﻝﺘﻲ ﺘﻘﺩﻡ  ﻭﻨﻭﻋﻬﺎ ﻤﻌﺩل ﺍﻝﻔﺤﻭﺼﺎﺕ 
، ﻭﻨﺴﺒﺔ ﻓﺤﺹ ﺍﻝﻘـﺩﻤﻴﻥ 6.19% ﻫﻭ(ﺍﻝﺭﻴﻕ)  ﻭﻨﺴﺒﺔ ﻓﺤﺹ ﺴﻜﺭ ﺍﻝﺼﻴﺎﻡ،%  3.42 ﻫﻭﻝﻠﻤﺭﻀﻰ
، ﻭ ﻨﺴﺒﺔ ﻤﻌﺩل ﻓﺤﺹ ﺍﻝﺒﺭﻭﺘﻴﻥ ﻓﻲ ﺍﻝﺒﻭل % 6.5 ﻓﺤﺹ ﺘﺨﻁﻴﻁ ﺍﻝﻘﻠﺏ  ﺇﺠﺭﺍﺀ  ، ﻭﻨﺴﺒﺔ % 8.61ﻫﻭ
 3.73، ﻭﻨﺴﺒﺔ ﻤﻌﺩل ﻓﺤﺹ ﺍﻝﻜﺭﻴﺎﺘﻴﻨﻴﻥ ﻫﻭ %  34،ﻭﻨﺴﺒﺔ ﻤﻌﺩل ﻓﺤﺹ ﻴﻭﺭﻴﺎ ﺍﻝﺩﻡ ﻫﻭ 6.35%ﻭ ﻫ
 ، ﻭﻗﻴﺎﺱ ﻤﺴﺘﻭﻴﺎﺕ ﺍﻝﺸﺤﻤﻴﺎﺕ ﻫﻭ %  1.48 ، ﻭﻗﻴﺎﺱ ﺍﻝﻀﻐﻁ ﻫﻭ% 2.11، ﻭﻓﺤﺹ ﺍﻝﻌﻴﻭﻥ ﻫﻭ%
 52 ﺍﻝﺩﺭﺍﺴﺔ ﺃﻥ ﻤﻨﹾﺴﺏ ﻜﺘﻠﺔ ﺍﻝﺠـﺴﻡ ﺃﻜﺜـﺭ ﻤـﻥ ﺃﻭﺠﺩﺕ، ﻜﻤﺎ 58% ، ﻭﻗﻴﺎﺱ ﺍﻝﻭﺯﻥ ﻫﻭ% 1.15
  .% 4.63 ﻓﻲ 2ﻡ/ﻜﻎ
ﻡ ﺩﺭﺍﺴﺔ ﻋﻭﺍﻤل ﺍﻝﺨﻁﺭ ﻤﻊ ﺍﻝﻤﻀﺎﻋﻔﺎﺕ ﺍﻝﻤﺭﻀﻴﺔ ﺍﻝﻤﺴﺠﻠﺔ ﻤﻥ ﻗﺒل ﺍﻝﻤﺭﻀﻰ ﺃﻭ ﺍﻝﻤﺸﺨﺼﺔ ﻤﻥ ﻜﻤﺎ ﺘ 
ﻗﺒل ﺍﻝﻁﺒﻴﺏ، ﺤﻴﺙ ﺃﻅﻬﺭﺕ ﺍﻝﻨﺘﺎﺌﺞ ﺃﻥ ﺍﻝﻌﻤﺭ ﺍﻝﺯﻤﻨﻲ ﻝﻠﻤﺭﻴﺽ ﻭﺍﻝﻤﺩﺓ ﺍﻝﻤﻌﺭﻭﻓﺔ ﻝﻠﻤﺭﺽ ﻫﻤﺎ ﻋـﺎﻤﻠﻲ 
ﺍﻝﺨﻁﺭ ﻝﻜل ﻤﻥ ﻤﺸﺎﻜل ﺍﻋﺘﻼل ﺍﻝﻌﻴﻥ ﺍﻝﻤﻜﺘﻭﺒﺔ ﻭ ﺍﻝﻤﺸﺨﺼﺔ ﺤﻴﺙ ﻜﺎﻨﺕ ﻫﻨﺎﻙ ﻋﻼﻗﺔ ﺍﻴﺠﺎﺒﻴـﺔ ﻭﺫﺍﺕ 
 ﻋﺎﻤل ﺨﻁﺭ ﻻﻋﺘﻼل ﺍﻷﻋﺼﺎﺏ ﺍﻝﻤﻜﺘﻭﺒـﺔ ﻭ  ﻫﻭ ﺍﻝﻌﻤﺭ ﺍﻝﺯﻤﻨﻲ ﻝﻠﻤﺭﻴﺽ   ﻜﺎﻥ ﺎﺌﻴﺔ، ﺒﻴﻨﻤ ﺩﻻﻝﺔ ﺇﺤﺼﺎ 
  . ﺍﻝﻤﺸﺨﺼﺔ ﺤﻴﺙ ﻜﺎﻨﺕ ﻫﻨﺎﻙ ﻋﻼﻗﺔ ﺍﻴﺠﺎﺒﻴﺔ ﻭﺫﺍﺕ ﺩﻻﻝﺔ ﺇﺤﺼﺎﺌﻴﺔ
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  ﺍﻝﻭﻀﻊ ﺍﻝﺼﺤﻲ ﻝﻤﺭﻀﻰ ﺕﺩﺭﺴ  ﺍﻝﺘﻲ ﻤﻥ ﻨﻭﻋﻬﺎ  ﺍﻷﻭﻝﻰ  ﺃﻨﻬﺎ ﻫﺫﻩ ﺍﻝﺩﺭﺍﺴﺔ  ﻤﻥ ﺃﻫﻡ ﻤﻴﺯﺍﺕ : ﺍﻻﺴﺘﻨﺘﺎﺝ
 ﺍﻝﻤﻀﺎﻋﻔﺎﺕ  ﻨﺴﺒﺔ  ﻫﺫﻩ ﺍﻝﺩﺭﺍﺴﺔ ﻭﺠﻭﺩ ﻜﺸﻔﺕ ﺍﻝﻔﻠﺴﻁﻴﻨﻲ، ﺤﻴﺙ ﺍﻝﺴﻜﺭﻱ ﻤﻥ ﺍﻝﻨﻭﻉ ﺍﻷﻭل ﻓﻲ ﺍﻝﻤﺠﺘﻤﻊ 
 . ﻓﻲ ﺒﻌﺽ ﺍﻝﺤﺎﻻﺕﺍﻝﻨﺎﺘﺠﺔ ﻋﻥ ﺍﻝﻤﺭﺽ ﻭﺍﻝﺘﻲ ﻝﻡ ﻴﺘﻡ ﺘﺸﺨﻴﺼﻬﺎ ﺒﻌﺩ
 ﺍﻷﻭﻝﻴﺔ ﻝﻠﻨﻤﻁ ﺍﻷﻭل ﻤﻥ  ﺍﻝﺼﺤﻴﺔ  ﺍﻝﺩﺭﺍﺴﺔ ﻋﻠﻰ ﺃﻥ ﺍﻝﺘﺩﺒﻴﺭ ﺍﻝﻌﻼﺠﻲ ﻤﻥ ﻗﺒل ﻤﺭﺍﻜﺯ ﺍﻝﺭﻋﺎﻴﺔ ﺕﺩﻝﱡﻜﻤﺎ  
 ﺴﻴﻥ ﻜﻲ ﻴﻤﻜﻥ ﺍﺘـ ـﱢﻘﺎﺀ ﺍﻝﻤـﻀﺎﻋﻔﺎﺕ ﺇﻝﻰ ﺘﺤ  ﺒﺤﺎﺠﺔ ﻪ، ﻭﺍﻨ ﺎﻝﻤﺴﺘﻭﻯ ﺍﻷﻤﺜل ﺒﻠﻤﺭﻀﻰ ﻝﻴﺱ ﻝﺍﻝﺴﻜﺭﻱ 
ﻭﻜﺫﻝﻙ ﺒﺭﺍﻤﺞ ﺘﺜﻘﻴﻑ ﺼﺤﻲ  ﻝﺫﺍ ﻴﺠﺏ ﺃﻥ ﻴﻜﻭﻥ ﻫﻨﺎﻙ ﻋﻨﺎﻴﺔ ﻁﺒﻴﺔ ﻤﺴﺘﻤﺭﺓ ﻝﻠﻤﺭﻀﻰ . ﺍﻝﻤﺯﻤﻨﺔ ﻭﺍﻝﺤﺎﺩﺓ 
  .ﻝﻜل ﻤﻥ ﺍﻝﻤﺭﻀﻰ ﻭﺍﻝﻌﺎﻤﻠﻴﻥ ﺍﻝﺼﺤﻴﻴﻥ ﻤﻥ ﺃﺠل ﺍﻝﻌﻨﺎﻴﺔ ﺍﻝﺠﻴﺩﺓ ﻝﻬﺅﻻﺀ ﻝﻠﻤﺭﻀﻰ
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1.1 Background 
Diabetes Mellitus is a complex; heterogeneous, and a metabolic disease that is characterized 
by abnormal blood glucose “sugar” concentration (WHO, 1991). This increase of blood sugar 
concentration is though to result from reduction in insulin secretion in the pancreas or reduced 
sensitivity to insulin in the peripheral tissues (WHO, 1994).  Therefore, two major types of 
diabetes are recognized. The first type is diabetes type1 (Insulin Dependent Diabetes Mellitus, 
IDDM) which is characterized by severe reduction of insulin secretion that is due to 
destruction of the mass of Beta cells responsible for insulin secretion in the pancreas.  The 
second type is diabetes mellitus type II (Non Insulin Dependent Diabetes Mellitus, NIDDM) 
which appears at older age than IDDM and represents 85% of diabetes (WHO, 1991).  The 
onset and progress of type 2 is less acute compared to type-1 and its developments of 
complications are less aggressive. NIDDM developments are due to insulin resistant in the 
muscle tissue and consequently increase insulin secretion (Haffiner, 1996). 
 
1.2 Study problem 
Worldwide there is an increase of the incidence of childhood type-1 diabetes mellitus 
(Karvonen et al., 2000). This increase makes this disorder a major public health problem 
because of its high and rapidly increasing contribution of diabetes to the morbidity and 
mortality in the affected population. Type-1 diabetes mellitus occur in childhood and its peak 
of onset is early in puberty.  Worldwide, it is the third most prevalent severe chronic disease of 
childhood after asthma and mental retardation (Rewers, 1997; Scherbaum, 2002). The 
incidence of childhood  type-1 varies widely, since there is more than 350 fold difference 
between  annual rates reported in the various countries, e.g. Finland annual rates 
(36.5/100000) compared with those for China (0.1/100000)(figure 1.1) (Watkins, 1996; 
Rewers ,1997). 
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Fig1.1 The incedence of IDDM in different countries
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Figure 1.1: The incidence of IDDM in different countries (Watkins ,1996; Rewers ,1997). 
 
Globally 10-20 million people are affected by diabetes type-1. Its incidence continues to 
increase by 3-5 % per year (Rewers ,1997; Scherbaum ,2002), and in the Arab countries such 
as Jordan and Kuwait, the annual incidence among children is 3.6 and 15.4 per100,000 
respectively (Punnose, 2002). This disorder development is thought to be due to complex of 
interactions between various environmental factors and the fact that the individual is 
genetically predisposed to the disorder.  The possible environmental triggers are viral 
infections, e.g. Coxsackie's B virus, various dietary factors and stress (Davidson ,1991;Sharma 
,1993). Studies in monozygotic twins suggest that the genetic component account for 30-40% 
of the total risk for having this disorder (Watkins, 1996).  
The goal of the clinical management of all forms of diabetes is to control metabolic 
abnormalities in order to prevent acute (hyperglycemia and hypoglycemia) and long-term 
complications (retinopathy, nephropathy, neuropathy and cardiovascular disease) without 
negatively impacting on quality of life (Canton, 2004; Punnose et al 2002 and Laron-Kenet et 
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al.,  2001).The appearance of these complications depends on the duration and severity of 
hyperglycemia and individual susceptibility (Punnose et al .,2002).  
Patients with long standing diabetes might develop significant vascular complications. The 
appearance of these complications depends on the duration and severity of hyperglycemia and 
individual susceptibility (Scherbaum, 2002). These complications are related to blood vessel 
disease and are generally classified into small vessel disease such as those involving the eyes, 
kidneys and nerves (microvascular disease)( Scherbaum, 2002; Canton ,2004; Sharma ,1993 ; 
Devendra, 2004),and large vessel disease involving the heart and blood vessels 
(macrovascular disease ) (Watkins, 2003). The prevalence of micro- vascular complication in 
a patient with short-duration (<5 years) type-1 diabetes was found to be 25%, whereas for 
patient with long term disease (>14 years) could reach 72 %( Scherbaum, 2002) .The risk for 
development of micro vascular complications in patient with short-term could be increased by 
smoking and family history of hypertension. Long-term microvascular complications 
increased by poor glycemic control, and elevated serum lipids, which is the main causes of 
premature death are renal failure and coronary heart disease (Scherbaum, 2002; Punnose et al., 
2002).  For diabetic retinopathy, the prevalence of retinopathy is strongly related to the 
duration of diabetes (Punnose et al 2002, Strippoli 2003), for patients with short duration (<5 
years), the prevalence of retinopathy was 25% and for long term disease (>14 years) was 72% 
(Punnose et al 2002).  Kidney damage from diabetes results in hemodilysis, renal 
transplantation or death (Laron-Kenet et al., 2001; Rogus.John et al., 1998).  The onset of 
nephropathy in type-1 detected by small amount of proteinuria after 7-10 years of diabetes, 
together with diabetic retinopathy but without evidence of other causes of renal disease 
urinary tract infection or heart failure (Leslie ,1989). Overt diabetic nephropathy occurs in 30-
40% of type-1 diabetes patient, 20-25 years after disease onset (Strippoli, 2003). 
Nerve damage in diabetes (neuropathy) is particularly a depilating complication of diabetes 
and account for significant morbidity by predisposing the foot to ulceration and lower 
extremity amputation (Gordois, 2003). Foot ulceration is a major complication of diabetes and 
consumes a major portion of the resources allocated for the treatment of diabetes (Pham Hau, 
2000)  It estimates show that foot ulceration may occur in up to 15% diabetic foot during their 
life time(Pham Hau, 2000). 
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Other factors, familiar and environmental factors also play a role in increasing the risk for 
having diabetes complications.  For example, the risk for development of microvascular 
complications in patient with sort-term was increased by smoking and family history of 
hypertension and for long-term, microvascular complications increased by poor glycemic 
control, and elevated serum lipids (Punnose et al., 2002; Davidson ,1991). 
 
1.3. Study Justification 
The Palestinian community is characterized as being in an epidemiological transition from 
communicable to non-communicable diseases.  This made the community belonging to the 
two spectrum of health problems worldwide at the same time;  i.e. the health problems of the 
developing countries such as infectious diseases and malnutrition, and the diseases of 
developed countries such as cardiovascular diseases, diabetes diseases, cancer diseases and 
hypertension.  In the recent years the prevalence of non-communicable diseases has 
manifested a steep growth referred to the dramatic change in the lifestyles of the Palestinian 
community. 
Diabetes is considered as one of the major health problem in the Palestinian community that is 
demonstrating an increased pattern due to different factors determining the occurrence of the 
disease (Shaar, 1998). Dietary change, physical inactivity, stress, and genetic factors are 
thought to affect the increase in the incidence of diabetes in Palestine (Shaar, 1998).   Efficient 
diabetes care for Palestinian patients faces many problems.  This “Western disease" and its 
care are totally lacking in a country under development “transition state”, where very few 
poorly equipped and staffed diabetes units are present.  In fact diabetes care has a low profile 
as any other chronic disease, and is not in the government priority area.  However, this 
perspective for chronic diseases primary and secondary prevention start to change lately.  
In general, in Palestine, there is under-diagnosis and under reporting of diabetes mellitus (DM) 
as a leading cause of deaths. According to the Palestinian Ministry of Health (MOH) reports, 
DM is considered the 9th leading cause of death with a proportion of 4.1% of the total deaths 
(heart disease 2nd, renal failure 5th).  DM prevalence rate is about 9% in 2000.  By the end of 
2003, there were 15,844 diabetic Palestinian refugee patients (including those with 
hypertension) under supervision of the United Nations for Refugees and Welfare Agency 
(UNRWA) in Gaza Strip. The estimated prevalence rate of diabetes mellitus among 
6 
 
Palestinian refugees aged 40 years and above was 4.3% in 2000 and 4.7% in 2001. The gap 
between the expected prevalence rates and cases under supervision requires special efforts to 
accelerate early case-finding activities in order to detect these diseases and meet the high cost 
of treating their complications and disabling consequences (MOH reports, 2003). 
Most studies that have been concerned with diabetes focused on diabetes mellitus type II. No 
published study was neither concerned with the situation of diabetes type-1 patients, nor has 
evaluated the services provided for such life-time threatened kind of disease.   
According to the experts of this disorder in Palestine, there is a high probability that the 
incidence of diabetes type-1 is increasing yearly, similarly to the rate of Jordan (i.e. 3.6 per 
100,000 individuals).  However, the reasons for such increase is not determined or proved yet. 
This probable increase in the morbidity severity and the raise up in the mortality rate could be 
due to the disease itself or its complications. This could eventually reflect in the enormous 
health care expenditures, made type-1 patients a primer target for secondary prevention, i.e. 
preventing its complications.  
To have an overview of the services provided for type-1 diabetic patients in Ramallah district, 
we carried out several interviews with key persons at the central governmental primary health 
care centre in Ramallah and the major clinics operated by the United Nation for Refugees 
Welfare Agency (UNRWA).  In addition, we visited the major private hospitals that could 
probably provide such services for these patients and several private internal medicine clinics 
in the district.  From these interviews we found that the services offered to the diabetic 
patients of type-1 is mainly provided by both MOH and UNRWA, since they provide the 
insulin therapy for free for those patients. But, to a large extent, the follow up for these 
patients was bio-medically oriented, i.e. fasting blood sugar level which is measured monthly.  
However, other tests such as cholesterol, and triglyceride levels are measured yearly, but 
albumin, ECG, and eye and foot examinations are rarely done for these patients.   HbA1C was 
not used by any means in any facility.    
Therefore, as researchers we suspect that this mismanagement of this disorder is leading to 
serious complications for these patients and which could be lethal in many cases.  Thus, we 
planned to carry out this baseline study in one of the big districts; i.e. Ramallah district (total 
population according to the PCBS at the mid year of 2004 was around 285,000)  
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In summary, there is no published study yet that is concerned with the situation of diabetes 
type-1 patients.  No research was concerned with either to evaluate the disease itself or the 
services that is provided for such life-time threatened kind of disease, which if improved will 
improve the diabetic health care.   
 
1.4  Study aim and objectives 
We planned a study that covers all patients of diabetes type I they receive medical treatment 
by MOH and UNRWA in primary health care centers at Ramallah district, and investigated 
diabetes type I complications and therapeutic protocol. Moreover this study is planned to be 
used as a baseline survey for a study on type I diabetes and its complications in Palestine 
.Therefore, the study aims to assess and describe the situation of patients with diabetes type-1 
in Ramallah district, which therefore will help us to assess the services provided and the 
complications of this disorder. 
 
General Objective   
To assess the health situation of patients with diabetes type-1 in Ramallah district 
To highlight the possible determinants of diabetes type-1 
To determine the appropriate method (s) for the follow up and management of type-1 disorder 
in Ramallah by the various care providers. 
 
Specific objectives 
To describe the various socio-demographic, physical and health condition, diabetes history of 
T1DM patients in this study. 
To highlight the services provided to diabetic patients with T1DM.  
To determine the prevalence of diabetes type-1 complications among the diabetics in 
Ramallah district. 
To carry out blood testing, eye examination and examination by an endocrinologist to evaluate 
the present condition of these patients. 
To determine the role of the various potential determinants for T1DM complications. 
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  1.5   Research questions 
What are the complications that result from T1DM in Ramallah district?  
What is the protocol used by the various health care providers in the treatment of T1DM to 
prevent or delay the occurrence of these complications? 
Does self management among T1DM has an important role on managing the disease among 
these patients?  
 
1.6 Study limitations 
Some patients could not be reached for the following reasons: 
1- Some patient did not come to PHC centers by themselves to take the monthly insulin and 
having medical examination, instead a relative or a friend came to pick the medications so 
interview could not be done. 
2- Due to the prevailing political condition and the continuous Israeli closer for areas, some 
patients could not be reached. 
 3- Lack of information in diabetic patient file like telephone numbers or exact address. 
4- A number of patients were already dead and their families refused to fill in the 
questionnaires. 
5- Some families refused their children participation in the survey. 
6- Some families fill in the questionnaire but refused doing the testing. 
7- Some families did the testing but refused seeing other physician than the one they see at the 
PHC. 
 
1.7 Thesis chapters’ description 
The thesis include six chapters starting from chapter one which discuss the aim, problem and 
the objectives of the study, also it include questions of the study and its limitations. 
Chapter two include literature review of the previous studies that are related to the present 
study, the informations were taken from journals, books, and the internet. 
Chapter three discuses the theoretical and conceptual frame works of the study. The theoretical 
include all types of diabetic complications and its risk factor plus the protocol of T1DM 
treatment. 
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Chapter four includes the methodology of the study, the way that was data collected; sample 
size, pilot study and statistical analysis of the data. 
Chapters five and six, include the results of the study found in form of tables and figures. 
While chapter six discuses the result of the study and its finding. Finally the last chapter 
includes also the conclusion of the study and the research recommendations.  
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Chapter two. Literature Review 
2.1   Introduction 
2.2   Previous Studies 
2.2.1 Diabetes type 1 situation worldwide 
2.2.2 Epidemiological studies of type 1 IDDM, complications and its risk factors 
2.2.3 The importance of glycemic control 
2.3    Summary 
 
 
 
 
11 
 
 
2.1 Introduction: 
The literatures review in this chapter will focus on dependent and independent variables that 
are related to the study and this will include epidemiological studies of Diabetes type 1, 
complication and its risk factors of diabetes type 1, and finally the important of glycemic 
control.  
 
2.2 Previous studies 
The previous studies that are related to our study will be divided into: 
2.2.1 Situation of diabetes type 1 worldwide 
2.2.2 Epidemiological studies of type 1 IDDM, complications and its risk factors 
2.2.3 Importance of Glycemic control 
 
2.2.1 Diabetes Type 1 situation worldwide 
The term 'prevalence' of Type 1 diabetes usually refers to the estimated population of people 
who are managing Type 1 diabetes at any given time. The term 'incidence' of Type 1 diabetes 
refers to the annual diagnosis rate or the number of new cases of Type 1 diabetes diagnosed 
each year.  
Several studies had been carried out in developed, developing and the Middle East countries. 
Epidemiological study of type 1 diabetes in children from 1990 to 1994 using a retrospective 
population-based registry in Philadelphia, PA, a city with large white, African-American, and 
Hispanic (Puerto Rican) populations in the USA.  Found that the overall age-adjusted 
incidence rate in Philadelphia was 13.3/100,000/year (Terri et al., 2002). The incidence of 
insulin-dependent diabetes mellitus in children aged 0-17 years in Colorado from 1978 to 
1988. Was 14.8/100,000 person-years. The rate was lower in individuals of Spanish origin 
(Hispanics) (8.7/100,000 person-years) compared with non-Hispanic individuals 
(15.5/100,000 person-years) .Incidence rates were higher in winter and lower in summer for 
children 5-17 years old. Children diagnosed before the age of 5 years showed no significant 
seasonal pattern, although peak incidences were observed in autumn and spring. No temporal 
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trend in diabetes incidence was observed overall or by ethnic group (Kostraba et al., 1992). 
The new cases of type 1 diabetes in children aged 0–14 years in the Mediterranean island of  
Sardinia were prospectively registered from 1989 to 1999 according to the EURODIAB ACE 
criteria show that A total of 1214 type 1 diabetic patients were registered yielding to an overall 
age- and sex-standardized incidence rate of 38.8/100000. There was a male excess with an 
overall male-to-female ratio of 1.4 (1.3-1.8). The increase of incidence during the 11 years 
analyzed was statistically significant (P = 0.002) with a yearly increasing rate of 2.8% (1.0-
4.7). No evidence of an effect of age and sex on this trend has been found. (Casu  et al., 2004). 
The highest annual incidence rate of childhood onset Type I diabetes in the world ever known 
was recorded in Finland in 1998 with 48.5 cases per 100 000 person-years (Podar et al., 2001). 
The crude annual incidence of Type 1 diabetes in children under 15 years in northern Thailand 
from 1991 to 1997 ranged from 0.31-0.56/100,000 per year, with an average incidence of 
0.37/100,000 per year. This very low figure had raised 2.2 fold (over 100%) from that reported 
in 1984 (Unachak et al.,2001). The overall ascertainment-corrected IDDM incidence rate in 
China was 0.51 per 100,000, the lowest rate ever reported. There was a 12-fold geographic 
variation (0.13-1.61 per 100,000) (Yang  et al., 1998).In the childhood age group, a highly 
variable incidence of IDDM is seen in many Arab countries. In the Sultanate of Oman, the 
incidence rates in the 0–14-year age group were 2.45 and 2.62/100 000 populations per year 
during 1993 and 1994, respectively (Soliman  et al., 1996).Similar study was conducted in the 
same age group among Jordanian children aged 0-14 y during 1992-1996 , Data were obtained 
retrospectively for the years 1992-1994 and prospectively for the years 1995 and 1996, the 
study show that the incidence rate for the years (1992 through 1996) was 2.8, 2.9, 3.2, 3.6 and 
3.6 per 100,000 populations, respectively (Ajlouni  et al.,1999).Another study conducted in 
Kuwait show that the incidence rate of IDDM among Kuwaiti children aged 0- 14 years was 
20.1/100000 during the period of 1991-1997(Shaltout   et al.,2002).In Israel the incidence of 
IDDM between the ages 0-17 years in the year 1998 was 9.1/100000,this study show that the 
incidence were higher for Jews 9.5/100000 than for Arab 8.0/100000(IIRSG,2002). 
The prevalence of insulin-dependent diabetes mellitus (IDDM) in the United States is 
estimated to be about 120,000 individuals' age less or equal 19 years and about 300,000-
500,000 individuals of all ages (Ronald et al.,1994).While the prevalence of adult-onset 
insulin-dependent diabetes mellitus (IDDM) in a nationally representative sample of adults 30-
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74 years of age of USA was 0.30% of the U.S. population 30-74 years of age and 7.4% of all 
diabetic patients diagnosed at 30-74 years of age (Harris  and Robbins,  1995). In England the 
prevalence is estimated to be about 166 000 persons which account 0.4% for all persons in 
England in 2001(Forouhi NG et al 2006). The prevalence rates of IDDM among children aged 
from 0-14 years in Slovakia (per 1,000) were 0.28-0.50% in the 8-year period of 1985 to 1992 
(Michalkova  et al., 1995). 
In southern Iran (Karamizadeh et al,. 1996) a Middle Eastern country, a study among children 
(0-18 years of age) found that the prevalence of diabetes type 1 was 40.83 per 100,000 
children (4/10,000). The annual incidence of diabetes in this age group was 4per 100,000 
children with a higher frequency in females. A seasonal variation was noted in the onset of 
symptoms which was the highest during October and the lowest during August (Karamizadeh 
et al., 1996). 
The prevalence data of IDDM in the Arab countries show different rates. A study in Kuwait 
(Mohamed et al., 2005) showed that IDDM was more prevalent in the age group 10-13 years 
347.3 per 100,000 and lowest in the age group 6-9 years 182.6 per 100,000 individuals.  
During the study period from October 2000 to September 2002, the prevalence of IDDM was 
269.9 per 100,000 with no significant between male and female.  The mean age at onset was 
9.2 and 8.1 years in male and female children, respectively, with no significant difference 
between regions of Kuwait.  
 Another household screening study in Saudi Arabia between years 1992-1996 of the adult 
population (more than 14 years), the prevalence of  IDDM among male and female in the all 
different regions was 0 .23 and 0.3, respectively (Warsy  et al.,1999). 
 
2.2.2 Epidemiology of Type 1 diabetes mellitus and its complications  
The epidemiology of diabetes type 1 and its complication were of great interest in the past 2 
decades.  Many researches and published work was concerned in studying the prevalence of 
microvascular disorders (retinopathy, nephropathy and neuropathy) and acute diabetic 
complications, and the metabolic control status. 
Table 2.1 summarizes some of the most important studies that were concerned for both acute 
and chronic complications of T1DM. 
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Table 2.1 Summary of studies that was concerned with type 1 diabetes complications 
Author, country of study sample size Study type, 
Patients age 
testing complications Notes 
EURODIAB IDDM 
Complications Study 
Europe   
3250 
IDDM patients 
cross-
sectional 
study  
− HbAIC 
Normal=16% 
− Retinopathy= 46% 
− Nephropathy=30.6% 
− Hypoglycemia=32.2% 
− Hospital admm =8.6% 
− Cardiovascular=19.3% 
Mean (SD) duration 
of diabetes was14.7 
(9.3) years 
ADA (1990) 657 
IDDM  
patient diagnosed between 
1950 and 1980 and currently 
aged 8-48 yr 
cross-
sectional 
study 
 
− Retinopathy=70 % 
− Nephropathy= 
            84%(male) 
           59% (females) 
_Cardiovascular= 
              11%(men) 
             30% (women) 
after 30 yr duration 
 
 (Blanco et al 2004) 
Catalonia-spain 
471 patients hospital records Cross-section 
for patients 
diagnosed 
between 
1987-1988 
− HbA1c 
<7.5=48% 
>10=11.5% 
− Retinopathy= 15% 
− Nephropathy=10.4% 
− Neuropathy=4.3% 
− Ketoacidosis=1.5% 
− Hypoglycemia=5.2% 
− Hospitaladmm =10.9% 
After 10 yrs  
Kozek et al (2003). 
Krakow-Poland 
 
 
 
 
 
clinical data from 241 
patients 
Retrospective 
analysis 
−  − Retinopathy= 41.5% 
− Nephropathy=17% 
− Neuropathy=29% 
− Hypoglycemia=32.2% 
− Cardiovascular=8.7% 
− Foot ulcer=8.3% 
diabetes duration 
10.00 +/- 8.6) in 
women, while in men 
11.78 +/- 11.08 years 
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Table 2.1…. continues 
Author, country of study sample size Study type, 
Patients age 
testing complications Notes 
(Olsen ,1999) 
Denemark 
339 patients Cohort 
follow-up 
study 
− HbAIC 
<8=11% 
 
 
− Retinopathy= 60% 
− Nephropathy=9% 
− Neuropathy=62% 
 
 
 
 
 
 
median diabetes 
duration 13.2 years 
(range 8.9-24.5). 
Nordwall et al (2006) 
Linkoping, Sweden 
 
 
 
 
80 children and adolescents 
with DM1, age 7-22yrs  
Cross-
sectional 
− HbA1c 
Mean HbA1c 
(SD)=8.4 
(0.9)% 
− Retinopathy= 27% 
− Nephropathy=5% 
− Neuropathy=59% 
DM1 duration=13 
years 
(Agardh  et al., 1997) 
Lund- Sweden 
442 type 1 adult diabetic 
patients 
follow-up 
study 
− HbAIC 
 
11 +/- 4% 
− Retinopathy= 41% 
 
After5 years 
Fagulha A et al 2004 
Coimbra- Portugal 
1009 patients Cross-section 
until 22 yr of 
age 
− HbA1c 
-<7.5=12.5% 
- > or =7.5 and 
< 8%=11.3% 
- > or =8 and 
<9.5 = 33.5% 
->9.5 =40.9% 
− Retinopathy=1.4%  
− nephropathy= 6.4% 
diabetes duration 5.2 
yr+/-3.95 
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Table 2.1…. continues 
Author, country of 
study 
sample size Study type, 
Patients age 
testing complications Notes 
Lievre M et al 2005 
Lyon-France 
562 children aged 10-
16 and 1691 adults 
aged 16-  
45cross-sectional 
study 
− HbA1c 
-<7=15%  
 Children and 
26% adults. 
 
 
− Retinopathy=  
Children (0.7%)  
Adults (28.3%) 
-micro-ormacro-albuminuria=  
children 10.2%  
adults 15.2%  
After 2 years of 
type 1 diabetes or  
Donaghue KC et al 
(2005) 
Westmead-Australia 
209 patients Cohort study 
children aged < 15 
years diagnosed 
between 1990and 
1992 
−  − Retinopathy=24% 
− albumin excretion rate  
(AER) > or = 7.5 microg/min = 
18% 
− albumin excretion rate  
(AER) > or = 20 microg/min 
=2% 
After 6 yrs  
Ramachandran A et al 
(2000) 
Chennai, India 
617 Type 1  diabetic 
patients  
 
 
 
 
Cross-sectional 
patients, aged < or 
=20 years at 
diagnosis of 
diabetes 
−  − Retinopathy=13.4 % 
− Nephropathy=7.1% 
− Neuropathy=3% 
− IschaemicHeart 
   disease=.5%  
-peripheral vascular disease in 
0.5% 
a minimum of 3 
year follow-up 
IDF (2003) 
Baku-Azerbaijan 
 
 
 
 
69 type 1 medical 
document 
Cross-sectional 
−  − Hypoglycemia=1.4% 
− Retinopathy=1.4% 
− Eyes cataract=5.8% 
− Neuropathy=24.4% 
− Nephropathy=1.4% 
Duration of 
disease3.5+/- .36 
Age=10.2+/-.35 
yrs 
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Table 2.1…..continues 
Author, country of 
study 
sample size Study type, 
Patients age 
testing complications Notes 
Rahlenbeck &  Gebre-
Yohannes (1997)  
Gondar –Ethiopia 
 
Type1 diabetic patients Cross-sectional 
 
− Nephropathy 
Microalbuminuria=33% 
Macroalbuminuria=23% 
 
duration of 
disease more than 
5 years 
Kalter-Leibovici 
O(1991) 
Petah Tikva- Israel 
231 young Jewish 
IDDM 
(Age range=  0.04-26.2 
yr), 
Cohort study 
  
− Nephropathy 
Microalbuminuria=31% 
Macroalbuminuria=7% 
− Retinopathy 
Nonproliferative=44% 
Proliferative=12%              
median duration 
of disease was 
15.3 yr 
(Ammari F 2004). 
Jeddah-Saudi Arabia 
100 
patients hospital files 
Retrospective study 
−  − Retinopathy= 7% 
− Nephropathy=2% 
− Neuropathy=6% 
− Hypoglycemia=32.2% 
− Cardiovascular=8.7% 
− Foot ulcer=8.3% 
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2.2.3 Type 1 diabetes therapy and glycemic control: 
Several studies were done to compare the different ways of achieving tight glycemic 
control. One of the major studies was a 10-year study that compared intensive therapy 
versus conventional therapy conducted by the Diabetes Control and Complications Trial 
(DCCT) (DCCT, 1993). The DCCT included 1,441 subjects with type 1 diabetes, whom 
were randomly assigned either to intensive therapy or conventional therapy. Intensive 
therapy consisted of insulin administered either by continuous subcutaneous insulin 
infusion with an external insulin pump or multiple daily insulin injections (three or more 
injections per day). Insulin therapy was guided by self-monitoring of blood glucose 
(SMBG) three to four times daily, with additional specified samples, including a weekly 
overnight sample. It also included meticulous attention to diet and monthly visits to the 
treating clinic. Conventional therapy consisted of no more than two daily insulin injections; 
urine glucose monitoring or SMBG no more than twice daily; periodic diet review; and 
clinic visits every 2-3 months.  The intensive group achieved median hemoglobin A1c 
(A1C) of 7.2% versus an A1C of 9.1% in the conventional group. Mean blood glucose was 
155 mg/dl in the intensive group and 230 mg/dl in the conventional group.                                                                            
In the DCCT study, risk reductions for micro vascular and neurological end points were 
dramatic: > 70% for clinically important sustained retinopathy, 56% for laser 
photocoagulation, 60% for sustained microalbuminuria, 54% for clinical grade 
nephropathy, and 64% for confirmed clinical neuropathy. Macro vascular end points 
demonstrated trends in risk reduction—42% risk reduction for all macro vascular events 
combined and 78% risk reduction for cardiac events (DCCT, 1993). 
Similar study was done at Alexandria University Children's Hospital, Egypt (Soliman  et 
al., 2006). The 125 type 1 diabetic children were included in this study  to compare 
glycemic control and insulin dosage in children with type 1 diabetes treated by a modified 
intensified insulin therapy (MII) using insulin pens (and premixed and regular insulin) with 
those on conventional insulin therapy .The result of the study show that in this study found 
that glycemic control is better during MII using insulin pens and premixed and regular 
insulin compared with conventional insulin therapy, without any significant change in  
insulin dose needed to achieve this level of control.                                                    
Another previous study done among children with type 1 diabetes diagnosed at 0–14 years 
in northern Sweden between 1981 and 1992 .This survey study the impact of glycemic 
control  HbA1c) early in disease and age at onset on the occurrence of incipient diabetic 
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nephropathy (MA) and background retinopathy (RP) in childhood-onset type 1 diabetes. 
The result of the study shows that inadequate glycemic control, also during the first 5 years 
of diabetes, seems to accelerate time to occurrence of micro vascular complications 
(Svensson et al., 2004). 
 
2.3 Summary 
In this chapter TIDM epidemiology and its various complications was discuss, Glycemic 
control and its role in delay and prevent diabetes complications was also discuss. From the 
previous study the researcher will determine sample size, statistical analysis, and to 
determine the hypothesis of the study. 
Epidemiological studies show that the incidence rates gathered during the last years in 
people under 15 years of age confirm the vast geographic variation of IDDM incidence 
worldwide with rates (per 100,000) ranging from 0.6 in Thailand  and China to 36 in 
Sardinia and Finland. This large variation was also observed in small areas of various 
countries such the Arabian Peninsula. Between continents the variation in incidence 
showed that the lowest rate was found in Asia, followed by Africa and South America; 
higher rates were recorded in Oceania (Australia and New Zealand) and North America, 
while the highest rates of all were recorded in Europe where the greatest intracontinental 
variation in incidence has been described. 
From the review of the past studies that are done on both acute and chronic complications 
of T1DM and there risk factors, the researchers could summarize the most important 
results of these studies as follows: 
♣ There is a significant relation ship between Duration of diabetes and the 
appearance of its complications. 
♣ There is a significant relation ship between smoking habit and the appearance 
of diabetic complications. 
♣ Onset of diabetes before puberty could be an additional risk factor for the 
appearance of diabetes complications. 
♣ There is no difference between males and females in the appearance and 
frequency of diabetes complications. 
♣ There is a significant relationship between poor glycemic control and the 
development of diabetes complications. 
♣ Earlier use of intensive insulin treatment lowers HbA1c to normal value. 
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♣ There is a significant relationship between irregular home monitoring and the 
appearance of diabetes complications. 
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Management & 
follow up 
 
Self Management 
Home monitoring 
Glycemic control 
 
 
servicesDiagnosis and  
 
Physical examinations 
Insulin therapy  
 
Risk factor 
Duration of diabetes 
Metabolic control 
Gender 
Age  
Lipid profiles 
Blood pressure 
BMI 
Genetic factors(family history) 
Age at onset 
Smoking 
Type 1 
complications 
Diagram 3.1 study conceptual 
3.1  Introduction: 
This chapter presents an overview of diabetes mellitus types, causes, diagnosis, and 
treatment protocols. In the chapter we will be discussing issues related to the under-
treatment of diabetes type 1, the different types of insulin used by the diabetic patient, 
follow up mechanisms used by health the various care services, as well as its 
complications. Moreover, the risk factors for diabetes type 1 complications will be 
discussed. Diagram 3.1 presents the conceptual framework model of diabetes type 1 
complications, as it is reflected in this thesis’ objectives. 
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3.2  Diabetes mellitus definition 
Diabetes mellitus is one of the oldest diseases that are in recorded history and which have 
been recognized in Egypt and India before Christianity (Halabi, 1996). However, even now 
relatively little is known about diabetes in developing countries, where the fight against 
communicable disease has attracted most attention (Halabi, 1996).  Diabetes has been 
recognized since antiquity, as a wasting disease associated with frequent eating, urination 
and weight loss, despite frequent eating (Halabi, 1996). 
The term Diabetes Mellitus describes a metabolic disorder of multiple etiologies. Davidson 
defined diabetes mellitus as a syndrome with metabolic, vascular, and neuropathic 
component that are interrelated. The metabolic syndromes characterize by alternation in 
carbohydrate, fat, and protein metabolism secondary to absent or insulin secretion or 
ineffective insulin actions (Davidson, 1991). 
The World Health Organization defined diabetes mellitus as metabplic disorder of multiple 
aitiology characterized by chronic hyperglycemia with disturbances of carbohydrate,fat 
and protien metabolism resulting from defect in insulin secreation,insulin action or both 
(WHO,1999).  The effects of diabetes mellitus include long damage, dysfunction and 
failure of various organs, and it includes progressive development of the specific 
complications of retinopathy, with potential blindness, nephropathy, that may lead to renal 
failure, and neuropathy with risk of foot ulcers and amputation. In addition, the diabetes 
patient is at risk for cardiovascular, peripheral vascular and cerebrovascular diseases 
(WHO, 1999).  
 
3.3  Types of diabetes 
Diabetes mellitus is a syndrome characterized by hyperglycaemia resulting from defects in 
insulin secretion, insulin action, or both. An actual etiologic classification suggested by the 
American Diabetes Association.  Table 3.1 presents this classification (Nordwall, 2006).   
I.  Type 1 diabetes 
This is known as IDDM, or juvenile diabetes in which the pancreatic beta cell fail to 
produce the insulin hormone when the immune system attacks the insulin-producing beta 
cells in the pancreas and destroys them, about 5-10% of patients has type 1 diabetes 
mellitus. This type 1s usually developed in the children and young adults, but the disorder 
may appear at any age. Symptoms are; increased thirst and urination, constant hunger, 
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weight loss, blurred vision and extreme tiredness. The risk factor of type 1 diabetes 
includes auto immune, genetic and environmental (WHO, 1999; WHO, 2000; Davidson, 
1991). 
 
 
Table 3.1: Etiological classification of diabetes mellitus 
 
 
I  Type 1 diabetes mellitus (beta cell destruction, leading to insulin deficiency) 
              a. Immune mediated 
              b. Idiopathic 
 
II  Type 2 diabetes mellitus (different grades of insulin resistance with different grades of 
relative insulin deficiency) 
 
III Other specific types 
a. Genetic defects of beta cell function (e.g MODY Maturity Onset Diabetes of the 
Young) 
b. Genetic defects in insulin action 
c. Diseases of exocrine pancreas (e.g. pancreatitis, cystic fibrosis) 
d. Endocrinopathies (e.g. Cushing’s syndrome) 
e. Drug- or chemical- induced (e.g. corticosteroids) 
f. Infections (e.g. congenital rubella) 
g. Uncommon form of immune-mediated diabetes mellitus 
h. Genetic syndromes associated with diabetes mellitus 
  
IV Gestational diabetes mellitus 
 
Source: Adapted from Maria Nordwall master thesis, Linköping University, 2006 
 
II. Type 2 diabetes 
This is known as non insulin-dependent diabetes mellitus or (NIDDM). It is the most 
common form of diabetes. About 90 to 95 percent of people with diabetes have type 2 
diabetes. Usually it is developed in adults over the age of 40, and about 80 percent of 
people with type 2 diabetes are overweight. In this type of diabetes, the pancreas produces 
insulin, but for some reason the body cannot use the insulin effectively, which results in 
the unhealthy build up of glucose in the blood. The symptoms here are not noticeable as in 
type 1diabetes. Symptoms include; feeling tired or ill, frequent urination, unusual thirst, 
weight loss, blurred vision, frequent infections, and slow healing of ulcers (WHO, 1999; 
WHO 2000; Davidson 1991). 
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III. Other specific type and secondary  
These conditions include diabetes and glucose intolerance that develop in association with 
disorders or factors such as pancreatic diseases, endocrinopathies, many genetic 
syndromes, and the diabetogenic effects of drugs, chemical agents, and toxins. The 
prevalence is ~1%-2% of all diabetes (Davidson, 1991). 
IV. Gestational diabetes 
 Is a (carbohydrate intolerance) resulting in hyperglycemia of variable severity with onset 
or first recognition during pregnancy, and usually disappears after the pregnancy is over, 
unless it was diabetes type 1. Diabetes in pregnancy may give rise to several adverse 
outcomes, including congenital malformations, increased birth weight and an elevated risk 
of prenatal mortality (WHO 1999; WHO 2000; Davidson, 1991). 
3.4  Pathogenesis of type 1 diabetes mellitus 
Type 1 diabetes is a disease characterized by “auto-destruction” of the pancreatic beta cells 
that produce insulin. Overtime, the body silently destroys these cells creating an insulin 
deficiency. Type 1 diabetes appears to stem from an inherited defect in the immune 
system, triggered by some environmental stimuli. The exact cause of the disease is still 
unknown; however, studies have isolated a few factors that may be related to development 
of the disease (Redondo et al., 2001). 
Mainly, diabetes type 1 was seen as a combination of genetic susceptibility and 
environmental factors “gene-environment interaction” that leads to an autoimmune 
cellular and humoral mediated destruction of the beta cells in the pancreas. Genetically, a a 
strong association was seen between certain HLA genes and risk for type 1 diabetes, , but 
the frequency of the high risk genotypes differs among children of different ages. Children 
with newly diagnosed diabetes have autoantibodies against glutamic acid decarboxylase 
(GADA), islet cells (ICA), insulin (IAA) or tyrosine phosphatase (IA - 2) in 85–98%, but 
the rate of antibody positivity varies among different age groups (Komulainen et al. 1999) 
(Fajardo et al., 2001).  The major genetic risk factor for the development of type 1 diabetes 
is the human leukocyte antigen (HLA) genes located on the short arm of the sixth 
chromosome (Davidson,1991).  
In the last decade, the rapid increase of type 1 diabetes incidence could not be explained by 
genetic changes in this short time perspective (Pundziute-Lycka, 2004). Studies in 
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monozygotic twins suggest that the genetic component account for 30-40% of the total risk 
(Peter, 1996; Rewers, 1997; Redondo et al., 2001; Kumar et al., 1993; Hyttinen et al., 
2003). These factors speak in favor of the importance of environmental factors for the 
development of type 1 diabetes. In epidemiological studies several environmental factors 
has been associated with diabetes. 
Evidence for a triggering role of environmental factors such as bovine albumin of milk or 
viral infection has also been postulated. The role of cow’s milk related to T1DM is not 
clear; some suggestions that albumin has a section that is capable of reacting with “beta-
cell specific surface proteins”, which could contribute to islet cell dysfunction. 
(Karjalainen et al., 1992). 
Several studies in humans suggest that persistent viral infection (e.g., Rubella virus, 
Coxsackie's B4, cytomegalovirus, Epstein-Barr, and so on) may be involved in some cases 
of IDDM (Wagenknecht et al., 1991).  The role of viruses in the pathogenesis of IDDM is 
also supported by direct isolation of virus from pancreas of infant who died of diabetic 
ketoacidosis. (Draznin et al., 1994). 
3.5  Burden and complications of Diabetes Mellitus  
 The complications of diabetes can be classified as: Acute problem (Otherwise termed the 
diabetic medical emergencies) which include Diabetic ketoacidosis and hypoglycemia, or 
chronic complications which include Micro vascular and macro vascular complications. A 
round four million deaths every year are attributed to complications of diabetes mellitus 
(WHO,2003). 
3.5.1 Acute diabetic complications  
I. Hypoglycemia is defined as blood glucose less than 50 mg/dl . The main symptoms are 
headeache, weakness, sweating, tremors, hunger, difficulty speaking, confusion, 
convulsion and coma. The eitiology of hypoglycemia in IDDM patient result from 
mismatch between insulin dose, carbohydrate ingestion and physical activity (Leslie et al., 
1995). Hypoglycemia is classified as: i) mild hypoglycemia in which patients are able to 
treat themselves when the feel the symptoms such as tremors, palpitation, sweating and 
hunger; ii) severe hypoglycemia in which the symptoms include constipation, drowsiness, 
coma and seizure due to a very low blood glucose level and the patient is not able to treat 
themselves and needs help from others (MOH, 2004; WHO, 2002a). 
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II.  Diabetic ketoacidosis:  
Diabetic ketoacidosis (DKA) is the most common hyperglycemic emergency in patients 
with diabetes mellitus. DKA most often occurs in patients with type 1 diabetes, but patients 
with type 2 diabetes are susceptible to DKA under stressful conditions, such as trauma, 
surgery, or infections. The incidence of ketoacidosis is about 1-5% in type 1 diabetics with 
a mortality of 3-9% (Berger, 1997).                                                                                                                
DKA is reported to be responsible for more than 100 000 hospital admissions per year in 
the US, and accounts for 4-9% of all hospital discharge summaries among patients with 
diabetes. Treatment of patients with DKA uses significant healthcare resources and 
accounts for 1 out of every 4 healthcare dollars spent on direct medical care for adult 
patients with type 1 diabetes in the US (Umpierrez , 2003; Christaki et al, .2001). 
3.5.2 Chronic complications 
Diabetes is associated several late stage complications that lead subsequent to mortality 
and morbidity. These late stage include microvascular and macrovascular complications. 
Microvascular diseases results from the impact of glucose intolerance on the smaller blood 
vessels and include retinopathy, nephropathy and neuropathy. Macrovascular disease 
involves the large blood vessels and is associated with atherosclerotic activity of these 
vessels (Davedson, 1991; ADA, 2004). Microvascular is more common complications in 
type 1 diabetes, although macrovascular complications are also increased. These 
complications are influence by several factors such as glycemic control, hypertension and 
hyperlipidmia. The primary risk factor for microvascular complications is hyperglycaemia, 
while other risk factors, such as hypertension and lipid control are the main for the 
development of macrovascular complications. Complications are therefore usually 
acquired after diagnosis (Bate and Jerums, 2003). 
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I.   Microvascular complications 
1)  Diabetic retinopathy:  
Diabetes is the most frequent cause of new cases of blindness among adults aged 20–74 
year. (Donald, 2003). Diabetic retinopathy is the cause of blindness in approximately 2.5 
million of the estimated 50 million blind people in the world (Viswanath et al., 2003). In 
economically developed societies, it is a major cause of visual disability in people aged 25 
years or older (King et al., 1996; WHO, 1997). Blindness is 25 times more common in 
people with diabetes than people not having diabetes (Klein et al., 1995; Palm berg, 1977). 
It causes 12,000- 24,000 new cases of blindness each year (CDC, 2002), an estimated 
63,000 cases of proliferative diabetic Retinopathy, 29,000 high risk proliferative diabetic 
retinopathy cases, 80,000 macular edma cases, 56,000 clinically significant macular edma 
cases, and 5,000 new cases of blindness occur each year as a result from diabetic 
retinopathy (Klein et al., 1995).  In type 1 diabetes, background retinopathy is rare before 5 
years of diabetes but its prevalence increases steadily thereafter to affect over 90 % of 
patients after 20 years. After several years of diabetes, the risk of proliferative changes is 
about 3% of patient per year, with cumulative total of over 60% after 40 years (Pickup et 
al., 1991). 
The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) which was a 
longitudinal study using a population based cohort of diabetes patient from Wisconsin 
found that PR is more prevalent in type 1 diabetes, also the study found that the 10 year 
follow up point, 30% of the younger onset group, 24% of older onset group taking insulin 
and 10% of older onset group not taking insulin developed retinopathy (Klein et al., 1994). 
Diabetic retinopathy is any disease of the retina, usually associated with impairment of 
vision, distortion of objects and edema, and sometimes hemorrhages into the substance of 
the retina. Retinopathy is classified as background retinopathy, pre-proliferative 
retinopathy and proliferative retinopathy. Background retinopathy (shown in figure 3.1) is 
where there is partial occlusion of the small blood vessels in the retina which result in 
microaneurysms in the capillary wall. These microaneurysms are weak and capillary fluids 
leak out causing edema and intra retinal hemorrhages. pre-proliferative retinopathy 
indicated further destruction of retinal capillaries. Proliferative retinopathy (shown in 
figure 3.2) is the severe form and the capillaries become occluded, and new blood vessels 
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are formed to supply the retina with blood. It is cause by damage to the sensitive blood 
vessels in the eyes. (Pickup et al., 1991; Watkins, 2003; Sharma et al., 1993). 
 
 
 
 
 
Figure 3.1: Moderate Non-Proliferative Diabetic retinopathy 
 
 
 
 
 
Figure 3.2: Proliferative diabetic retinopathy with neovascularisation elsewhere 
There are many epidemiological studies that have established the various risk factors and 
provided guidelines for the management of diabetic retinopathy .Poor glycemic control is 
associated with retinopathy (Viswanath et al., 2003). The Diabetes Control and 
Complications Trial (DCCT) has shown that in Type 1 insulin dependent diabetes mellitus 
(IDDM), good control of metabolic status will reduce the risk of progression of diabetic 
retinopathy and delays the onset of retinopathy in patients who do not have retinal changes 
at the time of presentation (DCCT). The United Kingdom Prospective Diabetes Study 
(UKPDS) has confirmed that good glycaemic control in Type 2 non-insulin dependent 
diabetes mellitus is also beneficial and delays the onset of retinopathy (UKPDS). The 
duration of diabetes is probably the strongest predictor for development and progression of 
retinopathy (Donald et al., 2003).  Hypertension reports have indicated that high diastolic 
blood pressure in young individuals and higher systolic blood pressures in older 
individuals can worsen the retinopathy (Viswanath et al., 2003). Pregnancy in women can 
be associated with worsening of the retinopathy (Viswanath et al., 2003). Elevated 
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triglyceride and low HDL-cholesterol (Chaturvedi et al.,2001;Chaturvedi  et al., 2001) , 
and increased total and LDL-cholesterol (Watts et al.,1996) have been reported to predict 
diabetic retinopathy and diabetic nephropathy. 
 
2) Diabetic Nephropathy: 
Diabetes is the leading cause of end-stage renal disease in the U.S. and Europe, accounting 
for 44% of new cases per a year. The majority of future ESRD cases from diabetic 
nephropathy are preventable (ADA, 2002a; CDC, 2002a). In 2001, 42,813 people with 
diabetes began treatment for end-stage renal disease. Also in 2001, a total of 142,963 
people with end-stage renal disease due to diabetes were living on chronic dialysis or with 
a kidney transplant (CDC, 2002a). The cost for treatment of diabetic patients with ESRD in 
1997 was in excess of $15.6 billion (ADA,2002).About 20–30% of patients with type 1 or 
type 2 diabetes develop evidence of nephropathy, but in type 2 diabetes, a considerably 
smaller fraction of these progress to ESRD(ADA, 2002a ). End-stage renal disease (ESRD) 
develops in 50% of type 1 diabetic individuals with overt nephropathy within 10 years and 
in >75% by 20 years (ADA, 2002a). 
 Diabetic nephropathy is characterized by persistent albuminuria (albumin excretion rate 
>300 mg/24 h, declining glomerular filtration rate (GFR) and rising blood pressure. At its 
most severe, diabetic nephropathy results in end stage renal disease requiring dialysis or 
transplantation, but in the early stages overt disease is preceded by a phase known as 
incipient nephropathy (or microalbuminuria), in which the urine contains trace quantities of 
protein (not detectable by traditional dipstick testing). Microalbuminuria is defined as an 
albumin excretion rate of 20-300 mg/24 h or 20-200 µg/min in a timed collection and is 
highly predictive of overt diabetic nephropathy, especially in type 1 diabetes (Pickup et al. 
1991; Watkins, 2003; Sharma et al., 1993).  
The prevalence of microalbuminuria in patients with type 1 diabetes at 30 years disease 
duration is approximately 40% (SIGN, 2001). The prevalence of microalbuminuria and 
overt nephropathy in the “Pittsburgh Epidemiology of Diabetes Complications Study” was 
84% (males) and 59% (females) at greater than or equal to 30 yr duration (Orchard et al., 
1990a).  Anderson et al found that the cumulative incidence of nephropathy in type 1 
diabetes (Denmark) to be 41% at greater than 25 year of disease (Andersen ,1983).  
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The natural history of diabetic nephropathy is a process that progresses gradually over 
years. Early diabetes is heralded by glomerular hyperfiltration and an increase in GFR. 
This is thought to be related to increased cell growth and expansion in the kidney, possibly 
mediated by hyperglycemia itself. Microalbuminuria typically occurs after 5 years in type 
1 diabetes. Overt nephropathy, with urinary protein excretion greater than 300 mg/day, 
often develops after 10 to 15 years. End-stage renal disease (ESRD) develops in 50% of 
type 1 diabetic, with overt nephropathy within 10 years' time (Pickup et al., 1991; Watkins, 
2003; Sharma et al., 1993).There are several risk factors associated with nephropathy. 
Glycemic control is the major factor associated with disease risk. The Diabetes control and 
Complications Trial (DCCT) found that a reduction in mean HbA1c from 9.0% to 7.3% in 
people with Type 1 diabetes was associated with a 39% reduction in microalbuminuria and 
54% reduction in proteinuria over 6.5 years. However, no clear benefit was seen in the 
treatment of established microalbuminuria in people with Type 1 diabetes (DCCT, 
1993).Higher blood pressure and hypertension is associated with progression of diabetes 
renal disease (Krolewski et al., 1985).  The 10-year incidence of proteinuria performed by 
a population-based study in southern Wisconsin of individuals with diabetes  was 
significantly related to higher glycosylated hemoglobin level and diastolic blood 
pressure(Klein R & et al., 1995a).Cigarette smoking consider as a risk factors for diabetic 
nephropathy in type 1 diabetes (Scott  et al, 2001). Elevated triglyceride and low HDL-
cholesterol (Chaturvedi   et al.,2001; Chaturvedi et al., 2001) , and increased total and 
LDL-cholesterol (Watts et al.,1996) have been reported to predict diabetic nephropathy. 
Male sex and duration of disease are two independent risk factors for nephropathy and 
renal insufficiency (Orchard et al., 1990a).  
3) Diabetic Neuropathy:  
Diabetic neuropathy (DN) is a common disorder and is defined as signs and symptoms of 
peripheral nerve dysfunction in a patient with diabetes mellitus (DM) in whom other causes 
of peripheral nerve dysfunction have been excluded (Bansal et al., 2006). It is a rarely 
cause of death, it is a major cause of morbidity. It causes clinical manifestations and 
disabilities of diverse spectrum and considerable severity. Both peripheral nerves (sensory 
and motor) and the autonomic nervous system can be affected (UNRWA, 2004). About 
60% to 70% of people with diabetes have mild to severe forms of nervous system damage. 
The results of such damage include impaired sensation or pain in the feet or hands, slowed 
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digestion of food in the stomach, carpal tunnel syndrome, and other nerve problems. 
Severe forms of diabetic nerve disease are a major contributing cause of lower-extremity 
amputations. (CDC, 2002a).One of the first study was to document  the prevalence of 
neuropathy was the Rochester Diabetic Neuropathy Study ,which was a population-based 
cohort study of both type 1 and type 2 diabetes subjects ,in which Sixty-six percent of 
IDDM patients had some form of neuropathy; the frequencies of individual types were as 
follows: polyneuropathy, 54%; carpal tunnel syndrome, asymptomatic, 22%, and 
symptomatic, 11%; visceral autonomic neuropathy, 7%, and other varieties, 3%(Dyck et 
al.,1993). Diabetic neuropathy can be classified into four categories (Davidson, 1991) as 
shown in table 3.2. 
Table  3.2 Classification of diabetic neuropathy  
1 Peripheral neuropathy 
2 Autonomic neuropathy 
            a- Cardiovascular 
b-Gastrointestinal 
c-Genito-urinary 
d- Sudomotor 
e-Hypoglycemia unawareness 
3 Acute-onset neuropathy 
4  Neuropathic diabetic cachexia 
 
Health behavior variables(recent medical contact, better control of dyslipidemia and blood 
pressure, regular glucose monitoring, lower glycated hemoglobin, physical activityin 
youth, and regular consumption (at least weekly) of alcohol) were more prevalent in 
subjects without complications. Using logistic regression, glycated hemoglobin level was 
the only independent predictor of complications after adjusting for health behavior 
Variables (Orchard, 1990b). 
II.   Macro vascular (Associated disease): 
1) Cardio vascular disease: Coronary artery, cerebrovascular, and peripheral vascular 
diseases are two to three times more common in people with diabetes than in general 
population (Davidson, 1991).Deaths from cardiovascular disease predominant in patients 
with diabetes of over 30 year's duration and in those diagnosed after 40 years of age 
(Pickup et al., 1991).Heart disease is the leading cause of diabetes-related deaths. Adults 
with diabetes have heart disease death rates about 2 to 4 times higher than adults without 
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diabetes. (CDC, 2002a). It accounts for approximately 50% of all deaths among people 
with diabetes in industrialized countries. (WHO, 2002), the risk for stroke is 2 to 4 times 
higher among people with diabetes, Risk factors for heart disease in people with diabetes 
include smoking, high blood pressure, high serum cholesterol and obesity( WHO 2002 ; 
Pickup J et al., 1991).The Pathogenesis of diabetic coronary heart and cardiovascular 
disease is not fully understood(Vinik and Flemmer, 2002). But it is likely that 
hyperglycemia promotes the reaction of glucose with components of the arterial wall to 
form advanced glycation products. These products cross-link with collagen, thereby 
increasing arterial stiffness (Bate and Jerums, 2003). In dyslipidaemia, increased levels of 
low-density lipoprotein (LDL) cholesterol, consisting mostly of small dense particles, 
promote atherogenesis. Hypertension promotes the development and progression of 
vascular disease (Bate and Jerums, 2003). 
The major risk factors for coronary heart disease are increased level of serum cholesterol 
and elevated level of blood pressure.70-90% of diabetic people have dyslipidaemia (Fagot-
Campagna et al., 2000).The UKPDS show that the risk of angina and myocardial infarction 
increase 1.57 fold time with an increase of 1mmol/L of LDL (Turner et al.,1998).Blood 
cholesterol was shown to be related to the coronary heart disease in the Steno clinic type 1 
populations(Jensen et al.,1987).In the UKPDS men with hypertension show higher 
prevalence to develop coronary heart disease and non-fatal and fatal  myocardial infarction 
(Turner et al.,1998). The prevalence of coronary heart disease in Pittsburgh Epidemiology 
diabetes complications study was associated with diabetes duration, hypertension, 
nephropathy and elevated TG (Maser et al., 1991).Among type 1 diabetic patient ,the 
WESDR study found that an significant association between HbA1c and four-year 
incidence of ischemic heart disease(Klein ,1995).There are many other risk factors that 
increase coronary heart disease .Microvascular complications increase the risk of coronary 
heart disease, microalbuminuria increase the risk for coronary heart disease in diabetic 
patients(Gall et al .,1995). 
2)   Diabetic foot: 
Foot ulceration, sepsis, and amputation in diabetic patient are almost present and increase 
with poor glycemic control and duration of diabetes, and this is a major cause of morbidity 
and disability of diabetic patient. Neuropathy and ischemia are the principal disorders 
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underlying foot problems. Figure 3.3 & figure 3.4 illustrate both ulcers how they are look 
in diabetic patient (Watkins, 2003).  
In the United State more than 60% of nontraumatic lower-limb amputations occur among 
people with diabetes. In 2000-2001, about 82,000 nontraumatic lower-limb amputations 
were performed annually among people with diabetes (CDC, 2002). The cause of a 
diabetic foot is peripheral neuropathy with loss of sensatation, peripheral vascular disease, 
callus, and foot bony deformity, and infection (WHO, 2002). 
 
 
 
 
 
Figure 3.3 Neuropathy ulcers in diabetic patient 
 
 
 
 
 
Figure 3.4 Ischemic ulcers in diabetic patient 
 
3.6 Diabetes diagnosis and services  
I.  Diagnosis 
The American Diabetes Association criteria for the diagnosis of diabetes include symptoms 
of diabetes and a casual plasma glucose ≥200 mg/dl (11.1 mmol/l). Casual is defined as 
any time of day without regard to time since last meal. The classic symptoms of diabetes 
include polyuria, polydipsia, and unexplained weight loss. The American Diabetes 
Association (ADA) recommends cutoff value for the diagnosis and classification of 
diabetes and for a fasting plasma glucose level indicative of diabetes mellitus. The 
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recommended cutoff point for the diagnosis of diabetes is now a fasting plasma glucose 
level of 126 mg/dl (7.0 mmol/L), versus the traditional value of 140 mg per dL (see table 
3.3) (7.8 mmol/L). Table 3.3 presents the criteria for the diagnosis of diabetes (ADA, 
2003; Peter, 2003).   
Diagnosis of type 1 diabetes is usually straightforward and requires little or no specialized 
testing. Most children and adolescents with type 1 diabetes present with a several-week 
history of polyuria, polydipsia, polyphagia, and weight loss, with hyperglycemia, 
glycosuria, ketonemia, and ketonuria. Glycosuria alone, especially without ketonuria, may 
be caused by a low renal glucose threshold. Thus, an elevated blood glucose concentration 
must be documented to diagnose diabetes (ADA, 2005).  
Table 3.3  Criteria for the diagnosis of diabetes  
• Symptoms of diabetes plus casual plasma glucose concentration 200 mg/dl (11.1 
mmol/l). Casual is defined as any time of day without re g a rd to time since last meal. 
The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight 
loss. 
Or  
 
• FPG 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h. 
 
Or 
 
• 2-h PG 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as 
described by the World Health Organization, using a glucose load containing the 
equivalent of 75-g anhydrous glucose dissolved in water. 
 
In the absence of unequivocal hyperglycemia with acute metabolic decompensate, these criteria should be 
confirmed by repeat testing on a different day. The third measure (OGTT) is not recommended for routine 
clinical use. Adapted from the report of the expert committee on the diagnosis and classification of diabetes 
mellitus (ADA, 2003). 
 
 
2)    Insulin therapy and action 
The patient with type 1 diabetes has lost the ability to produce insulin and is therefore 
dependent upon externally administered insulin without which they would die. The 
treatment of type 1 diabetes is therefore relatively straight forward; insulin, which act  as a 
major tool in the treatment of type 1 diabetes in spite of the impossibility of giving it in a 
physiological way (Larsson , 1997). Factors such as onset, peak and duration of action can 
influence the ability of a particular insulin regimen to help control glucose levels. Patient 
factors, including individual variations in insulin absorption, levels of exercise and types of 
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meals consumed, also influence the effectiveness of an insulin regimen. (Hirsch, 1999; 
Raskin et al., 2000). The different types of insulin injection range from short-acting and 
intermediate to long-acting, the important characteristics of each type of insulin are: the 
onset (i.e. when it starts to work), the peak activity (i.e. when it works hardest), and the 
duration (i.e. how long it lasts). Table 3.4 summarizes the different kinds of human insulins 
and how they act. 
 
Table 3.4 Kinds of human insulin and how they act 
Type Onset Peaks Duration 
 Regular   
NPH 
Lente 
Ultralente 
Lispro (Humalog) 
70/30 
30-60 minutes  
2-4 hours 
3-4 hours 
6-10 hours 
Less than 15 
minutes 
15-30 minutes 
2-3 hours  
4-10 hours 
4-12 hours 
minimal peaking 
30-90 minutes 
2-3 hours & 8-12 hours 
4-6 hours  
14-18 hours 
16-20 hours 
20-30 hours 
Less than 5 hours 
18-24 hours 
 
The major function of insulin is to counter the concerted action of a number of 
hyperglycemia-generating hormones and to maintain low blood glucose levels between 54-
144 mg/dl (3-8 m mole/L). When food ingestion and absorption causes arise in blood 
glucose which almost factors that stimulate insulin secretion from the beta cell of the 
pancreas which act to maintain a constant level of blood glucose by decreasing glucose 
output from the liver and increasing glucose intake and glycogen formation in the muscles 
.Insulin increases the conversion of glucose to glycogen in the liver , promotes the uptake 
and utilization of glucose by muscles and adipose tissue, and suppress the production of 
glucose from fats and proteins in the liver. Insulin also Stimulates entry of amino acids into 
cells, enhancing protein synthesis, enhances fat storage and prevents mobilization of fat for 
energy (lipolysis) (Alberti et al., 1997). 
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In developed countries the problem with insulin therapy lies not in access to insulin, 
syringes or blood glucose monitoring, as it does in developing countries, but in how to use 
them correctly to achieve near-normoglycaemia (King et al., 1999). In the EURODIAB 
IDDM Complications Study of Type 1 diabetic patients in 16 European countries, only 
16% of patients had a normal HbA1c (EURODIAB IDDM Complications Study, 1994).  
 
3.7 Management and follow up and control 
There is no known method to prevent type 1 diabetes according to diabetes control and 
prevention of WHO (WHO, 1994; Rewers, 1997). The high and increasing incidence, 
associated with severe morbidity, mortality and enormous health care expenditure, makes 
Insulin dependent diabetes Mellitus (IDDM) a prime target for prevention. The aim of 
treatment is to achieve glycemic control and to reduce and delay the appearance of 
diabetic complications. In treatment of type 1 diabetes, self-care and education, insulin 
therapy type and dose, health care provider, Screening for the long-term complications of 
diabetes ,diet and home monitoring of glucose are consider to play a corner stone role in 
controlling the disease and in prevention or the delay of early and late complications                
( LeRoith  et al., 2005; Doresy et al. ,2006). Self-control led therapy is vital in the 
treatment of  IDDM, allowing as it does, correct insulin therapy, a reduction in 
hospitalization and modification of therapy for individual needs in relation to various 
factors. Undoubtedly it is the responsibility of the diabetes team (doctors, nurses, 
dietician, psychologist and social assistant) to instruct the patient and help him /her in this 
new situation.( Lombardo  et al.,2003). 
1) Monitoring and Glycemic Control Assessment: 
Glycemic control is fundamental to the management of diabetes. The goal of therapy is to 
acheive an HbA1c as close to normal as possible (representing normal fasting and 
postprandial glucose concentrations) in the absence of hypoglycemia.HbA1c is a measure 
of the non-enzymatic attachment of glucose to the ß chain of hemoglobin and is expressed 
as the percentage of hemoglobin that is glycated. In the non-diabetic population this is 
approximately four to six per cent. Since the life-span of a red blood cell is approximately 
120 days, HbA1c gives an indication of average glycaemia over a 60 day period (BMA, 
2004).Although the relationship between HbA1c and plasma glucose is complex, the 
extensive data collected from the DCCT has been defined table 3.5. 
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Table 3.5 Relationship between HbA1c and approximate mean plasma glucose levels  
Percentage HbA1c Approximate mean 
plasma glucose (mmol/l) 
4 3.5 
5 5.5 
6 7.5 
7 9.5 
8 11.5 
9 13.5 
10 15.5 
11 17.5 
12 19.5 
 
Prospective randomized clinical trials such as the DCCT and the U.K. Prospective Diabetes 
Study (UKPDS) have shown that improved glycemic control is associated with sustained 
decreased rates of retinopathy, nephropathy, and neuropathy. In these trials, treatment 
regimens that reduced average A1C to 7% ( 1% above the upper limits of normal) were 
associated with fewer long-term microvascular complications (DCCT, 1993; UKPDS, 
1998). 
 
2)    Home monitoring and Self-care: 
Home blood glucose monitoring is one of the corner-stones in the management of type 1 
diabetes (Blohme , 1983). Major clinical trials assessing the impact of glycemic control on 
diabetes complications have included SMBG as part of multifactorial interventions, 
suggesting that SMBG is a component of effective therapy (ADA, 2003). Good metabolic 
control was associated with numerous daily measurements of blood glucose whereas no 
independent connection was found between the form of treatment and the level of 
regulation (Wengler et al., 1989). The decrease in hemoglobin A1C concentration 
associated with increase number of   reagent strips used (Josie et al., 1999). 
Diabetic patients should be taught and encouraged to test their urine for glucose and 
ketones, although this is not as accurate as blood glucose monitoring, they need to be 
taught that the basis for urine glucose measurement is that glucosuria is correlated with 
hyperglycemia. Ketone testing is an important part of monitoring in type 1 diabetic patient, 
in pregnancy with pre-existing diabetes, and in gestational diabetes. The presence of 
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ketones may indicate impending or even established ketoacidosis, a condition that requires 
immediate medical attention. Patients with type 1 diabetes should test for ketones during 
acute illness or stress or when blood glucose levels are consistently elevated (e.g., >300 
mg/dl [>16.7 mmol/l]), during pregnancy, or when any symptoms of ketoacidosis, such as 
nausea, vomiting, or abdominal pain, are present (ADA, 2003, Bassili et al., 2001). 
Home blood pressure monitoring is of value in the management and monitoring of diabetic 
children (Gompels and Savage, 1992). In general every 10 mmHg reduction in systolic 
blood pressure the risk of any complication related to diseases is reduced by 12%, and can 
reduce heart disease by approximately 33% to 50 % and can reduce micro vascular disease 
by approximately 33% (CDC, 2002 b). 
 
3) Protocols of follow up of diabetes type-1 patients: 
Primary care providers are the main source of care for patients with chronic disease 
(Clancy et al., 1997).Studies examining the quality of care delivered by provider type 
(generalist or specialist physician) in chronic diseases have generally demonstrated that 
specialists adopt newer, more effective treatment techniques and may be more cost-
effective when compared with generalists (Levetan et al .,1999). Attendance at diabetic 
clinics forms part of diabetic management. Diabetic patient should attend diabetic clinics 
monthly for check up or as indicate by health care providers. Diabetic clinics exist to 
review treatment and control blood glucose, to screen for early detection of complications 
and for ongoing health education. Poor glycemic control was found in diabetic patient who 
were attending diabetic clinic infrequently compared to those who attended regularly 
(Jacobson  et al., 1997). 
The recommended protocol for monitoring patients with diabetes according to American 
Diabetes Association include two basic guidelines physical assessment and lab 
examination  as shown in table 3.6 (ADA ,2002).  
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Table 3.6  ADA Protocols for diabetes diagnosis 
Physical Assessment Lab Exam 
Blood Pressure, Weight (for children, add 
height; plot on growth chart) Every visit. 
Blood pressure target goal<130/80 mmHg 
(children<90 pctl age standard). 
 Children: normal weight for height (see 
standard growth chart). 
HbA1c 
Quarterly, if treatment changes or is not 
meeting goals; 1-2 times /year if stable. 
Target goal < 7% 
Foot Exam 
Through visual inception every diabetes visit; 
pedal pulses , neurological exam annually. 
Kidney Exam(Microalbuminuria) 
Albumin/Creatinine Ratio 
Type 1: 5 years post diagnosis, then every 
year until confirmed positive. 
Eye Exams  
Type 1 diabetes: comprehensive eye 
examination by an ophthalmologist within 3-5 
years after the onset of diabetes, then every 
year 
Pregnant women (diabetic) should have a 
comprehensive eye examination in the firs 
trimester and follow up through pregnancy and 
for 1 year postpartum 
Blood lipids 
In children >2 years of age, perform a 
lipid profile after diagnosis of diabetes 
and when glucose control has been 
established. If values are considered low 
risk and there is no family history, 
assessments should be repeated every 5 
years. 
 
 
3.8 Risk factors for diabetes type 1 and its complications 
Several risk factors have been suggested to be of importance for development of macro and 
microvascular complications in type 1 diabetes ( Table 3.7).Long-term glycemic control 
and diabetes duration are well-known risk factors for the development of microvascular 
complications in type 1 diabetes, and it has also been shown that intensive insulin treatment 
and improved glycemic control delays the onset and slows the progression of these 
complication, while the other association have been more controversial with partly 
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contradictory finding in different studies. The causal relationship between these factors and 
the development of complications is unclear and better term would be risk markers. 
Table 3.7 Possible risk factors for long term diabetic complications 
I.         Duration of diabetes 
II.        Metabolic control 
III.       Gender 
IV.        Age at onset and Puberty 
VI         Lipid profile 
VII        Blood pressure 
VIII.      BMI 
IX.         Smoking 
X.          Genetic factors 
XI.          Insulin resistance 
  
 
I.         Duration of diabetes  
 
Practically all studies demonstrate increasing prevalence of severe complications after 
longer diabetes duration, but the pattern differs between nephropathy, retinopathy, and 
neuropathy. 
By 25 years’ duration of type 1 diabetes, 25–40% of patients will have developed renal 
complications. The incidence of diabetic nephropathy increases steeply after 10 years of 
disease and then declines once again after 30 years (Andersen et al., 1983; Rossing et al., 
1995). The incidence peak of diabetic nephropathy occurs during the second decade of 
TIDM and declines thereafter (Andersen et al., 1983). While only a slight increase in the 
prevalence of microalbuminuria has been observed during the second decade of diabetes in 
young adult patients (Joner et al., 1992). 
Most studies demonstrating a relationship between microalbuminuria and progression to 
diabetic nephropathy have included subjects with a mean duration of diabetes <17 years 
(Mathiesen et al., 1994)  
The duration of diabetes may have less influence on diabetic nephropathy and 
microalbuminuria than on retinopathy. Prevalence of retinopathy increases with increasing 
duration of the disease, since one third of patients with duration between 10 and 12 years 
have retinopathy (Kernell et al., 1997), and nearly all of those with duration of 20 years or 
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over have it to some degree (Olsen et al., 2000; Kokkonen et al., 1994). Patients with type 
1 diabetes diagnosed between 10 and 30 years of age may experience significant retinal 
changes within ten years thereafter (Joner et al., 1994), and proliferative retinopathy 
appears to 4% of those who have had diabetes for 10 years, 25% of those with 15 years of 
diabetes (Klein et al., 1984), and 30% of those who have had it for over 20 years 
(Kokkonen et al., 1994). 
Most studies show that duration of diabetes in addition to poor diabetic glycemic control 
have a negative impact on peripheral nerve function in children and adolescents with type 
1 diabetes (Ziegler et al., 1991;DCCT, 1993). 
Macrovascular complications developed in people who were older, and had longer duration 
of diabetes (Latika et al., 2006) 
Metabolic control 
Several studies have demonstrated the effects of improved glycemic control on 
microvascular ,macrovascular, and neurological complications of diabetes. The rate of 
background retinopathy in the Berlin Retinopathy Study was found to increase with 
deteriorating glycaemic control, the greatest progression being observed in patients with 
long-term HbA1c within the highest quartile (Danne et al., 1994). The progression of 
diabetic retinopathy in adolescent patients with high HbA1c and long duration of diabetes 
was twice comparing to patients without these risk factors (Bonney et al., 1995). Javitt et al 
models predicted that 72% of patients with type 1diabetes and inadequate metabolic 
control would develop proliferative retinopathy at some stage in their life-time (Javitt et 
al., 1989). 
In patients with type 1 diabetes mellitus the progression of minimal albuminuria and the 
development of microalbuminuria are determined primarily by poor long term glycaemic 
control (Powrie et al., 1994), and poor control during the first years of diabetes in particular 
may later predispose to microalbuminuria (Rudberg et al., 1993). 
Rossing et al reported that the relative risk for progression from normoalbuminuria to 
micro- or macroalbuminuria in a large prospective study from Denmark was 1.13 (95% 
confidence interval, CI 1.04–1.23) for patients with poor metabolic control (Rossing et al., 
2002). Improvement of metabolic control will improve nerve conduction, which is slightly 
reduced at the time of diagnosis of type 1 diabetes, (Dahl-Jørgensen  et al., 1986), and 
long-term normoglycaemia retards the development of peripheral nerve dysfunction 
(Amthor et al., 1994). The Oslo study show that decreases in motor and sensory nerve 
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conduction velocities along with deterioration of glycaemic control, independently of other 
parameters (Amthor et al., 1994). The role of chronic hyperglycemia for the development 
of Cardiovascular disease in type 1 diabetes is unknown (Nathan et al., 2003). 
Gender 
The effect of sex on the risk of microvascular complications of type 1 diabetes is partly 
controversial. Men have a higher risk of nephropathy than women (Andersen et al., 1983), 
whereas no such clear relationship with sex has been demonstrated for elevated urinary 
AER or microalbuminuria (Canton et al., 2004; Ammari, 2004). 
The risk of ESRD did not differ significantly between sexes (Finne, 2005).  Retinopathy is 
more frequent in males (Pinto-Figueiredo et al., 1992). The EURODIAB Study reported 
moderate non-proliferative diabetic retinopathy to be significantly less frequent in women 
than in men, but mild nonproliferative and proliferative diabetic retinopathy did not differ 
between the sexes (Sjolie et al., 1997). Distal symmetrical polyneuropathy shows a 
constant rise with duration and is only marginally higher in men (Orchard et al., 1990). 
coronary heart disease (CHD) incidence rate was slightly higher in males, while lower-
extremity arterial disease (LEAD) incidence rate was slightly higher in females( Forrest et 
al., 2000),in other study the prevalence was the same in both sexes(9% in men and 10% in 
women) (Koivisto, 1996). 
 
Age at onset and Puberty 
 
The observation that puberty is the watershed for the development of diabetic 
complications indicates that hormonal factors may be important.  
The prevalence of early diabetic retinopathy in pubertal patients with type 1 diabetes was 
significantly greater than prepubertal subjects (Rogers et al., 1987), while it is extremely 
rare in children younger than 10 years, regardless of the duration of diabetes (McNally et 
al., 1993). In a Swedish multi center study, regardless of diabetic retinopathy stage, it was 
detected in 6% of the prepubertal patients compared with 18% of the post pubertal patients 
with a similar duration of diabetes (Kernell et al., 1997). 
Prepubertal hyperglycemia in type 1 diabetes contribute to the risk of microalbuminuria 
during puberty and postpubertal(Schultz et al., 1999). Pubertal development seems to 
initiate or accelerate the progression of microalbuminuria or early kidney damage in type 1 
diabetes (Schultz et al., 1999; Barkai et al., 1998).  
Some studies have emphasized that microalbuminuria is more frequent in early than late 
puberty (Janner et al., 1994). The progression of AER and the risk of persistent 
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microalbuminuria are higher in pubertal patients than in prepubertal or postpubertal ones 
(Barkai et al., 1998), while if microalbuminuria is diagnosed at the end of puberty, it is 
more likely to progress than regress (Rudberg and Dahlquist , 1996). 
 
Lipids and lipoproteins 
 Elevated triglyceride and low HDL-cholesterol (Chaturvedi et al.,2001; Chaturvedi et al., 
2001) , and increased total and LDL-cholesterol (Watts et al.,1996) have been reported to 
predict diabetic retinopathy and diabetic nephropathy. High density lipoprotein cholesterol 
predicts CVD in EURODIAB IDDM Complications Study, while triglycerides and 
hypertension predict CVD in the Pittsburgh Epidemiology of Diabetes Complications 
Study (EDC) (Orchard et al., 1998). 
Blood pressure 
Numerous studies have demonstrated that increased systolic or diastolic blood pressure is a 
powerful predicator of microvascular complications. The 10-year incidence of proteinuria 
performed by a population-based study in southern Wisconsin of individuals with diabetes 
was significantly related to higher glycosylated hemoglobin level and diastolic blood 
pressure (Klein et al., 1995). Although hypertension is almost always associated with 
diabetic nephropathy in TIDM, elevations in routine office BP have not consistently been 
identified before the onset of MA (Schultz et al., 2001). However, one small study reported 
that an increased night to day ratio of arterial BP might precede the development of MA in 
which measured 24 hour ambulatory BP was measured (Poulsen et al., 1994), although BP 
may not be important in the initiation of diabetic retinopathy, a higher diastolic BP, even 
within the normal range, may increase the risk of progression of retinal lesions( Lloyd et al 
1995). The presence of micro- or macroalbuminuria may also modify the effect of BP on 
the progression of retinopathy (Lloyd et al., 1995). Hypertension showed the greatest 
impact on the development of  clinical neuropathy in adult patients with type 1 diabetes, in 
addition to other risk factors such as poor metabolic control, smoking, duration of diabetes 
and height(Forrest et al., 1997). 
BMI 
Overweight (BMI 25 kg/m2) and obesity (BMI ≥30 kg/m2) are becoming increasingly 
prevalent in the industrialized world, not only in type 2 but also in type 1 diabetic patients 
(Christophe et al., 2005). The role of body weight/BMI in the development of vascular 
complications of diabetes is unclear. However, information on the possible role of BMI on 
45 
 
retinopathy in type 1 diabetes is scarce. Zhang et al revisited data from the Diabetes 
Control and Complications Trial and observed that besides diabetes duration and metabolic 
control, BMI had a significant predictive value in developing retinopathy (Zhang et al., 
2001). In Sweden, Henricsson et al observed that time to develop retinopathy among 
young adult people with diabetes was related to high HbA1c (A1C) and high BMI 
(Henricsson et al., 2003). Only one recent report suggested a role of BMI in neuropathy 
(Tesfaye et al., 2005). BMI above 30 kg/m2 show significant relation ship with CVD 
(Ammari, 2004; Latika et al., 2006).  
Smoking 
The evidence for cigarette smoking as a risk factor for diabetic nephropathy in type 1 
diabetes has been inconsistent. Many studies have found significant association between 
cigarette smoking and advanced stages of diabetic nephropathy (Muhlhauuser et al.,1986; 
Mühlhauser et al., 1996), but other study has not supported this association (Klein et al., 
1995). The discrepancies might have resulted from increased mortality of those who 
smoked cigarettes. Significant association between the development of microalbuminuria 
and smoking was reported in a few studies (Chase et al., 1991, Chaturvedi et al., 1995), 
while other studies have not show like this association (DCCT, 1995).The connection 
between smoking and retinopathy is also controversial. Some authors have found clear 
association between progressions, prevalence and worsen of retinopathy and smoking 
(Muhlhauser et al., 1996, Chaturvedi et al., 1995; Chase et al., 1991), while other authors 
failed to demonstrate this connection (Moss et al., 1996). The diverging results could in 
part be explained by not adjusting for the possible confounding effect of metabolic control 
in some studies. Psychosocial factors could speculatively affect both smoking habits and 
the possibility to achieve a good metabolic control (Chaturvedi et al., 1995). 
 
Genetic factors 
 
The risk of diabetic complications is most likely partly inherited. A family history of either 
diabetic nephropathy or retinopathy is associated with an increased risk of these 
complications in relatives with TIDM (DCCT, 1997). The risk of nephropathy is increased 
in patients who have siblings with type 1diabetes and nephropathy. This familial clustering 
suggests that genetic factors are important in the development of renal disease (Seaquist et 
al., 1989; Quinn et al., 1996). Furthermore, parental hypertension and parental type 2 
diabetes are also associated with nephropathy risk in the offspring (Roglic et al., 1998; 
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Krolewski et al., 1988; Fagerudd et al., 1999). However, one study investigated parental 
factors in 300 young subjects and found that familial cardiovascular disease were 
associated with MA in the offspring(Rudberg et al., 1998).Thus family phenotypes may be 
useful markers of risk of microvascular disease. 
 
Insulin resistance 
Is emergent risk factor for both macro- and microvascular complications in type 1 DM 
(Chaturvedi et al., 2001; Chaturvedi et al., 2001). but it is not clear if this phenomenon is 
mediated by associated risk factors (Porta et al .,2001)) or a common genetic determinant 
(De Cosmo et al .,2000 ;Lustman et al.,2000). 
 
3.9       Summary 
As was shown in the conceptual framework diagram, this model content has been reflected 
in the questionnaire and the objective testing and physical examination that was done in 
this survey. This was done in the following matter: 
In the questionnaire: Questions 1-13 reflects the demographic factor, questions 14-20 
reflects physical measurement .questions 21-28 reflect diabetes history. Questions 29-30 
reflect diabetes treatment, questions 31-41 reflect diabetes complications, questions 42-47 
reflect self monitoring, and questions 48-55 reflect PHC services and physical and 
screening examinations. 
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4.1   Introduction 
      
This study focuses on diabetic patients’ type 1. The emphasis was on identifying the 
treatment and follow up protocols used for those patients and the prevalence of disease 
complications. In this chapter the research methodology: i.e. the study geographical area, 
study population, study design, and the sampling method are described.  Study tool and the 
objective testing that were used to collect the data and testing those patients, in addition to 
statistical analysis method are also described.  
    
4.2   Ramallah socio-demographic and geographic area description 
 
Ramallah District is located in the middle part of the West Bank, extends from Jerusalem 
District in the south to Nablus District in the north and from Jericho District in the east to 
the 1948 cease-fire line between Israel and Jordan from the west (see figure 4.1A,and 
figure4.1B).  
 
 
Figure 4.1: Ramallah District location 
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 Figure(4.1B):Ramallah district 
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Demographic trends in Ramallah District, as is the case of other districts in the West Bank, 
have been closely related to the political situation. According to the population statistics 
estimated by the Palestinian Center Bureau of Statistics (PCBS), the mid year total 
population of 2004 was around 285,000 individuals, which includes the four refugee camps 
population. The population of Ramallah and Al-Bireh cities comprises approximately 26% 
of the total population of the district, while those living in rural areas present 65% of the 
total population. Approximately 9% (16,500) lives in the four refugee camps, i.e. Al-
Ama'ri, Al-Jalazone, Qaddura and Deir A'mmar (PCBS, 1994; UNRWA Report, 1994).  
Ramallah District has a very young population with 58.4 % less than 18 years old, with a 
1:1 male to female ratio.   
The dominant economic activity in Ramallah District is the manufacturing industry. The 
major industrial activities are centered on food processing and the manufacture of 
pharmaceuticals (Center for Engineering and Planning, 1993). The economy of Ramallah 
District is affected by the political situation in the area. Approximately 63.2% of the 
working age population (16-59) is employed. Out of which 81.3% are permanently 
employed, 6.1% have seasonal employment, and 12.6% have part-time jobs. The 
unemployment rate is nearly 36.8% (PARC & Arab Thought Forum, 1994). A large 
number of people from Ramallah District have immigrated to other countries especially to 
the United States of America. Those people retain their strong relations with their families 
and their homeland and send money back to be invested in economic activities. With these 
added resources, Ramallah became the economic center in the West Bank. During the past 
two years, Ramallah city has developed at a high rate where many new commercial centers 
and housing projects have been constructed and many investors started their own 
businesses.  
 
4.3   Health services in Ramallah District 
 
The Palestinian health care system is a mixture of governmental, non-governmental, 
United Nation Relief and Work Agency (UNRWA) and private (profit and non-profit) 
service delivery.  These health providers are over lapping in services, and none of these 
sector can provide comprehensive health services. 
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A- Primary Health Care services 
There are approximately 55 primary health care clinics (PHC) in Ramallah District, 41 are 
sponsored by the Ministry of Health (MOH), 9 PHC clinics are operated by various non-
governmental organizations, and UNRWA runs 5 PHC clinics serving the refugees (MOH-
PHIC, 2004). 
 
B- Secondary health care services: 
Five hospitals provide the secondary health care services to the residents of Ramallah 
District. In total, there are 186 hospital beds which are insufficient to provide satisfactory 
health services to more than 176,154 people in the district. The main governmental 
hospital is Ramalllah hospital, which is always crowded and patients must wait several 
weeks for an appointment. While there are higher quality hospitals in Jerusalem, closure of 
Jerusalem greatly restricts people living in Ramallah District from using these facilities 
even though they are only few kilometers away (PCH ,1994). 
 
C-Health care services provided for diabetic patients 
Two main health care providers provide health care for diabetes type I patients, i.e.  the 
MOH and UNRWA PHC centers at Ramallah district.   These two providers provide care 
and treatment especially insulin for type I diabetic patients.  The Governmental health 
sector is providing special health services to diabetes patients through the clinics present in 
every PHC centers in all cities of the Palestine. The diabetes program of MOH is to a large 
extent biometrically oriented. Diabetic patients who are insulin dependent and have health 
insurance get their insulin free of charge. Similarly, the UNRWA provides services for the 
diabetic registered refugee patients free of charge and also provide them monthly with the 
needed insulin (personal communications, 2006). 
 
4.4        Study population  size 
 
It is well known that PHC centers are the main venues for regular and systematic care for 
diabetic patients. Management services for non-communicable diseases care are integrated 
within the PHC centers at MOH & UNRWA centers.  For our study the source of data was 
found in one MOH clinic and three UNRWA clinics at different PHC centers at Ramallah 
district.  
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The study focus on type 1 diabetes mellitus patients receiving health care in the PHC 
centers of UNRWA and MOH at Ramallah district. The original sample consists of all 
patients of diabetes type 1 of both males and females in the different age groups.    
Information about these patients was extracted from their files that presented in the clinics 
and a prepared list was done to approach these patients when they come in their monthly 
visits to the clinics.  
According to the registration’s files of diabetic patients at primary health care centers of 
MOH and UNRWA at Ramallah district, the number of patients with type 1 diabetes was 
142 patients, but only 116 were included in the study. The distributions and agreement to 
participate in this study is shown in table 4.1. 
 
Table 4.1: the distributions and participation of diabetic type I 
No response 
No (%) 
Agree 
No (%) 
No of patient 
21(14.8%) 81(57%) MOH 102 (71.8%)  
5 (3.6%) 35(24.6%) UNRWA 40 (28.2%) 
26(18.3%) 116(81.7%) Total number 142(100%) 
. 
 
4.5       Study design 
The study was cross-sectional  . This design was chosen to meet the objective of the study, 
namely to determine the complications of diabetes and primary health care services for 
type 1 diabetic patients at Ramallh district. Information on complications, primary health 
care services, and other risk factors was collected at two levels, the first one included  
interview-only data and the second with objective testing( HbA1c testing, lipid profile 
...etc) and physician’s examination(Eye examination, neuropathy ...etc). 
 
4.6    Study tools and equipment 
4.6.1  The interview questionnaire  
A pre-designed questionnaire was used by the researcher.  Previously validated 
questionnaires were used to develop the study questionnaire. This questionnaire was 
selected from different previous studies (Abu Mousa, 1998; Siddiqui et al., 2003) 
Questionnaire was developed for the study with the aim to cover the most important areas 
of interest regarding the patient s life and the services offered in the studied PHC centers.  
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The study interview questionnaire was divided into the following sections: 
1. First part: demographic data such as sex, age, marital status, education completed, 
occupational history. 
2. Second part: the vital measurement of people with diabetes such as present weight, 
height, blood pressure, HbA1c value.  
3. Third part: the history of disease. 
4. Fourth part: diabetes management through diet, and insulin medications.  
5. Fifth part: clinical status and complications (history of cardiac disease, presence of 
neuropathy, presence of retinopathy, presence of nephropathy, presence of 
amputation, hypertension and hospitalization due to diabetes) 
6. sixth part: primary  health care therapy protocol e.g., blood glucose testing, insulin 
administration, number of visits to physicians, etc. 
7. Seventh part: Includes questions on home monitoring (testing blood glucose, 
measure BP, and urine glucose and ketone test (see appendix 1). 
  
4.6.2 Questionnaire piloting and validation 
 
The questionnaire was piloted before using in the field. At initial stage of survey, a pilot 
test was provided on patients from the two settings of interest. Twenty patients of type II 
diabetic for pilot study were selected from those who attended the diabetic clinics of MOH 
and UNRWA. Interview was held in the clinic after the patient has been told about the 
study and its’ aims, acceptance to participate in the study was noted in most patients. 
The main aim of the pilot study was to examine the study instrument (the questionnaire) 
and to determine the ability of the study method to cover and efficiently lead to the desired 
goals .As a result of the pilot study, there were some necessary modifications on some 
questionnaire elements. 
For questionnaire validation, the contents of the questionnaire were discussed with experts 
and specialists in the field of diabetes mellitus in governmental, UNRWA and NGOs to 
ensure that the core content is highly valid and reliable.  
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 4.6.3 The objective testing: 
All patients filling the questionnaire at the first stage were scheduled for having biomedical 
testing, blood pressure and ECG, ophthalmologist consultation and endocrinologist 
consultation.  
 
a- Biochemical blood testing:   
A fasting blood sample was taken by venipuncture; this sample was divided into two tubes. 
One tube has an EDTA anti coagulant used for measurement of HbA1c, the second tube 
which is an plane tube used for measurement of   Glucose ,Urea ,Creatinine ,and Lipid 
profile.  
      1. Glycohemoglobin HbA1-Test: measurement of HbA1c using the Fast Ion- 
  Exchange Resin Separation method produced by Human Company which has a     
       Batch no 10658. Normal and abnormal control was run with each set of 
       analysis to insure internal quality control.                                                                                 
2. Fasting blood testing: Glucose determination was done by GOD-PAP assay without 
deproteinisation produced by Randox Company which has batch no 057802. Semi 
micro procedure was used in which 10µl of serum sample, standard, and control were 
added to 1 ml of glucose reagent, then incubation at 37˚ C for the required time. 
Reading for the test tubes was taken by spectrophotometer and finally calculation was 
done to get the final result depending on the result of controls.  
 
3.   Creatinine was measured by colorimetric method (picric acid), produced by 
Randox company which has patch no 1040CR. Semi micro procedure was used in 
which 100µl of serum sample, standard, and control were added to 1 ml of working 
reagent of picric acid and sodium hydroxide, then incubation at 37˚ C for the required 
time. Reading for the test tubes was taken by spectrophotometer and finally calculation 
was done to get the final result depending on the result of controls.  
4. Urea, BUN: Urease-modififed Berthlot reaction was used in the determination of 
Urea. Kit which is used was produced by BioMerieux Company which has patched no 
61912. 10µl of serum sample, standard, and control were added to 1 ml of working 
solution (urease added to color reagent), then incubation for 5 min at room temperature 
, after that 200 µl of alkaline reagent added to each test tubes then incubation for 10 
min at room temperature. Reading for the test tubes was taken by spectrophotometer 
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and finally calculation was done to get the final result taking in the consideration the 
result of controls.  
5.Cholesterol measurement: was done by Enzymatic Endpoint Method manual 
method. Kit which is used was produced by Randox Company which has patch no 
054457. 10µl of serum sample, standard, and control were added to 1 ml of cholesterol 
reagent, then incubation at 37˚ C for the required time. Reading for the test tubes was 
taken by spectrophotometer and finally calculation depending on the following 
equation was done to get the final result taking into consideration the result of controls. 
Conc. Of cholesterol in sample= ∆ A sample     × conc. standard 
                                                     ∆ A standard             
                                                                                           
6.HDL-cholesterol: was determined by precipitant manual method. Kit which is used 
was produced by Randox Company which has patched no 055408. Macro procedure 
was used in which 0.5 ml of serum sample, standard, and control were added to 1 ml of 
precipitant reagent, then incubation for 10 min at room temperature. Separation off the 
clear supernatant within tow hours and determine the cholesterol content by the 
CHOD-PAP method by adding 100µl of serum sample, standard, and control to 1 ml of 
cholesterol reagent, then incubation at 37˚ C for 5 min. Reading for the test tubes was 
taken by spectrophotometer and finally calculation depending on the following 
equation was done to get the final result taking into consideration the result of controls. 
Conc. Of HDL- cholesterol in sample= ∆ A sample     × conc. standard 
                                                               ∆ A standard             
                                                                                           
7. LDL cholesterol: the following equation was used for determination of LDL LDL-
Cholesterol=Total cholesterol-Triglyceride/5-HDL cholesterol 
8. Triglyceride measurement: was determined by GPO-PAP method. Kit which is 
used was produced by Randox company which has patch no 760TR. 10µl of serum 
sample, standard, and control were added to 1 ml of TG reagent, then incubation at 37˚ 
C for the required time. Reading for the test tubes was taken by spectrophotometer and 
finally calculation depending on the following equation was done to get the final result 
taking into consideration the result of controls. 
Conc. Of TG in sample= ∆ A sample     × conc. standard 
                                         ∆ A standard             
  
Quality control Sera : were used to achieve internal quality control for each test, this 
control was manufacture by Randox Company which is the same company that the kit was 
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used for Biochemistry test except for Urea test which used another control. Duplication 
and repeat the tests was done to check the accuracy of results. 
 
b- Blood pressure and electro-cardio gram (ECG) examination 
Each patient was scheduled to have an ECG testing and Blood pressure measurment at the 
day of having an endocrinologist consultation. 
c- Ophthalmic examination 
The procedure for eye examination at ophthalmologist clinic include the following ; 
Vision examination was done by Snellen's chart first without glasses then with glasses and 
refraction is done to each patient for the best corrected visual acuity. 
Intra ocular pressure is done by applanation Goldman Tonometer. 
Each patient his fund was examined after pupillary dilation with tropic amide (0.5% 
Mydramide) two to three drops for at least 30 min, and then funds are examined.  
Classification of diabetic retinopathy was done according to American Academy of 
Ophthalmology. 
Patient who is at higher risk where asked to be checked closely .While patients with poor 
visions which can not be explained by diabetic retinopathy were underwent more 
ophthalmic examinations to diagnose there poor vision (see appendix 2). 
D-Diabetes specialist evaluation criteria 
The evaluation of diabetic patient   situation was done by an expert in the field of this 
disease depending on laboratory tests, ECG reading , Blood pressure measurement, patient 
examination ,previous history finding of patient, and the result of eye examination which 
done by an ophthalmologist. 
 
 
4.7 Data Collection 
I) Questionnaire: 
For the interview questionnaire, patients who were registered in the pre-prepared lists in 
the two main centers, i.e. Ramallah PHC center and Al-Ama'ri, Al-Jalazone and Qalandia 
PHC centers were approached at the day of their visit to fill in the questionnaire. The 
questionnaire was answered by the patients themselves or by their parents in case of being 
a child.  After signing the informed consent and understanding the aim and objectives of 
this study, a pre-trained nurse and the research himself asked the questions and filled in the 
answers as reported by the patients or their guardian.    
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The participants were not obligated and they had the right to refuse or take part in this 
study. However, when the patient refused to participate, because he/she was in hurry or not 
feeling well or did not have an interest to survey, they were approached again in the 
following month. Also those patients were given the researcher phone number in case they 
change their decision.  Also, they were given a copy of the questionnaire in case they 
decided to fill it by themselves at their houses.   
 
II)  The objective testing and seeing the consultants 
After finishing the questionnaire filling, patients fill in a form of acceptance to participate 
in the following part of the survey, i.e. attending the physicians’ consultations and doing 
the objective testing.   They were asked for a phone number through which they will be 
invited to do the testing. Patients were invited by a telephone call to do objective testing 
freely. In case of not responding to do objective testing, they were called again for a 
coupled of  times at different dates.  In a third call, if they did not show up, they were 
called to ask for a confirmation that this is the last chance, and if they apologized, they 
were considered as no response. 
   
III)  Protocol and forms of organizing the survey 
Special forms were prepared and were presented at the study laboratory (see appendix3).  
Patients were given the address of the laboratory.  As they arrive to the laboratory, the 
technician explained the nature of tests he/she will go through, took a blood sample and 
gave them appointments for the ophthalmologist and the diabetes specialist.   Table 4.2 
shows the response rate for every type of examination and testing. 
 
Table 4.2   Response rate for every type of examination and testing 
Type of test  Number  of patients 
N=142 
percent 
Questionnaire filling 116 81.7% 
Laboratory testing 80 56% 
Ophthalmic evaluation  74 52% 
ECG examination 68 48% 
Diabetes evaluation 68 48% 
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All results were then collected from the laboratory and the ophthalmologist and referred to 
the endocrinologist for evaluating their diabetes condition. At the day of consultations, 
patients ECG and blood pressure were measured.  Finally the overall results of the 
previous tests were evaluated by an expert of diabetes plus direct examination of the 
patient by this expert.  
 
4.8        Ethical considerations: 
 
The conducting of research requires not only expertise and diligence but also honesty and 
integrity. This is done to recognize and protect human subject right. To render the study 
ethical, the right to self -determinations, anonymity, confidentiality and informal consent 
were done. 
Before the permission to conduct the interviews with the patients at the clinic of PHC 
centers, we had arranged for a meeting personally with the two different 
People who are responsible or director of the PHC centers of the two both health provider 
MOH and UNRWA. . The first meeting was with the doctor responsible for the health 
program at the UNRWA. The second meeting was with the doctor responsible for treating 
the diabetic patients at the Palestinian Ministry of Health after sending a letter to the 
director of PHC centers of the ministry. In these two interview a good idea of the health 
system in general and diabetes in specific was obtained. As well as the location of different 
clinics that provide care for type I diabetes especially UNRWA.  We contacted the clinics 
through these people. In addition a letter was sent from Al-Quds University to these 
clinics, in which the study was explained and an official permission has been asked for the 
researcher to visit the clinics and to conduct the interviews. The clinics were visited before 
interviewing the patients started, in order to get to know the place, to introduce the 
researcher, to ask the staff about the working hours. After that, the place where the 
researcher could meet with the patient, privately without disturbances was discussed. 
Before starting with the data collection, the researcher made sure to show responsibility to 
the informants. It was explained that there is no financial benefit for them after finishing 
the study. But explained briefly what the purpose of the study is, and what the results will 
be used for. Nothing was promised which could not be kept. 
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Protection of the informants’ rights had been taken into account. To insure confidentiality, 
mentioning the right to stop or withdraw, considering the consequences of the information, 
and to make sure not to harm the informants. 
A short but fair introduction about the research has been given to the informants. He/she 
will be the person with diabetes, and he/she will be the same person who is going to be 
interviewed. The information will be written on a paper, in Arabic language, and a special 
informed consent to be signed by the participants or their guardians. In case of difficulties 
in getting a signature of the participants, and this is understood due to the current sensitive 
political situation, the signature of the researcher after telling all the information about the 
study had been considered enough (see appendix (4) for the two form). 
 
4.9      Data analysis 
The collected data was entered and analyzed by using the statistical package for the social 
sciences (SPSS version 11.5). The analysis process divided into different stages. 
First stage include calculations of frequencies of all variable, then univariate analysis was 
done to compare metabolic control(HbA1c) with all other variable (demography, diabetes 
history, vital measurement, diabetes complications, PHC services and home monitoring) 
using Person chi-square test of significance at 5% significance level . 
Second stage include univariate analysis was done to compare metabolic control with 
objective testing, and evaluated complications. Using Person chi-square test of significance 
at 5% significance level. 
Third stages of analysis which will present in the next chapter include: Part a Univariate 
analysis comparing relationship between demographic data with objective testing, 
evaluated complications, and reported complications. Part B includes Univariate analysis 
comparing relationship between objective testing with evaluated complications, and 
reported complications. 
 
4.10     Operational Definition of Variables: 
Age: The age of the participant (in completed years at the time of conducting the survey. 
Age categories: composed of three catagoreis 
A- Children: all children less than 16 years of age 
B-Adult: individual between 16-30 years of age 
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C-Older adult: individual who are above 30 years age? 
Gender: Male or female of the participant 
Marital status: In terms of legal status at the time of the interview. The scale of it was 
divided into two scales single and married. 
Place of residence: Place in which participant lives (City, Rural and Camp) 
Educational Level: Years of education of the participant. 
 Education categories: composed of two categories 
A -0-12 years 
B- 13 years and above 
Occupation: Composed of three categories 
A. Worker 
B.Student 
C. Non worker 
Body Mass Index (BMI): depend on the calculation of BMI was weight (kilograms) 
divided by the square of height (meters). BMI divided into three categories 
A. Under weight in which BMI <20 
B. Normal where BMI 20-25 
C. Over weight and obese >25    
Type-1 diabetes: Insulin dependent diabetes mellitus diagnosed in participant below age 
30 year. 
Diabetes type-1 reported complications  
Reported retinopathy: Patient was asked if the diabetes affect his eye. 
Reported nephropathy: Patient was asked if the diabetes affect his kidney. 
Reported neuropathy: Patient was asked if the diabetes affect his nerves.                    
Reported cardiovascular disease: Patient was asked if the diabetes affect his cardiac . 
Reported diabetic foot: It was considered by asking patients if he had ulcer in his foot. 
Reported amputation:  If patients had previously amputation due to gangrene. 
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Diabetes type-1 evaluated complications 
Retinopathy: The presence of retinopathy was calculated on the basis of examinations 
performed by an ophthalmologist through this study. Two different levels of retinopathy 
were defined: no retinopathy, and retinopathy. 
Nephropathy: Patient was considering having nephropathy as evaluated by the 
endocrinologist depending on laboratory tests, or by previous history of nephropathy. 
Neuropathy: Patient was considering having neuropathy as evaluated by the 
endocrinologist.  
Cardiovascular disease: Patient was considering having CVD as evaluated by the 
endocrinologist depending on ECG test or previous history of CVD.  
Metabolic control: The value of HbA1c during the last 6 months. Two categories of 
metabolic control 
A-Good metabolic or controlled diabetes when the value less than8.5%. 
b- Uncontrolled diabetes when the value equal or greater than 8.5%. 
Self-monitoring of blood glucose: SMBG was defined as self-monitoring of blood glucose 
at least once per day at home. 
 
4.11       Summary 
 
This study is a cross-sectional study of complications in type 1 diabetes and therapy 
protocol, it is comprised of two levels (level 1 includes survey only and level 2 includes 
examination). All participants were diagnosed at <30 years of age. All complications were 
assessed by consultation or self-report. The validity and reliability of the questionnaire was 
tested by pilot study, after that this questionnaire was used in collection of data (Level 1). 
Study protocol of examination (level 2) for participant's patients includes four stages: 
Stage 1 laboratory testing, stage 2 include ophthalmic examination, stage 3 include ECG 
measurement for adult and blood pressure, and finally evolutions for patients depending on 
the result of the previous stages by endocrinologist. 
Univariate analysis was done to compare the relationship between complications of 
diabetes (micro and Macrovascular) and the metabolic control (HbA1c), demographic 
variable, and objective testing, using Pearson chi-square test of significance at 5% 
significance level 
Examinations results were statistically analysis, frequencies were done for each test, and 
then univariate analysis was done to compare the relationship between objective testing 
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and complications of diabetes (evaluated and reported), using Person chi-square test of 
significance at 5% significance level. 
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Chapter Five. Results 
5.1 Introduction 
This study has been conducted to identify diabetes complications among diabetic patients’ 
type 1 and the therapeutic protocol used in their treatment at Ramallah district, at the 
primary health care (PHC) of both the MOH and the UNRWA. 
The first part of the results presents the diabetic patients’ socio-demographic, physical and 
health condition, diabetes history as reported by patients themselves in the interview.  The 
second part shows the univariate analysis between the various determinants and the 
reported complications by the patients. Third part presents the relationships between the 
objective-testing with the various determinants as seen by the questionnaire data.  The 
forth part presents of diabetic patient diagnosed complications and self care.The fifth part 
presents the management protocols by the various health care providers.   At the end of 
results, multivariate analysis was done for the major complications including glycemic 
controls determinants.  
5.2 Part 1 results 
5.2.1 Study population socio-demographic characteristic  
The response rate of the study was 81.7%. The number of diabetic patients type 1, as 
presented in the filing system of the MOH and UNRWA was 142 patients.  Only 116 
registered patients participated in the survey. However, 9 of the 116 patients did not do the 
objective testing, in particular the HbA1c, therefore, not included in the analysis. 
Therefore, 107 patients (92.2%) were included in the analysis. All the 107 patients filled in 
the study questionnaire and have been tested for at least HbA1c.   
In the study, 47.7% of the study population were males (see Figure 5.1). The mean age of 
the group was 23.5± 10.4 (mean+ S.D) (see figure 5.2). Two third of the study population 
were singles (n=71 patients, 66.4%, see figure 5.3), and 53.3% lived in villages (see figure 
5.4). Of the study population, 82.2% had less than 12 years of education (see figure 5.5), 
and 41.1% were students (see figure 5.6).  
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Figure 5.1: Distribution of Study 
population by gender 
Figure 5.2: Distribution of study population by 
age group. 
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Figure 5.3: Distribution of study 
population by marital status 
Figure 5.4: Distribution of study population by 
place of residency 
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Figure 5.5: Distribution of study 
population by years of education 
Figure 5.6: Distribution of study population by 
type of occupation 
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5.2.2 Study population physical and health condition characteristics  
We calculated the Body Mass Index (BMI) for each patient as reported in the 
questionnaire. The calculated index in figure 5.7 shows that 36.4% were overweight and 
obese (BMI ≥ 25) and 23.4% were under-weight (BMI < 20).  Mainly all study had normal 
blood pressure, but 58.8% had fasting blood sugar ≥ 140 mg/dl, and 82 % had high random 
blood sugar testing. Of the study population, 50% reporting having HbA1c testing (see 
figure 5.7), and did not remember its normality.  
49,5%50,5%
82%
18%
58,8%
41,2%
92,6%
40,2% 36,4%
23,4%
3,7% 3,7%
<20 20-
24,99
≥25 Low Normal High <140 ≥140 <180 ≥180 Done Not
done
BMI Blood Pressure Fast blood sugar Random Blood
sugar
HbA1c
 
Figure 5.7: Study population physical and health condition characteristics 
5.2.3 Diabetes history among study population as reported by patients themselves 
As shown in figure 5.8, the duration of diabetes illness of the study population varied 
between 5-15 years, where 16.8 % of the registered patients have been registered for more 
than 15 years. The peak incidence of diabetes type 1 patient ranged 10-15 years of age, 
where 48.6% of patients were diagnosed between 10-20 years of age. More than half of the 
patients were diagnosed by general practitioners, and 5% found that themselves.  Also, 
53% were diagnosed due to the repeated symptoms of diabetes itself, and 25% during 
hospitalized for some other reasons than diabetes itself. When diabetes was detected most 
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Patients did not know why they got diabetes, but 25% thought it might be due to stress (see 
figure 5.8).  
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Figure 5.8: Distribution of Diabetes history among study population 
Interestingly, 64% of the study population reported a family history of diabetes and 13.8% 
reported having at least one of their siblings with diabetes type 1 (see figure 5.9).   
63.8
13.8
Family history Siblings/Type 1
 
Figure 5.9: Distribution of study population by their family history of diabetes 
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5.3 Part 2 results  
5.3.1 Association between reported diabetes-related complications and 
demographic variables    
Of the study population, 48.5% reported having one or more of the common chronic 
diabetes-related complications. These diabetes-related complications included symptoms 
of cardiovascular diseases, retinopathy-related symptoms, nephropathy-related symptoms, 
neuropathy-related symptoms and diabetic foot-related symptoms. Of these patients, 39 
patients  (36.4%) reported a retinopathy problems, 4 patients  (3.7%) reported heart 
diseases symptoms, 8 patients (7.5%) reported a nephropathy-associated symptoms, 28 
patients (26.2%) a neuropathy-associated symptoms, 11 patients (10.3%) reported having 
diabetic foot, one patient  (0.9%) reported an amputation, 74 patients (69.2%) reported 
suffering from hypoglycemia complications, and 12 patients (11.2%) reported a high blood 
pressure  (see figure 5.10). 
A significant difference was found between the frequency of retinopathy-associated 
symptoms with the type of occupation (P <0.05, see Table 5.1).  No association was found 
between the presence of retinopathy-associated symptoms with place of residency, with 
patient educational level, or with age of patient at diagnosis of disease (P>0.05, see Table 
5.1). A significant association was found between neuropathy-associated symptoms with 
patients’ occupation and with age (P <0.05, see Table 5.2), but no association was found 
with sex, and educational level (P >0.05).   
Table 5.3 presents the associations between hypoglycemia complications with the various 
demographic variables, however, only a significant association was found with age (P 
<0.05 ).   
Number of patients with diabetic foot-related symptoms, heart diseases-associated 
symptoms, and nephropathy-related symptoms according to possible determinants for 
diabetes were less than 11 patients (see appendix 5, table 5.1).  
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Figure 5.10: Complications reported by diabetic patients 
Table 5.1: The distribution of reported retinopathy-associated symptoms with the 
various demographic variables for the 107 patients in Ramallah district  
Variable Retinopathy-
associated 
symptoms 
No: 39 
(36.4%) 
No-retinopathy -
associated 
symptoms 
 
No: 68 (63.6%) 
Total 
N=107(100
%)  
 
P 
value 
Age 
Children (0-16 yr) 
Adult (16-30 yr) 
Older adult (>30 yr) 
 
4 (3.7%) 
21 (19.6%) 
14 (13.1%) 
 
25 (23.4%) 
26 (24.3%) 
17 (15.9%) 
 
29 (27.1%) 
47 (43.9%) 
31 (29%) 
 
 
<0.05 
Gender 
Male 
Female 
 
22 (20.5%) 
17 (15.9%) 
 
29 (27.1%) 
39 (36.5%) 
 
51 (47.6%) 
56 (52.4%) 
 
 
>0.05 
Occupation 
Working 
Not working  
Student 
 
19 (17.7%) 
11 (10.3%) 
10 (9.4%) 
 
22 (20.6%) 
11 (10.3%) 
34 (31.7%) 
 
41 (38.3%) 
22 (20.6%) 
44 (41.1%) 
 
 
<0.05 
Marital status 
Single 
Married 
 
23 (21.5%) 
16 (14.9%) 
 
48 (44.9%) 
20 (18.7%) 
 
71 (66.4%) 
36 (33.6%) 
 
 
>0.05 
Residency 
City 
Village 
Camp 
 
15 (14%) 
19 (17.7%) 
5 (4.7%) 
 
23 (21.6%) 
38 (35.5%) 
7 (6.5%) 
 
38 (35.6%) 
57 (53.2%) 
12 (11.2%) 
 
>0.05 
Educational level 
0-12 year 
>12 year 
 
33 (30.8%) 
6 (5.6%) 
 
56 (52.4%) 
12 (11.2%) 
 
89 (83.2%) 
18 (16.8%) 
 
 
>0.05 
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Table 5.2: The distribution of neuropathy-associated symptoms with the various 
demographic variables for the 107 patients in Ramallah district  
Variable Neuropathy
-associated 
symptoms 
N=28 
(26.2%) 
 
No-neuropathy-
associated 
symptoms 
N=79 
(73.8%) 
 
Total 
 
 
N=107  
(100%) 
P 
value 
Age 
Children (0-16) 
Adult (16-30) 
Older adult (>30) 
 
1 (0.9%) 
14 (13.1%) 
13 (12.2%) 
 
28 (26.2%) 
33 (30.8%) 
18 (16.8%) 
 
29 (27.1%) 
47 (43.9%) 
31 (29%) 
 
 
<0.05 
Gender 
Male 
Female 
 
17 (15.9%) 
11 (10.3%) 
 
34 (27.1%) 
45 (36.5%) 
 
51 (47.6%) 
56 (52.4%) 
 
 
>0.05 
Occupation 
Work 
Not working 
Student 
 
14 (13.1%) 
11 (10.3%) 
3 (2.8%) 
 
27 (25.2%) 
11 (10.3%) 
41 (38.3%) 
 
 
41 (38.3%) 
22 (20.6%) 
44 (41.1%) 
 
 
 
<0.05 
Marital status 
Single 
Married 
 
15 (14%) 
13 (12.2%) 
 
56 (52.4%) 
23 (21.4%) 
 
71 (66.4%) 
36 (33.6%) 
 
 
>0.05 
Residency 
City 
Village 
Camp 
 
11 (10.3%) 
14 (13.1%) 
3 (2.8%) 
 
27 (25.3%) 
43 (40.1%) 
9 (8.4%) 
 
38 (35.6%) 
57 (53.2%) 
12 (11.2%) 
 
 
* 
Educational level 
0-12 year 
>12 year 
 
23 (21.5%) 
5 (4.7%) 
 
66 (61.7%) 
13 (12.1%) 
 
88 (83.2%) 
19 (16.8%) 
 
 
* 
*Chi square not calculated since expected count in one cell less than 5 
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Table 5.3: The distribution of Hypoglycemia complications with the various 
demographic variables for the 107 patients in Ramallah district 
Variable Hypoglycemia 
N=74 
No (%) 
No- Hypoglycemia 
N=33 
No (%) 
Total 
N=107  
No (%) 
P 
value 
Age 
Children (0-16) 
Adult (16-30) 
Older adult (>30) 
 
14 (13.1%) 
37 (34.6%) 
23 (21.5%) 
 
15 (14%) 
10 (9.4%) 
8 (7.5%) 
 
29 (27.1%) 
47 (43.9%) 
31 (29%) 
 
 
<0.05 
Gender 
Male 
Female 
 
39 (36.4%) 
35 (32.8%) 
 
12 (11.2%) 
21 (19.6%) 
 
51 (47.6%) 
56 (52.4%) 
 
 
>0.05 
Marital status 
Single 
Married 
 
46 (43%) 
28 (26.2%) 
 
25 (23.4%) 
8 (7.4%) 
 
71 (66.4%) 
36 (33.6%) 
 
 
>0.05 
Occupation 
Work 
Not working 
Student 
 
 
32 (29.9%) 
18 (16.8%) 
24 (22.5%) 
 
 
9 (8.4%) 
4 (3.8%) 
20 (18.6%) 
 
 
41 (38.3%) 
22 (20.6%) 
44 (41.1%) 
 
 
* 
 
Educational 
level 
0-12 year 
>12 year 
 
 
59 (55.2%) 
15 (14%) 
 
 
30 (28%) 
3 (2.8%) 
 
 
89 (83.2%) 
18 (16.8%) 
 
 
>0.05 
Residency 
City 
Village 
Camp 
 
29 (27.1%) 
38 (35.6%) 
7 (6.5%) 
 
9 (8.5%) 
19 (17.6%) 
5 (4.7%) 
 
38 (35.6%) 
57 (53.2%) 
12 (11.2%) 
* 
*Chi square not calculated since expected count in one cell less than 5 
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5.3.2 Association between reported diabetes-related complications and the various 
possible determinants for diabetes 
We studied the relationship between diabetes–related complication and some determinant 
that affect these complications (i.e. family size, family history, smoking status, duration of 
disease, age at diagnosis, and diagnosis cause).  
Table 5.4 presents the relationship between retinopathy-associated symptoms and the 
various possible determinants of diabetes type 1. Significant associations were seen 
between retinopathy-associated symptoms and family size, duration of disease and age at 
diagnosis. Significant associations were seen between neuropathy-associated symptoms 
and family history of diabetes, duration of disease and age at diagnosis (see Table 5.5).    
Number of patients with diabetic foot-related symptoms, heart diseases-associated 
symptoms, and nephropathy-related symptoms according to possible determinants for 
diabetes were less than 11 patients (see appendix 5, table5. 2).  
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Table 5.4: The distribution of retinopathy-associated symptoms with the various 
possible determinants for the 107 patients in Ramallah district 
Variable Retinopathy-
associated 
symptoms 
N=39 
No (%) 
No-retinopathy 
-associated 
symptoms 
N=68 
No (%) 
Total 
 
N=107  
No (%) 
P value 
Family size people at 
household 
≤ 4  
>4 
 
 
13(12.1%) 
26(24.3%) 
 
 
9(8.4%) 
59(55.2%) 
 
 
22(20.5%) 
85(79.5%) 
 
 
<0.05 
Number of children* 
≤3 
>3 
 
7(19.4%) 
8(22.2%) 
 
14(38.9%) 
7(19.4%) 
 
21(58.3%) 
14(41.7%) 
 
>0.05 
Family history of 
diabetes 
Yes 
No 
 
 
26(24.3%) 
13(12.1%) 
 
 
41(38.3%) 
27(25.3%) 
 
 
67(62.6%) 
40(37.4%) 
 
 
>0.05 
A sibling with diabetes 
Yes 
No 
 
8(7.5%) 
31(28.9%) 
 
6(5.6%) 
62(58%) 
 
14(13.1%) 
93(86.9%) 
 
>0.05 
Smoking  now 
Yes 
No 
 
13(12.1%) 
26(24.3%) 
 
15(14%) 
53(49.6%) 
 
28(26.1%) 
79(73.9%) 
 
>0.05 
Disease duration    
 ≤5                                           
>5                                       
 
8(7.4%) 
31(29%) 
 
38(35.5%) 
30(28.1%) 
 
46(42.9%) 
61(57.1%) 
 
<0.05 
Diagnosis age                       
<10                              
 10-20                        
 >20   
 
9(8.4%) 
18(16.8%) 
12(11.2%) 
 
20(18.7%) 
34(31.8%) 
14(13.1%) 
 
29(27.1%) 
52(48.6%) 
26(24.3%) 
 
>0.05 
Diagnosis cause  
Psychological stress 
Neurological stress other 
disease causes            
Do not know 
 
12(11.2%) 
6(5.6%) 
6(5.6%) 
15(14%) 
 
14(13.1%) 
10(9.4%) 
13(12.1%) 
31(29%) 
 
26(24.3%) 
16(15%) 
19(17.7%) 
46(43%) 
 
>0.05 
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Table 5.5: The distribution of neuropathy-associated symptoms with the various 
possible determinants for the 107 patients in Ramallah district 
Variable Neuropathy-
associated 
symptoms 
N=28 
No (%) 
No-neuropathy-
associated 
symptoms 
N=79 
No (%) 
Total 
 
 
N=107  
No (%) 
P 
value 
Family size: people at 
household 
≤ 4  
>4 
 
 
9(8.4%) 
19(17.8%) 
 
 
13(12.1%) 
66(38.3%) 
 
 
22(20.5%) 
85(79.5%) 
 
 
>0.05 
Number of children* 
≤3 
>3 
 
6(16.7%) 
6(16.7%) 
 
15(41.7%) 
9(24.9%) 
 
21(58.4%) 
15(41.6%) 
 
 
>0.05 
Family history of 
diabetes 
Yes 
No 
 
 
22(20.5%) 
6(5.7%) 
 
 
45(42.1) 
34(31.7%) 
 
 
67(62.6%) 
40(37.4%) 
 
 
<0.05 
Smoking  now 
Yes 
No 
 
9(8.4%) 
19(17.8%) 
 
19(17.8%) 
60(56%) 
 
28(26.2%) 
79(73.8%) 
 
>0.05 
Disease duration     
 ≤5                                                               
>5 
 
5(4.7%) 
23(21.5%) 
 
41(37.4%) 
38(35.5%) 
 
45(42.1%) 
44(41%) 
 
 
<0.05 
Diagnosis age                  
<10                                
10-20                            
>20 
 
4(3.7%) 
16(15%) 
8(7.5%) 
 
25(23.4%) 
36(33.6%) 
18(16.8%) 
 
29(27.1%) 
52(48.6%) 
26(24.3%) 
 
 
>0.05 
Diagnosis cause  
Psychological stress 
Neurological stress other 
disease causes            
Do not know 
 
8(7.5%) 
8(7.5%) 
4(3.7%) 
8(7.5%) 
 
18(16.8%) 
8(7.5%) 
15(14%) 
38(35.5%) 
 
26(24.3%) 
16(15%) 
19(17.7%) 
46(43%) 
 
 
 
>0.05 
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5.4   Part 3 results 
The distribution of the objective testing by the various demographic variables is presented 
in appendix number 5(table5. 3, 5.4A, 5. 4B, and5. 4C).   Also, the associations between 
the objective testing and the various demographic variables are presented in appendix 
5(table5.5, 5. 6, 5.7, and 5.8).  
When Comparing the reported complications with the diagnosed complications, data 
showed that 20.5% (9 of 46 patients reported no retinopathy) who reported that they never 
had retinopathy was diagnosed with it.   Also 8 patients who reported having retinopathy 
were not diagnosed with this disorder.  But only 2 patients (one was found without the 
disease although he reported it and the other was the opposite) did not report correctly 
having or not having nephropathy.  Also, for neuropathy, one patient was not diagnosed, 
but 7 patients (41%) were reported having it but blood testing did not show it.    Therefore, 
Cronbach Alpha for reliability agreement beyond chance between reported and diagnosed 
was 0.61 for retinopathy, 0.85 for nephropathy, and was for neuropathy.   This means that 
retinopathy is the most under-diagnosed complications among diabetic patients.  
In the following sections diagnosed and reported complications associations with the study 
demographic variables, objective testing will be presented. 
5.4.1  Associations between diagnosed complications by consultations in relation 
with all demographic variables 
Table 5.6, 5.7, and appendix table 5.9, and appendix table 5.10. present data for the 68 
patients who did the full consultations with ophthalmologist, endocrinologist and did all 
the laboratory testing. As diagnosed by the ophthalmologist, retinopathy was found in 
33.8% of the patients (n=23). Males showed a higher possibility to developed retinopathy 
compared to females (P <0.05).  Significant difference in the frequency of retinopathy was 
seen in different age group among patients (P <0.05). Married cases showed a higher 
possibility to developed retinopathy compared to single cases (P <0.05, see table 5.6). 
Nephropathy was found in 7.4% of the patients (n=5) .Since the number of nephropathy 
cases was small the univariate analysis is not presented (see appendix 5, table 5.9). Clinical 
neuropathy was present in 16.2% of patients (n=11). Significant association with sex was 
observed (P <0.05, see appendix 5, table 5.10).  
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5.4.2 Association between the diagnosed complications by consultations in relation 
with the various possible associated determinants 
Table 5.7 present data for the relationship between diagnosed retinopathy of 68 patients 
who did the full consultations with ophthalmologist, endocrinologist and did all the 
laboratory testing with various possible associated determinants. Family size showed no 
significant association with developing retinopathy (P >0.05). Patient with more diabetes 
duration showed a higher possibility to developed retinopathy compared to diabetic patient 
with less disease duration (P <0.05). Age of diagnosed diabetic patients shows a significant 
association with developing retinopathy (P value <0.05).  People who used to smoke 
cigarette show also a higher possibility to developed retinopathy compared to diabetic 
patient who did not smoke (P<0.05). Patient with more diabetes duration showed a higher 
possibility to developed neuropathy compared to diabetic patient with less disease duration 
(P <0.05, see appendix 5, table 10). 
                                                                                
5.4.3 Association between objective testing and diagnosed complications by 
consultation.  
Significant associations were found between having retinopathy and metabolic control 
(HbA1c) and lipid profile tests (Cholesterol, triglyceride and LDL) (P <0.05). No 
association found between HDL and retinopathy (P >0.05, see table 5.8). Significant 
associations were found between clinical neuropathy and triglyceride (P <0.05, see table 
5.9).  
5.4.4   Association between objective and diagnostic testing and patients’ reported 
complications.  
In this part of results, the association between reported complications (retinopathy,  
neuropathy, nephropathy, and macro vascular disease) with objective testing and 
diagnostic testing will be presented. Reported retinopathy-associated symptoms showed no 
significant association with any of the objective or diagnostic testing (P >0.05) (Table 
5.10). While reported neuropathy-associated symptoms showed significant associations 
with lipid profile testing (P <0.05, see Table 5.11). 
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Table 5.6:  The distribution of the diagnostic retinopathy with demographic variables 
for the 68 patients in Ramallah district 
Variable Diagnosed 
Retinopathy 
N=23 
No (%) 
No 
retinopathy 
N= 45 
No (%) 
Total  
 
N=68 
No  (%)  
P 
value 
Age 
Mean ± SE  (yrs) 
 
31.96±2 
 
17.7±1.2 
  
23.54±0.96 
 
P<0.05 
Age      
Child 2(2.9%) 19(27.9%) 21(30.8%)  
Adults 6(8.8%) 22(32.3%) 28(41.2%) P<0.05 
Older adults 15(22.1%) 4(5.9%) 19(28%)  
Sex     
Male 15 (22.1%) 17 (25%) 32 (47%)   
Female 8 (11.7%) 28 (41.2%) 36 (53%) P<0.05 
Marital status     
Single  8 (11.7%) 37 (54.4%) 45 (66.2)   
Married 15 (22.1%) 8 (11.7%) 23 (33.8) P<0.05 
Occupation     
Work 16 (23.4%) 11 (16.2%) 27 (39.6%)  
Not working 5 (7.4%) 5 (7.4%) 10 (14.8%) * 
Student 2 (3%) 29 (42.6%) 31 (45.6%)  
Place of 
residency 
  
  
City 8 (11.8%) 14 (20.6%) 22 (32.4%)  
Village 10 (14.7%) 25 (36.7%) 35 (51.4%) * 
Camp 5 (7.4%) 6 (8.8%) 11 (16.2%)  
Education level     
0-12 year  20 (29.4%) 40 (58.8%) 60 (88.2%)   
>12 year 3 (4.4%) 5 (7.4%) 8 (11.8%) * 
*Chi square not calculated since expected count in one cell less than 5 
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Table 5.7: The distribution of the diagnostic retinopathy with various possible 
associated determinants for the 68 patients in Ramallah district. 
Variable Diagnosed 
Retinopathy 
N=23 
No  (%) 
No 
Retinopathy  
N=45 
No  (%) 
Total 
N=68  
No  (%) 
P 
value 
Family history of diabetes 
Yes 
No 
 
16(23.5%) 
7(10.3%) 
 
27(39.7%) 
18(26.5%) 
 
43(63.2%) 
25(36.8%) 
 
>0.05 
 Current Smoking   
Yes 
No 
 
9(13.3%) 
14(23.5%) 
 
8(11.8%) 
37(51.4%) 
 
17(25.1%) 
51(74.9%) 
 
<0.05 
BMI                      
Underweight                      
Normal                            
Over weight and obese 
 
3(4.4%) 
10(14.7%) 
10(14.7%) 
 
14(20.5%) 
19(28%) 
12(17.7%) 
 
17(24.9%) 
29(42.7%) 
22(32.4%) 
 
>0.05 
Disease duration                
≤5                                      
>5                                                                                                          
 
1(1.5%) 
22(35.3%)
 
32(47.1%) 
13(19.1%)
 
 
33(48.6%) 
35(54.6%) 
 
 
<0.05 
Diagnosis age                
<10                                    
10-20                               
>20 
 
4(5.9%) 
11(16.2%) 
8(11.7%) 
 
17(25%) 
20(29.5%) 
8(11.7%) 
 
21(30.9%) 
31(45.6%) 
16(23.5%) 
 
 
<0.05 
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Table 5.8:   The distribution of diagnostic retinopathy and the objective testing for 
the 68 patients in Ramallah district 
Variable Diagnosed 
Retinopathy 
N=23 
No  (%) 
No-retinopathy 
 
N=45 
No  (%) 
Total 
 
N=68 
No  (%) 
P 
value 
HbA1c  (%) 
HbA1c <8.5 
HbA1c ≥8.5 
 
11 (16.2%) 
12 (17.6%) 
 
33 (48.6%) 
12(17.6%) 
 
44 (64.8%) 
24 (35.2%) 
 
<0.05 
Sugar (mg/dl) 
<140   
≥140 
 
1(1.5%) 
22(32.3%) 
 
22(32.3%) 
37(33.9%) 
 
23(33.8%) 
45(66.2%) 
* 
Urea (mg/dl) 
<45   
≥45 
 
19(27.9%) 
4(5.9%) 
 
45(66.2%) 
__ 
 
64(94.1%) 
4(5.9%) 
 
* 
Creatinine (mg/dl) 
<1.4 
≥1.4 
 
16(23.5%) 
7(10.3%) 
 
42(61.8%) 
3(4.4%) 
 
58(85.3%) 
10(14.7%) 
* 
Cholesterol  (mg/dl) 
<200 
≥200 
 
7 (10.3%) 
16 (23.5%) 
 
32 (47.1%) 
13 (19.1%) 
 
39 (57.4%) 
29 (42.6%) 
 
<0.05 
Triglyceride  (mg/dl)  
<150 
≥150 
 
6 (8.8%) 
17 (25%) 
 
30 (44.1%) 
15 (22.1%) 
 
36 (52.9%) 
32 (47.1%) 
 
<0.05 
LDL  (mg/dl) 
<100 
≥100 
 
3 (4.4%) 
20 (29.4%) 
 
19 (28%) 
26 (38.2%) 
 
22 (32.4%) 
46 (67.6%) 
 
<0.05 
HDL  (mg/dl) 
<40 
≥40 
 
12(17.6%) 
11 (16.2%) 
 
20 (29.5%) 
25 (36.7%) 
 
32 (47.1%) 
36 (52.9%) 
 
>0.05 
*Chi square not calculated since expected count in one cell less than 5 
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Table 5.9:  The distribution of diagnostic neuropathy and the objective testing for the 
68 patients in Ramallah district 
Variable Diagnosed 
Neuropathy 
N=11 
No  (%) 
No-Neuropathy 
 
N=57 
No  (%) 
Total 
 
N=68 
No  (%) 
P 
value 
HbA1c  (%) 
HbA1c <8.5 
HbA1c ≥8.5 
 
6(8.8%) 
5(7.4%) 
 
38(55.8%) 
19(28%) 
 
44(64.6%) 
24(35.4%) 
* 
Sugar (mg/dl) 
<140   
≥140 
 
0 
11 (16.2%) 
 
9 (13.3%) 
48 (70.5%) 
 
9 (13.3%) 
59 (86.7%) 
* 
Urea (mg/dl) 
<45   
≥45 
 
10 (14.7%) 
1 (1.5%) 
 
54 (79.4%) 
3 (4.4%) 
 
64 (94.1%) 
4 (5.9%) 
* 
Creatinine (mg/dl) 
<1.4 
≥1.4 
 
7(10.3%) 
4(5.9%) 
 
51(75%) 
6(8.8%) 
 
58(85.3%) 
10(14.7%) 
* 
Triglyceride  (mg/dl) 
<150 
≥150 
 
1 (1.5%) 
10 (14.7%) 
 
35 (51.4%) 
22 (32.4%) 
 
36 (52.9%) 
32 (47.1%) 
 
<0.05 
Cholesterol  (mg/dl) 
<200 
≥200 
 
0 
11 (16.2%) 
 
39 (57.4%) 
18 (26.4%) 
 
39 (57.4%) 
29 (42.6% 
* 
LDL  (mg/dl) 
<100 
≥100 
 
1 (1.5%) 
10 (14.7%) 
 
21 (30.9%) 
36 (52.9%) 
 
22 (32.4%) 
46 (67.6%) 
* 
HDL  (mg/dl) 
<40 
≥40 
 
6 (8.8%) 
5 (7.4%) 
 
30 (44.1%) 
27 (39.7%) 
 
36 (52.9%) 
32 (47.1%) 
 
 
>0.05 
*Chi square not calculated since expected count in one cell less than 5 
 
 
 
 
 
 
 
80 
 
Table 5.10: The distribution of the objective testing and patients reported retinopathy 
for the 80 patients in Ramallah district 
Variable Reported 
retinopathy 
 
N=30 
No (%) 
Normal 
Reported-
retina 
N=50 
No (%) 
Total 
 
 
N=80  
No (%) 
P value 
HbA1c  (%) 
<8.5 
≥8.5 
 
 
19 (23.8%) 
11 (13.7%) 
 
 
35 (43.8%) 
15(18.7%) 
 
 
54 (67.6%) 
26 (32.4%) 
 
 
>0.05 
Sugar (mg/dl) 
<140   
≥140 
 
1 (1.3%) 
29 (26.2%) 
 
9 (13.2%) 
49(61.3%) 
 
10 (12.5%) 
70 (87.5%) 
* 
Urea (mg/dl) 
<45   
≥45 
 
27 (33.7%) 
3 (3.8%) 
 
49 (61.3%) 
1 (1.2%) 
 
76 (95%) 
4 (5%) 
* 
Creatinine (mg/dl) 
<1.1 
≥1.1 
 
24(30%) 
6(7.5%) 
 
44(55%) 
6(7.5%) 
 
68(85%) 
12(15%) 
* 
Cholesterol   (mg/dl) 
<200 
≥200 
 
16 (20%) 
14 (17.5%) 
 
31 (38.8%) 
19 (23.7%) 
 
47 (58.8%) 
33 (41.2%) 
 
>0.05 
Triglyceride  (mg/dl) 
<150 
≥150 
 
13 (16.3%) 
17 (21.2%) 
 
29 (36.2%) 
21 (26.3%) 
 
42 (52.5%) 
38 (47.5%) 
 
>0.05 
LDL  (mg/dl) 
<100 
≥100 
 
7 (8.8%) 
23 (28.7%) 
 
17 (21.2%) 
33 (41.3%) 
 
24 (30%) 
56 (70%) 
 
>0.05 
HDL  (mg/dl) 
<40 
≥40 
 
14 (17.5%) 
16 (20%) 
 
25 (31.25%) 
25(31.25%) 
 
39 (48.75%) 
41 (51.25%) 
 
>0.05 
*Chi square not calculated since expected count in one cell less than 5 
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Table 5.11: The distribution of reported neuropathy and the objective testing for the 
80 patients in Ramallah district 
Variable Diagnosed 
Neuropathy 
N=21 
No  (%) 
No-neuropathy 
 
N=59 
No  (%) 
Total 
 
N=80  
No  (%) 
P value 
HbA1c  (%) 
HbA1c <8.5 
HbA1c ≥8.5 
 
 
11 (13.7%) 
10 (12.5%) 
 
 
 
43(53.8%) 
16(20%) 
 
 
 
54 (67.5%) 
26 (32.5%) 
 
 
 
>0.05 
Sugar (mg/dl) 
<140   
≥140 
 
0 (0%) 
21 (26.2%) 
 
10 (12.5%) 
49 (61.3%) 
 
10 (12.5%) 
70 (87.5%) 
* 
Urea (mg/dl) 
<45   
≥45 
 
18 (22.5%) 
3 (3.8%) 
 
58 (72.5%) 
1 (1.2%) 
 
76 (95%) 
4 (5%) 
* 
Creatinine (mg/dl) 
<1.1 
≥1.1 
 
14(17.5%) 
7(8.8%) 
 
54(67.5%) 
5(6.2%) 
 
68(85%) 
12(15%) 
* 
Cholesterol   (mg/dl) 
<200 
≥200 
 
 
7 (8.8%) 
14 (17.5%) 
 
 
40 (50%) 
19 (23.7%) 
 
 
47 (58.8%) 
33 (41.2%) 
 
 
<0.05 
Triglyceride  (mg/dl) 
<150 
≥150 
 
 
6 (7.5%) 
15 (18.8%) 
 
 
36 (45%) 
23 (28.7%) 
 
 
42  (52.5%) 
35  (47.5%) 
 
 
<0.05 
LDL  (mg/dl) 
<100 
≥100 
 
2 (2.5%) 
19 (23.7%) 
 
22 (27.5%) 
37 (46.3%) 
 
24 (30%) 
51 (70%) 
 
<0.05 
HDL  (mg/dl) 
<40 
≥40 
 
 
11 (13.8%) 
10 (12.5%) 
 
 
28 (35%) 
31 (38.7%) 
 
 
39 (48.8%) 
41 (51.2%) 
 
 
>0.05 
*Chi square not calculated since expected count in one cell less than 5 
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 5.5            Part 4 results 
5.5.1 Associations between diagnosed complications and home monitoring and 
self-care assessment as reported by patients themselves 
 
Self-monitoring of blood glucose (SMBG) is an important component of modern therapy 
for diabetes mellitus. SMBG has been recommended for people with Insulin treated 
diabetes and their health care professionals in order to achieve a specific level of glycemic 
control and to prevent hypoglycemia. In this part of results, the association between SMBG 
and the frequency of blood glucose measurement at home, and blood pressure 
measurement at home with glycemic control (HbA1c) are presented. As shown in table 
5.12, no significant associations were seen between home monitoring and glycemic control 
(HbA1c) (P >0.05).  Also, patients without diagnosed retinopathy did not show a 
significant difference in using any practice method of home monitoring compared to 
diagnosed patients (P >0.05, see table5.13). For diagnostic neuropathy univariate analysis 
was not done (see table5.14).  Similarly, those who reported having retinopathy and 
neuropathy-associated symptoms showed no significant association with any practice 
method of home monitoring (P >0.05, see tables 5.15, and 5.16) 
 
Table 5.12:  Association between home monitoring with glycemic control 
 
Variable HbA1c ≥8.5 
N=41 
No (%) 
HbA1c <8.5 
N=66 
No (%) 
Total 
N=107 
No (%) 
P 
value 
Blood Pressure Device 
Yes 
No 
 
14 (13.1%) 
27 (25.2%) 
 
14 (13.1%) 
52(48.6 %) 
 
28 (26.2%) 
79 (73.8%) 
 
>0.05 
Glucose measurement 
Yes 
No 
 
26 (24.3%) 
15 (14.1%) 
 
48 (44.9%) 
18(16.8%) 
 
74 (69.2%) 
33 (30.8%) 
 
>0.05 
Glucose frequency 
testing  
Daily 
Not Daily 
 
 
21(28.4%) 
10(13.5%)  
 
 
27 (36.5%) 
16 (21.6%) 
 
 
48 (64.9%) 
26 (35.1%) 
 
 
>0.05 
 
Glucose in urine 
Yes 
No 
 
1(0. 9%) 
40(37.4%) 
 
2(1.9%) 
64(59.8%) 
 
3(2.8%) 
104(97.2%) 
* 
Ketone in Urine 
Yes 
No 
 
___ 
41(38.3%) 
 
1(0.9%) 
65(60.8%) 
 
1(0.9%) 
106(99.1%) 
* 
*Chi square not calculated since expected count in one cell less than 5 
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Table 5.13: The distribution of diagnostic retinopathy and the Home monitoring for 
the 68 patients in Ramallah district 
Variable Diagnosed 
Retinopathy 
N=23 
No (%) 
No-retinopathy 
 
N=45 
No (%) 
Total 
 
N=68 
No (%) 
P 
value 
Blood Pressure Device 
Yes 
No 
 
7 (10.3%) 
16 (23.5 %) 
 
15 (22.1%) 
30 (44.1%) 
 
22 (32.4%) 
46 (67.6%) 
 
>0.05 
Glucose measurement 
Yes 
No 
 
15(22.1%) 
8(11.7%) 
 
39(57.4%) 
6(8.8%) 
 
54(72.2%) 
14(27.8%) 
* 
Glucose frequency  
Daily 
Not daily 
 
8(14.8%0 
7(13%) 
 
23(42.6%) 
16(29.6%) 
 
31(57.4%) 
23(42.6%) 
 
 
>0.05 
Glucose in urine 
Yes 
No 
 
------ 
23(33.8%) 
 
3(4.4%) 
42(61.8%) 
 
3(4.4%) 
65(95.6%) 
* 
Ketone in Urine 
Yes 
No 
 
____ 
23(33.8%) 
 
1(1.5%) 
44(64.7%) 
 
1(1.5%) 
67(98.5%) 
* 
*Chi square not calculated since expected count in one cell less than 5 
 
Table 5.14:   The distribution of diagnosed neuropathy and the Home monitoring for 
the 68 patients in Ramallah district 
Variable Diagnosed 
Neuropathy 
N=11 
No  (%) 
No-neuropathy 
 
N=57 
No  (%) 
Total 
 
N=68  
No  (%) 
P 
value 
Blood Pressure Device 
Yes 
No 
 
2 (3%) 
9 (13.2 %) 
 
20 (29.4%) 
37(54.4%) 
 
22 (32.4%) 
46 (67.6%) 
* 
Glucose measurement 
Yes 
No 
 
8 (11.8%) 
3(4.4%) 
 
46 (67.6%) 
11 (16.2%) 
 
54(79.4%) 
14 (20.6%) 
* 
Glucose frequency* 
Daily 
Not daily 
 
4 (7.4%) 
4(7.4%) 
 
27 (49.9%) 
19(35.3%)  
 
31 (57.3%) 
23 (42.7%) 
* 
Glucose in urine 
Yes 
No 
 
0 
11(16.2%) 
 
3 (5.5%) 
54(78.3%) 
 
3 (5.5%) 
65(94.5%) 
* 
Ketone in Urine 
Yes 
No 
 
0 
11 (16.2)% 
 
1 (1.5%) 
56 (82.3%) 
 
1 (1.5%) 
67(98.5%) 
* 
*Chi square not calculated since expected count in one cell less than 5 
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Table 5.15:   The distribution of reported retinopathy and the Home monitoring for 
the 107 patients in Ramallah district 
Variable Reported 
retinopathy 
 
N=39 
No (%) 
Normal 
reported 
retina 
N=68 
No (%) 
Total 
N=107 
No (%) 
P 
value 
Blood Pressure Device 
Yes 
No 
 
13 (12.1%) 
26 (24.3 %) 
 
15(14.1%) 
53 (49.5%) 
 
28 (26.2%) 
79 (73.8%) 
 
>0.05 
Glucose measurement 
Yes 
No 
 
24 (22.4%) 
15 (14%) 
 
50 (44.2%) 
18 (17.8%) 
 
74 (68.2%) 
33 (31.8%) 
 
>0.05 
Glucose frequency  
Daily 
Not a daily  
 
10 (13.6%) 
14 (19%) 
 
33(44.6%) 
17 (22.8%)  
 
43 (58.2%) 
31 (41.8%) 
 
 
<0.05 
Urine glucose 
measurement 
Yes  
No 
 
 
0  
39 (36.4%) 
 
 
3 (0.9%) 
65 (60.8%) 
 
 
3 (2.8%) 
104(97.2%) 
 
 
*  
Ketones measurement 
(urine) 
Yes 
No 
 
 
0  
39 (36.4)% 
 
 
1 (0.9%) 
67 (62.7%) 
 
 
1 (0.9%) 
106(99.1%) 
 
 
* 
*Chi square not calculated since expected count in one cell less than 5                                
Table 5.16:   The distribution of reported neuropathy and the Home monitoring for 
the 107 patients in Ramallah district 
Variable Reported 
neuropathy 
N=28 
No (%) 
No- reported 
neuropathy 
N=79 
No (%) 
Total 
 
N=107 
No (%) 
P 
value 
Blood Pressure Device 
Yes 
No 
 
9 (8.4%) 
19(17.8 %) 
 
19(17.8%) 
60 (56%) 
 
28 (26.2%) 
79 (73.8%) 
 
>0.05 
Glucose measurement 
Yes 
No 
 
17 (15.9%) 
11 (10.3%) 
 
57 (52.3%) 
22 (21.5%) 
 
74 (68.2%) 
33 (31.8%) 
 
>0.05 
Glucose frequency * 
Daily 
Not daily 
 
10 (13.5%) 
7 (9.5%) 
 
33(44.6%) 
24(32.4%)  
 
43 (58.1%) 
31 (41.9%) 
 
>0.05 
Glucose in urine 
Yes 
No 
 
0  
28 (26.2%) 
 
3 (2.8%) 
76 (71%) 
 
3 (2.8%) 
104(97.2%) 
 
* 
Ketone in Urine 
Yes 
No 
 
0  
28(26.2)% 
 
1 (0.9%) 
78 (72.9%) 
 
1 (0.9%) 
106(99.1%) 
 
* 
*Chi square not calculated since expected count in one cell less than 5 
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5.6     Part five results 
 
5.6.1   Patients follow up and treatment by PHC centers 
 
Primary health care centers are the main source of care for patients with diabetes type 1 at 
Ramallah district. The purpose of these services is to prevent complications and control the 
main precursors of these complications (i.e. poor blood glucose, blood pressure and blood 
lipid). The impact of these conditions can be moderate or prevented through appropriate 
treatment and screening. In our study we consider physical examinations, fundus 
examination, blood glucose measurement and control, blood chemistry tests  (i.e. lipid 
profile, kidney function, and enzymatic test), ECG, weight, hight measurement, specialist 
consultations and blood pressure measurement and control as screening test and indicators 
for assessment of PHC services. Figures 5.11, 5.12A, and 5.12B summarize the percent of 
screening tests among diabetic patients that receive from the PHC centers as they reported 
by themselves.   
A-Diet regiment  
It was proposed that food habits are a basic factor in diabetes.  In this study, patients were 
asked if they follow the recommended diet regiment for diabetic patients. Of the 107 
patients, only 60 patients (56.1%) reported following a diet regiment. However no 
statistical significant association was found between diet regiment and good glycemic 
control (P >0.05, see table 5.17). 
B.   Management according to insulin therapy type 
Of the study population, 77.6% reported using insulin mixture in there treatment at time of 
interview. No statistical significant relationship between Insulin type used by diabetic 
patients and glycemic control, and reported complications (P >0.05, see Table 5.17). 
C.   Availability of health insurance 
 
A 51.7% of study population reported having governmental health insurance, 12% were 
UNRWA health insurance, 36.3% had private health insurance,. However, no statistical 
significant association was found between health insurance and glycemic control (P >0.05, 
see table 5.17). 
D. Management according to place of care 
During interview the patients were asked about the place from which they used to receive 
their management services including insulin and laboratory test: 62.6% receive care at 
MOH, PHC centers only. 30.1% from UNRWA, PHC centers only, while the rest from 
more than one place, which could be considered as duplication of service. No statistical 
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significant relationship between existing place of care and glycemic control (P >0.05, see 
table 5.17). 
 
Table 5.17: Association between diabetes management according to diet regiment and 
health insurance with glycemic control in the 107 patients in Ramallah district 
 
Variable HbA1c ≥8.5 
N=41 
 No (%) 
HbA1c <8.5 
N=66 
No (%)  
Total 
N=107 
 No (%) 
P value 
Diet regiment 
Yes 
No 
 
23 (21.6%) 
18(16.8%) 
 
37 (34.5%) 
29 (27.1%) 
 
60 (56.1%) 
47 (43.9%) 
 
>0.05 
Health insurance type 
Governmental 
UNRWA 
Private 
 
17 (15.9%) 
8(7.5%) 
16(15%) 
 
37 (34.5%) 
5 (4.7%) 
24(22.4%) 
 
54 (50.4%) 
13 (12.2%) 
40(37.4%) 
 
>0.05 
Insulin therapy type* 
Rapid 
Mixture 
 
6(12.1%) 
34(64.5%) 
 
12 (4.7%) 
49 (13.1%) 
 
18 (16.8%) 
83 (77.6%) 
 
 
>0.05 
First source of 
treatment 
MOH 
UNRWA 
Private 
More than one source 
 
 
 
34 (31.8%) 
21 (19.6%) 
21 (19.6%) 
11 (10.3%) 
 
 
 
8 (7.5%) 
4 (3.7%) 
6 (5.6%) 
2 (1.9%) 
 
 
 
42 (39.3%) 
25 (23.3%) 
27 (25.2%) 
13 (12.2%) 
 
 
 
 
>0.05 
Source of treatment 
MOH 
UNRWA 
 
24 (24.5%) 
13(13.3%) 
 
43 (43.8%) 
18 (18.4%) 
 
67 (68.3%) 
31 (31.7%) 
 
 
>0.05 
 
5.6.2 Management according to screening test 
24.3% of the patients reported that they were tested for HbA1c at PHC, 5.6% reported that 
they were tested for ECG, 2.8% reported that they were tested for chest X-ray, 6.5% 
reported that they were tested for liver enzymes, 43.6% reported that were tested for 
triglyceride and cholesterol, 84.1% reported that they were tested for blood pressure see 
figure 5.11A, and figure 5.11B. No significant association was seen between screening 
tests and its frequency with glycemic control (P >0.05, see table 5.18, and table 5.19): 
however protein test frequency in urine show significant association with HbA1c (P value 
<0.05). 
Ninety three patients (86.9%) have not been examined for retinopathy, 66% of them have 
been diagnosed with diabetes before 5 years.3.7% of the patients have been examined by 
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neurologist, 80.4% of the patients have not been examined for diabetic foot.  2.8%of the 
patient reported that they were tested by nutrients (figure 5.12).  
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Figure 5.11A: The distribution of screening tests for the 107 patients in Ramallah 
district 
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Figure 5.11B: The distribution of screening tests for the 107 patients in Ramallah 
district 
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Figure 5.12: The distribution of physical examination tests for the 107 patients in 
Ramallah district 
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Table 5.18 : Association between laboratory screening tests with glycemic control 
 
Variable HbA1c 
<8.5 
N=57 
 (%) 
HbA1c 
>=8.5 
N=34 
 (%) 
Total 
N=107 
 (%) 
P value 
HbA1c* 
Yes 
No 
 
18 (19.8%) 
39 (42.9%) 
 
8 (8.8%) 
26 (28.5%) 
 
26(28.6%) 
65 (71.4%) 
 
>0.05 
Urine protein* 
Yes 
No 
 
27 (30.3%) 
29 (32.6%) 
 
21 (23.6%) 
12 (13.5%) 
 
48 (53.9%) 
41 (46.1%) 
 
>0.05 
 
triglyceride & 
Cholesterol* 
Yes 
No 
 
 
29 (31.5%) 
29 (31.5%) 
 
 
18 (19.6%) 
16 (17.4%) 
 
 
47 (51.1%) 
45 (48.9%) 
 
>0.05 
Urea 
Yes 
No 
 
24 (25.8%) 
34 (36.6%) 
 
16 (17.3%) 
19 (19.3%) 
 
40 (43.1%) 
53 (56.9%) 
 
>0.05 
Creatinine 
Yes 
No 
 
26 (28%) 
32 (35.4% 
 
20 (21.5%) 
15 (15.1%) 
 
46 (49.5%) 
47 (50.5%) 
 
 
>0.05 
Uric Acid* 
Yes 
No 
 
8 (9%) 
47 (52.8%) 
 
7 (7.8%) 
27 (30.4%) 
 
15 (16.8%) 
74 (83.2%) 
 
>0.05 
Urine ketones* 
Yes 
No 
 
23 (27.4%) 
29 (34.5%) 
 
18 (21.4%) 
14(16.7%) 
 
41 (48.8%) 
43 (51.2%) 
 
>0.05 
Height* 
Yes 
No 
 
23 (24.3%) 
36 (37.9%) 
 
18 (18.9%) 
18 (18.9%) 
 
41 (43.1%) 
54 (56.9%) 
 
>0.05 
BMI* 
Yes 
No 
 
22 (21.2%) 
42 (41%) 
 
17 (16.6%) 
22 (21.2%) 
 
39 (37.8%) 
64 (62.2%) 
 
>0.05 
 
*Some cases were excluded from the analysis since answer not remember or missing data. 
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Table 5.19 :  Association between frequencies of laboratory screening tests with 
Glycemic control   
 
Variable HbA1c ≥8.5 
N= 
No (%) 
HbA1c <8.5 
N= 
No (%) 
Total 
N= 
No (%) 
P value 
HbA1c 
Once every six month 
Once a year 
Do not do 
 
4(4%) 
5(5%) 
27(27%) 
 
11 (11) 
9(9%) 
44(44%) 
 
15 (15%) 
14(14%) 
71(71%) 
 
 
>0.05 
Urine protein 
Once every six month 
Once a year 
Do not do 
 
11(11.8%) 
21 (22.6%) 
24(25.8%) 
 
10 (10.8%) 
5 (5.4%) 
22(23.6%) 
 
21 (22.6%) 
26(28%) 
46 (49.4%) 
 
 
<0.05 
 
Ketone test 
Once every six month 
Once a year 
Do not do 
 
12(14%) 
16 (18.6%) 
25(29%) 
 
5 (5.8%) 
4 (4.7%) 
24(27.9%) 
 
17 (19.8%) 
20(23.3%) 
49 (56.9%) 
 
 
>0.05 
 
triglyceride& Cholesterol 
Once every six month 
Once a year 
Do not do 
 
9(9.7%) 
19 (20.4%) 
30(32.3%) 
 
12 (12.9%) 
12 (12.9%) 
11(11.8%) 
 
21 (22.6%) 
31(33.3%) 
31 (44.1%) 
 
 
>0.05 
 
Creatinine test  
Once every six month 
Once a year 
Do not do 
 
7(7.1%) 
23 (23.6%) 
31(31.6%) 
 
7 (7.1%) 
11 (11. 2%) 
19(19.4%) 
 
14 (14.2%) 
34(34.8%) 
50 (56.9%) 
 
 
>0.05 
 
 
 
5.6.3 Association between frequencies of laboratory screening tests with diagnostic 
complications 
We studied the association between diagnostic retinopathy and neuropathy with screening 
tests done for patients at PHC centers. Triglyceride and cholesterol show no significant 
association with diagnostic retinopathy (P value >0.05) (table 5.20and 5.21).While other 
association can not be done since chi square can not be calculated.  
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Table 5.20 : Association between frequencies of laboratory screening tests with 
reported retinopathy 
 
Variable Diagnosed 
Retinopathy 
No (%) 
No-
retinopathy 
No (%) 
Total 
 
No (%) 
P value 
HbA1c 
Once every six month 
Once a year 
Do not do 
 
2(3.2%) 
4(6.5%) 
14 (22.6%) 
 
6(9.7%) 
6(9.7%) 
30(48.3%) 
 
8(12.9%) 
10(16.2%) 
44(70.9%) 
* 
Urine protein 
Once every six month 
Once a year 
Do not do 
 
11(20%)  
2(3.6%)  
6(10.9%)  
 
6(10.9%) 
10(18.2%) 
20(36.4%) 
 
17(30.9%) 
12(21.8%) 
26(47.3%) 
* 
Ketone test 
Once every six month 
Once a year 
Do not do 
 
7(13.5%)  
2(3.8%)  
9(17.3%)  
 
5(9.6%) 
8(15.4%) 
21(40.4%) 
 
12(23.1%) 
10(19.2%) 
30(57.7%) 
* 
triglyceride& 
Cholesterol 
Once every six month 
Once a year 
Do not do 
 
 
8(15.1%)  
8(15.1%)  
5(9.4%)  
 
 
7(13.2%) 
10(18.7%) 
20(28.5%) 
 
 
15(28.3%) 
18(33.8%) 
20(37.9%) 
 
 
>0.05 
Creatinine test  
Once every six month 
Once a year 
Do not do 
 
4(8%)  
7(14%) 
9(18%) 
 
5(10%) 
12(24%) 
23(46%) 
 
9(18%) 
19(38%) 
32(64%) 
* 
*Chi square not calculated since expected count in one cell less than 5 
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Table 5.21 :Association between frequencies of laboratory screening tests with 
reported neuropathy 
Variable Diagnosed 
neuropathy 
N= 
No (%) 
No-
neuropathy 
N= 
No (%) 
Total 
No (%) 
P value 
HbA1c 
Once every six month 
Once a year 
Do not do 
 
1(1.6%)  
3(4.8%)  
6(9.7%)  
 
7(11.3%) 
7(11.3%) 
38(61.3%) 
 
8(12.9%) 
10(16.1%) 
44(71%) 
 
* 
Urine protein 
Once every six month 
Once a year 
Do not do 
 
4(7.3%)  
1(1.8%)  
5(9.1%)  
 
13(23.6%) 
11(20%) 
21(38.2%) 
 
17(30.9%) 
12(21.8%) 
26(47.3%) 
 
* 
Ketone test 
Once every six month 
Once a year 
Do not do 
 
2(3.8%)  
1(1.9%) 
6(11.5%)  
 
10(19.2%) 
9(17.3%) 
24(46.3%) 
 
12(23%) 
10(19.2%) 
30(57.8%) 
 
* 
triglyceride& 
Cholesterol 
Once every six month 
Once a year 
Do not do 
 
 
3(5.2%)  
5(8.6%)  
3(5.2%)  
 
 
12(20.7%) 
13(22.4%) 
22(37.9%) 
 
 
15(25.9%) 
18(31%) 
25(43.1%) 
 
* 
Creatinine test  
Once every six month 
Once a year 
Do not do 
 
2(4%)  
4(8%)  
4(8%)  
 
7(14%) 
15(30%) 
28(56%) 
 
9(18%) 
19(38%) 
32(64%) 
 
* 
*Chi square not calculated since expected count in one cell less than 5 
Part 6 
5.7:  Multivariate analysis  
According to the results above, multivariate models for the major complications, i.e. 
retinopathy, neuropathy, nephropathy and HbA1C, with the significant above associations 
were investigated in multivariate models.  However, due to the small numbers of patients 
(<68 patients in total) and the number of patients having the disorder, none of the models 
were significant to be presented in this data analysis.  
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The distinguishing feature of this study is that it is the first to investigate in T1DM in 
Palestine. This study provides a baseline for further studies to improve diabetes health care 
and self-management, which therefore affects its complications.   
The study was performed in primary health care centers that belong to the MOH and 
UNRWA health services in Ramallah district. It is an explorative study, which was used to 
identify possible complications among diabetic patients and problems in diabetes services 
from these primary health care centers. 
 
6.1 Summary of study findings 
The response rate of the study was 81.7%. The number of diabetic patients type 1, as 
presented in the filing system of the MOH and UNRWA, was 142 patients.  Only 116 
registered patients participated in the survey. However, 9 of the 116 patients did not do the 
objective testing, in particular the HbA1c and were not included in the analysis. Therefore, 
107 patients (92.2%) were included in the analysis. All the 107 patients filled in the study 
questionnaire and have been tested for at least HbA1c.  Several reasons played a role in 
this response rate (81.7%).  The most probable reasons for were that patients were very 
afraid that anyone might find out about their children diabetes so refused to appear in the 
study clinic, or some informed the investigators that their family doctors did not encourage 
them to engage with this research, and others did not have the interest to be part of any 
research.  
In describing the study population, T1DM was more prevalent in the age group 10-20 
years with a mean age 23.6 (SD ±10.5 years) and with no difference between males and 
females.  The mean disease duration was 8.4 years (SD±7.2 years) and ranges 5-15 years.  
One third of these patients were obese and 23% were under weight. A 63.8% reported a 
family history of diabetes and 13.8% reported having at least one of their siblings with 
diabetes type 1.   
Results showed the frequency of screening test for T1DM by PHC centers.  Most patients 
did not have at least one of the needed tests to follow up these patients, as recommended 
by the international guidelines for T1DM. For example, neither any of them had physical 
eye examination nor had HbA1c level since a year or more.  
In describing the complications among these T1DM patients, either as reported by patients 
themselves or as evaluated by the study consultants, early micro-vascular complication was 
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found to be very common among a population of young adults with mean 8.4 years of 
diabetes duration. The prevalence of retinopathy and nephropathy were similar by reported 
symptoms and by evaluation. However, clinical neuropathy was reported symptoms more 
by the patients themselves compared to evaluation.  
The association between of risk factors with diabetic complication (reported and evaluated) 
was also investigated.  The basis of the risk estimation was control of blood glucose, lipid, 
pressure, and socio demographic data. Diabetes duration and age were the only common 
significant risk factors for development of both evaluated and reported retinopathy. For 
neuropathy, duration, HbA1c and age were the only common significant risk factors for the 
development of both evaluated and reported complications.  
The gap and variations of results between evaluated and reported complications could be 
due to one or more of the following reasons: 
− Some patients were not tested by an ophthalmologist since the onset of their 
diabetes. 
− Lack of interest among physicians regarding early detection of complications. 
− Poor feedback and reporting system at the level of PHC centers. 
− Socioeconomic and cultural factors affect negatively the compliance of patients to 
do the testing either due to its availability, access at the health service, or if not 
covered by insurance could be expensive. 
− Many patients or their families hided the fact that they have such a disease.  
Therefore, did not do the testing since their families used to bring them their 
medication, so physically never attend the PHC for any follow up.   This was 
clearly seen with the low compliance of these patients to do the testing and 
consultations in this study, although it was free of charge. 
− Lack of enough and appropriate comprehensive services and this may due to its 
high cost. 
− Lack of professional’s skills among the health staff working at the PHC centers to 
link the complication with risk factors. 
− Lack of appropriate specialists' consultations at the level of PHC centers. 
 
In the coming sections the study results will be discussed and compared to the present 
literature in details. 
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6.2 Socio-demographic factors 
 
Age, sex, marital status, place of residence, occupation type and educational level were the 
main socio-demographic factors that were of concerned in this study conceptual model.  
The mean age of the study group was 23.5± 10.4 years, and only 27% were children less 
than 16 years of age. Since this study was concerned with T1DM patients, it was expected 
that the studied group would represent a younger population.   Studies around the world 
showed a younger T1DM patients (Fagulha  et. al., 2004, and Donaghue et. Al., 2005), 
while other studies showed a more older patients (Lievre  et. al., 2005).  But, this study 
results were similar to others (Orchard et .al., 1997) which showed that the mean age of 
population in a study conducted in USA was 27.9 years. Also, in the Spanish population, 
Blanco  showed that the mean age of T1MD was 24.8 ±6.7 (Blanco et. al., 2004), while in 
the Saudi Arabia the mean age group of patients was 43.1±15.5 (Ammari, 2004). Taking 
into consideration that our study is cross-sectional study, the result where the mean age of 
diabetic patients increase might be explained by the increase in the survival rate, so the 
survival rate among T1MD in our community is very low. 
 
In general, males and females have similar risk of type 1 diabetes (Gale, and Gillespie 
,2001). Our results showed that there was no difference in the overall prevalence of T1DM 
between males and females (47.7% vs. 52.3%). Similar findings were seen in other 
countries such as Kuwait, Lebenon, and United Arab Emirates (Mohamed et al., 2005; 
Yusef, 2000; and Punnose et al., 2002). However, in other studies conducted on the 
diabetes type 1 population, T1MD was prevalent more among females  in Poland where 
66% of the study population were females  (Kozek  et. al., 2003), and was 62% females 
among the T1DM in Saudi Arabia (Ammari , 2004). The possible explanation for this 
finding is that the overall sex ratio is roughly equal in children diagnosed under the age of 
15 years, while populations with the highest incidence(>20/100,000) all showed it to be 
higher among males, the lowest risk populations studied (<4.5/100,000), mostly of non-
European origin, characteristically showed a female bias (Gale ,and Gillespie ,2001). 
 
Although the majority of cases in our study were singles, marital status was considered as a 
risk factor for T1DM complications. The percent of married cases in our sample 
populations was 33.6%. Similar findings were seen in other countries such as a study 
conducted by Ammari at Saudi Arabia in which married cases were 27 %(Ammari, 2004). 
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In our study significant association was found between marital status and retinopathy, but 
El-Shazly from Egypt found that there was no association between diabetic retinopathy and 
marital status (El-Shazly et.al, 2000). 
 
In developing countries the prevalence of diabetes mellitus is reported to be lower in rural 
areas compared to urban areas. This difference has been attributed to lifestyle factors 
associated with the higher socio-economic status of those living in urban areas (Mennen et. 
al., 2000; and Sobngwi and colleagues, 2002). However, in this study the prevalence of 
diabetes according to residency place showed that only 35.5% of diabetic population lived 
in cities. This is attributable to lifestyle changes of Palestinian community associated with 
urbanization and westernization. Rural lifestyle in Palestine is characterized by changes in 
dietary habits involving an increase in the consumption of refined sugars and saturated fat 
and a reduction in fiber intake, obesity and more stress due to social, cultural, political and 
economic environment. 
 
Education has been shown to be a powerful and unique predictor of health outcomes - 
lower levels of education are associated with poor health and higher levels of education are 
associated with better health.  This study showed that 83.2% of the participants did not 
finish high school. They were either illiterate, student, or did not finish the 12 years of 
basic education. When looking at different demographic groups participating in the study, 
big differences in the attended school years were detected. 
 
 Refugee camps residents had the lowest educational level in this study, whereas village’s 
and city’s populations had the same percent of high educational level. No significant 
difference was seen between male and female, both have the same percent of low and high 
education. Nicolucci found that educational level can determine a complication risk not 
dissimilar from hard clinical variables, such as hypertension and diabetes duration 
(Nicolucci et. al., 1998). Chaturvedi in his study found that healthy lifestyles are more 
prevalent in better educated men and women with IDDM, but these are not reflected in 
heart disease prevalence in men. The lower prevalence of severe micro vascular 
complications was seen in better educated men (Chaturvedi et al., 1996). Whereas El-
Shazly from Egypt found that there was no significant association between the 
development of eye complications and educational level of diabetic patients (El-Shazly et 
al., 2000). In this study, education appears to have no affect on diabetes prognosis. A 
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possible explanation for this study finding might be related to the low understanding of the 
illness and therefore low commitment of self care. In this study, in spite of a longer mean 
duration of diabetes, those with a college education had the same complication rate as less 
educated (complication rate38% vs. 33% for less educated). 
 
The study showed that 38.3% of the participants are worker, i.e. employed, marcher, 
unskilled worker (cleaner) etc.  Patients who are currently employed or working had higher 
diagnostic retinopathy (23.4%) as compared to those not working (7.4%) or student (3%). 
In other studies they found no significant association between the development of eye 
complications and occupation of diabetic patients (El-Shazly et. al., 2000)     
 
 
6.3  Study population physical and health characteristic 
 
Overweight (BMI ≥25 kg/m2) and obesity (BMI 30 kg/m2) are becoming increasingly 
prevalent in the industrialized world, not only in type 2 but also in type 1 diabetic patients. 
The role of body weight/BMI in the development of vascular complications of T1DM is 
unclear. A study conducted in Belgium by Christophe found that BMI above ≥25 kg/m2   
was 47 % among type 1 diabetic patients ( Christophe et. al., 2005). In Saudi Arabia, 
Ammari found that the BMI >30 was 61 %  among T1DM patients ( Ammari ,2004).While 
Punnose in his study at United Arab Emirates found that obesity present in 12.5% of 
diabetic patients and super-obesity found in 9% (Punnose et. al .,2002). In the studied 
population, 36.4% of the participant had BMI over 25, which means that this proportion of 
the sample is categorized in the obese group.  
 
Intensive insulin therapy, as shown in the Diabetes Control and Complications Trial, is 
associated with an increase in body weight (DCCT, 1993). Possible explanations for 
weight gain with improvement of glycemic control include elimination of caloric loss from 
glycosuria, shift in fuel use from fatty acids to glucose, and an insulin-induced increase in 
appetite (Carlson, and Campbell., 1993). However, this could not be observed in the 
present study. Overweight and non-overweight subjects injected a similar insulin 
dose/kilogram body weight. Theoretically, insulin resistance could contribute to the 
development of chronic diabetes complications. Recent studies of type 1 diabetic patients 
have shown that a higher BMI is associated with hypertension and an atherogenic lipid 
profile as part of the insulin resistance syndrome. The adverse lipid profile consists of 
99 
 
higher triglyceride and LDL cholesterol levels and lower HDL cholesterol levels (Purnell 
et al., 1998). Christophe in his study observed a positive correlation between BMI and total 
cholesterol, LDL cholesterol, and non-HDL cholesterol in men but not in women. 
Overweight men had a more unfavorable risk profile than overweight women, with higher 
blood pressure and worse lipid profile. In our study men with BMI ≥25 kg/m2 have higher 
average of cholesterol and Triglyceride compared with women in the same categories 
(210and 195vs.181 and 141). 
 
For blood pressure diagnosis, the MOH and UNRWA considered patients to be diagnosed 
with high blood pressure if he had blood pressure persistently ≥140 mm Hg systolic or ≥90 
mmHg diastolic. Using this cut-off level in our study, 3.7 % of participant only had 
reported having high blood pressure. In comparison, 4.4% were diagnosed to suffer from 
hypertension through objective testing when patients were consulting with endocrinologist. 
The EURODIAB IDDM Complications Study examined 3250 randomly selected Type 1 
diabetic patients with a mean duration of diabetes of 14.7±9.3, of whom 24% patients 
reported having hypertension (Collado-Mesa, 1999). Blanco in his study found that was 
20.4% of T1DM had hypertension (Blanco et al., 2004), while Ammari found that the 
prevalence of hypertension was 25% among Saudi diabetic patients (Ammari, 2004). The 
low percent of high blood pressure in our study might be due to that most patients are 
young in age and have not long period of disease duration. Many studies have 
convincingly demonstrated the valuable effect of blood pressure level as a risk factor for 
the initial development of diabetic retinopathy and nephropathy (Chaturvedi et al., 2001; 
Olsen et al., 1999; and Schultz et al., 2001), perhaps partly explained by not adjusting for 
the confounding effect of metabolic control, diabetes duration and early stages of 
nephropathy. Since the number of patients diagnosed with hypertension was very low, our 
study does not support the importance of higher blood pressure levels for the development 
of microvascular complications. However, the role of blood pressure levels must still be 
considered unclear and intervention studies with early antihypertensive therapy and long 
follow up are necessary to eventually investigate the clinical importance and create 
guidelines for clinical practice. 
 
For blood glucose monitoring, UNRWA health centers use two hours postprandial blood 
glucose values for monitoring of blood glucose, therefore, a blood glucose <180 mg/ml 
considered controlled blood glucose. MOH use fasting blood glucose (FBG) for 8 hours, 
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therefore, FBG <140 mg/ml considered controlled blood glucose. According to the last 
blood glucose readings reported by patients, 58.8% of the sample were considered to have 
uncontrolled fast blood glucose. While 82% of the sample were considered to have 
uncontrolled random blood glucose. This high result of uncontrolled blood glucose will 
accelerate the development of diabetes complications. The mean postprandial blood 
glucose level (mg/dl ± SE) in our study was 225±10.6. This finding is much higher 
compared with a multicenter randomized open label 6-month study conducted by Raskin at 
USA and Canada include subjects with type 1 diabetes found that the mean postprandial 
blood glucose levels (mg/dl ± SEM) were significantly lower for subjects in the IAsp 
group compared with subjects in the HI group after breakfast (156 ± 3.4 vs. 185 ± 4.7) 
(Raskin et al., 2000). 
 
Several studies such as the DCCT and the United Kingdom Prospective Diabetes Study 
(UKPDS) had clearly demonstrated that improved glycemic control (HbA1c) reduces the 
development and progression of several micro- and macrovascular complications in both 
type 1 and type 2 diabetes mellitus. UNRWA dose not include HbA1c in its routinely 
screening test for diabetic patients, However MOH newly entered HbA1c in its services 
depending on its availability at PHC centers.  In the studied population, there were 50 % of 
participant who reported having been tested for HbA1c during the last six months. This 
percent give us a clear idea about diabetes monitoring. This finding is similar compared 
with a Retrospective cohort study conducted by Christaki at USA that include subjects 
with type 1 diabetes found that only 54% in the year 1997 had their HgA1c checked by 
PHC (Christaki et al., 2001).  
 
Smoking is a serious health problem, and in diabetic patients it adds to the increased risk of 
coronary artery disease and micro vascular disease. In our study 26.2% of diabetics 
patients reporting being smokers compared with 33.2% reported by Blanco (Blanco et al., 
2004).Where Chaturvedi found that the prevalence of smoking was 35% in men and 29% 
in women (Chaturvedi et al., 1995). It was suggested that smoking which is a major main 
variable in diabetes and can affect glycemic control .How ever, there was no significant 
relationship between smoking and glycemic control in our study. This could be explained 
by that poorer glycemic control can account for some of the increased risk of complications 
in smokers, and that quitting smoking would be effective in reducing the incidence of 
complications (Chaturvedi et al., 1995). 
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6.4       Diabetes history among study population 
In this study, 57.1% of patients had diabetes for more than five year (mean duration of the 
disease was 8.3 years.  This study finding is higher than the duration of disease found by a 
study conducted at Portugal by Fagulha in which disease duration was 5.2 yr+/-3.95 
.another study conducted at Azerbaijan has duration of disease 3.5+/- .36yr (IDF, 2003). 
While the mean duration of disease in EURODIAB IDDM Complications Study 
was14.7±9.3 (The EURODIAB IDDM Complications Study, 1994). Olsen in his study at 
Denemark found median diabetes duration 13.2 years (range 8.9-24.5) (Olsen, 1999).  
 
As shown in literature, patients having diabetes for more than 5 years need a regular 
physical eye examination. However 25.9 % of the registered study patients have been 
registered as T1DM for more than 10 years in The UNRWA and MOH. These patients are 
likely to have various diabetes mellitus complications and they are in bad need for 
comprehensive care to avoid irreversible severe complications that may lead to early 
disability, morbidity and mortality.  Not unexpectedly, duration of diabetes in our study 
was a significant independent risk factor for both reported and evaluated retinopathy, and 
also between reported and evaluated neuropathy, which is also in concordance with other 
studies. Since blood pressure, BMI, lipid values and prevalence of history of CVD and 
smoking increase with age, this of course highly correlates with diabetes duration. 
 
The hormonal changes and rapid growth that take place during puberty usually have an 
unfavorable effect on the metabolic balance in T1DM. Together with psychological 
changes and poor compliance, these events form a challenging equation in the clinical care 
of adolescent patients with this disease. Based on age at time of diagnosis, 48.6% of the 
sample was diagnosed between 10-20 years of age, which concordance with other studies 
finding and the literature about the peak incidence of DT1 occurrence between ages 10-15 
years. The results show that the mean age at diagnosis was 15.5±7.4 yr (range 1-30 year), 
this is congruent with the result of Blanco (Balnco et al. 2004) that showed a mean age at 
diagnosis of 13.8±6.9 years. While Punnose in his study at United Arab Emirates  found 
mean age of onset of Type 1 DM 9.2±4.1 years with the peak incidence being in the 10–
14-year age group (Punnose et al . 2002). 
 
In this study, 56.9% of the sample population were diagnosed by general practitioners who 
run the PHC centers. This segment of doctors who are the most important link in early 
102 
 
diagnosis and guiding the patient properly, but are often not well trained to handle diabetes 
related issues, unaware of the latest trends, or unable to devote time to diabetes due to their 
busy practice. This study is consistent with the study of Abu Mousa (1998), which shows 
that 73.4% were diagnosed by general practitioners. Rayappa from India found in his study 
that most of the respondents (type1 and type 2), over 91%, initially visited a non specialist 
for diagnosis (Rayappa, 1999). Punnose in his study at United Arab Emirates show that all 
patients in his study had a diagnosis of diabetes mellitus at the Al-Ain hospital(Punnose et 
al ., 2002). 
Most patient who develop T1DM can not tolerate having diabetes without treatment and 
daily insulin injection, while patient with type 2 diabetes can live years without diagnosis. 
So the diagnosis of T1DM will be after the appearance of symptoms directly within few 
days. Each patients was asked about the circumstances or health events led to diagnosis of 
diabetes. 53% of the sample population were diagnosed following appearance of classical 
symptoms of diabetes mellitus; weight loss, polyuria, polydepsia, general tiredness and 
easy fatigability, polyphagia, blurred vision and repeated infections. Abu Mousa (1998) in 
his study found that 35.1% of the sample population was diagnosed following appearance 
of classical symptoms of diabetes mellitus.Punnose in his study at United Arab Emirates 
found 94.2% of the type 1 diabetic patients had 
glycaemic symptoms for several days prior to the diagnosis and 60% of them were 
symptomatic for15 days ( Punnose et al.,2002). 
The exact cause of the disease is still unknown which make it to be considering as 
idiopathic disease. However, our study showed that most cases reported that they do not 
know  the cause of their disease. Genes that are responsible for transmitting the diabetes 
disease determine opportunities for health and susceptibility to diseases, while 
environmental factors determine which susceptible persons will develop illnesses. In this 
study the prevalence of positive family of diabetes i.e. mother, father …etc was 64%, this 
seems that genetic and hereditary factors may play a role in the development of diabetes 
type 1. The result of this study is consist with that done by Punnose in United Arab 
Emirates (2002), which found the family history of T2DM was obtained in 57% and Type 
1 DM in 6% patients (Punnose et al .,2002). However our results is higher than that done 
by Ammari in Saudi Arabia which found 33% of patients had positive family of diabetes 
(Ammari, 2004).  
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6.5 Evaluation of Diabetes-Related Complications 
48.5% reported having one or more of the common chronic diabetes-related complications. 
This is a striking finding reflecting the extremely high prevalence of complications in the 
Palestinian diabetic type 1 population. Knowing that only 18.7% of the studied population 
had HbA1c less than 7%, and that 38.3% had HbA1c above 8.5%, there is reason to think 
that the studied population is at risk regarding the development of serious diabetes 
complications.  The most common reported complication of diabetes in this study was 
found to be retinopathy (36.4%). 
 The result of this study is consistent with a study in USA  Siddiqui et al (2001) in which 
eye problem related to diabetes was 43.4% . Similar finding was seen by a study conducted 
by (Feleke1 and Enquselassie, 2005) in Ethiopia in which diabetes related eye disease was 
33%. 
 
 The prevalence of retinopathy is strongly related to the duration of diabetes, but prolonged 
hyperglycemia might accelerate early development of retinopathy due to early and 
progressive changes in the retinal capillary bed (Pickup et al., 1991, and Viswanath et al., 
2003). In our study both duration and age of diabetic patients showed a significant 
association with reported retinopathy while glycemic control did not. This could be due 
that some patient reported not to have retinopathy but when they are tested by 
ophthalmologist was found to have one of retinopathy classification.   The under-diagnosis 
of retinopathy was found in 10 patients (13.2%) who did not report that when interviewed.  
 
A 26.2% of the sample reported neuropathy complications which were considered positive 
by having a reported positive answer to any of these symptoms: having pain at the site of 
peripheral nerves, loss of sensation, numbness, burning sensation, muscular weakness, 
impotence and bladder dysfunction, postural hypotension, dizziness chronic headache. The 
DiaComp study which is a multinational (17 countries) cross-sectional study examining 
892 T1DM patients diagnosed at age <15 year with diabetes duration of 5–24 years found 
that reported neuropathy by patients in Lithuania was 22.1% vs. 12.4% when tested by 
Michigan Neuropathy Screening Instrument exam for neuropathy, while in Slovakia 
(Martin) reported neuropathy was 10% vs. 6.9% for examined (ADA, 2004). Patients with 
peripheral neuropathy need visual perception to normalize gait, avoid injury, and detect 
emerging foot ulcerations.              
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Reported neuropathy show high prevalence than evaluated neuropathy by consultation, this 
may be due to that patient consider lipodystrophy as a neuropathy complication.   
         
7.5% of the sample population reported nephropathy complications.  Most of these patients 
who reported having diabetic nephropathy have undergone kidney dialysis or past 
diagnosed with renal disease, so the exact prevalence of nephropathy might be higher than 
the reported nephrohapthy. This might be due to the fact that the PHC centers of both 
UNRWA and MOH do not test patients for micro and macroalbuminuria in their routine 
screening tests which is an early detection for nephropathy. The DiaComp study found that 
reported nephropathy by patients in Japan was 4.3% vs. 23.1% when tested for 
microalbuminuria (MA), while in UK was 8.1% vs. 23.1% (ADA,2004).    
 
 4 (3.7%) of the sample reported cardiovascular complication. This low prevalence might 
be due to the fact that macrovascular diseases are more common among patients with 
diabetes type 2 than T1DM. As known, uncontrolled blood glucose might lead to 
accelerated heart disease by increasing arterial stiffness (Bate and Jerums, 2003).  In our 
study the average value for HbA1c of the patients that reported heart disease was 9.2 
(standard error ±0.8).  Other risk factor for developing heart disease could be duration of 
disease (Latika et al., 2006). In this study, the average duration of disease for patient that 
reported heart disease (X±SE) was 12.0±4.2 year.   
 
Poor glycemic control and duration of diabetes was shown to increase the occurrence of 
diabetic foot (Watkins, 2003). 11 (10.3%) of the sample reported having diabetic foot 
complication, and the average HbA1c for these patients was 8.2 (SE±0.4). This increase in 
HbA1c value may play as risk factors for developing diabetic foot. Other risk factors could 
be the duration of disease, the average duration for diabetic patients with reported diabetic 
foot was 11 (SE±2.2).                         
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6.6 Evaluation of objective testing by the various demographic variables 
 
A: Glycemic control  
The present data suggested a lack of public awareness about T1DM in the Palestinian 
community. This study’s patients had a delayed presentation as evidenced by very high 
mean plasma glucose 203±9 mg/dl (range: 37-510).  This result is much higher than the 
normal range for glucose or the recommended value for diabetic patient according to ADA. 
This could be explained by the effect of low insulin dose in monitoring blood glucose. The 
ADA recommends that the goal of therapy should be an HbA1c concentration <7% and 
that treatment regimens should be reevaluated if HbA1c values are consistently >8%. 
Similar finding to this study results was shown by the DCCT study in which the mean 
blood glucose was 230 mg/dl in the conventional group, while it is155 mg/dl in the 
intensive group (DCCT, 1994). Also, in a study in United Arab Emirates, the mean plasma 
glucose among the investigated patients was 497±198 mg/dl (Punnose 2002).   
The normal range as recommended by the ADA for HbA1c is 4.5-7% (ADA, 2004) . In 
this study the average of objective HbA1c was 7.8 (SE±0.16).  According to this result this 
study diabetic patient are at the risk range or above the recommended value of HbA1c.  In 
relation to metabolic control result, this study’s patients had lower HbA1c than other 
groups (Nordwall et al., 2006). This could be explained by the younger age of the patients 
included in the previous study, with a higher percentage of children and adolescents, in 
whom metabolic control is more difficult. The results presented herein are quite similar to 
the data reported in Spanish population (Blanco et al., 2004).  
 
B: Kidney function testing 
In this study, investigators used urea and creatinine to test the kidney function. The mean 
serum urea was 28.2 mg/dl (SE ±1.4, range: 6-88).  The mean serum creatinine was 0.9 
mg/dl (SE±0.05, range: 0.4-4.1).  These results are within the normal range of blood urea 
and creatinine, which are similar to Blanco et al study results in Spain (Blanco et al., 
2004). Patient classification according to demographic data show normal value for urea. 
This finding could be explained by the high result of urea only found in patient with 
diagnosed nephropathy in which the average urea was 61 (SE±11.4) compared to 27(SE 
±1) in patient without nephropathy. Rehman and Hamayun in there study that was 
conducted in Pakistan found that the mean blood urea for T1DM patients with nephropathy 
was 158 (SE±1.93) ( Rehman and Hamayun,2004). 
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Patient’s classification according to demographic data show high value for creatinine 
among the non worker. This finding could be explained by the high result of creatinine 
only found in patient with diagnosed nephropathy and most of them have kidney dialysis 
which makes them unable to work. In our study the average of creatinine for patients 
diagnosed with nephropathy was 2.3 (SE±.56) which lower than that found by Rehman and 
Hamayun (2004) among Pakistani patients diagnosed with nephropathy where mean blood 
creatinine was 6.94 (SE±0.07) ( Rehman and Hamayun,2004). 
 
C: Lipid profiling 
 
Recent studies of type 1 diabetic patients have shown that a higher BMI is associated with 
hypertension and an atherogenic lipid profile as part of the insulin resistance syndrome. 
The adverse lipid profile consists of higher triglyceride and LDL cholesterol levels and 
lower HDL cholesterol levels.HbA1C correlated positively with total and LDL cholesterol 
and triglyceride in men. 
In this study total cholesterol was 191 mg/dl (SE ±5.1). Yusef in his study that conducted 
at UNRWA primary health care facilities in Lebanon found that mean cholesterol level 
(185 ± 52 mg/dL) (Yusef, 2000). Similar result was found in a study conducted by Blanco 
(2004) in Spanish patients in which total cholesterol was 182.6±35.6.In our patients, 
triglyceride concentration was higher (142 ±11.1 vs. 70.4±47.7), serum LDL cholesterol 
concentration was significantly higher (123±4.7 mg/dl vs. 109.1±31.3 mg/dl) and HDL 
concentration significantly lower (42±0.8 mg/l vs. 58.5±14.5 mg/dl) comparison with 
Spanish diabetic patients at Blanco study(Blanco et al ., 2004) .While Yusef in his study 
conducted at UNRWA primary health care facilities in Lebanon found   the mean 
triglyceride level (170 ± 154 mg/dL) for type 1 diabetes patients (Yusef,2000). 
Serum lipid profile i.e. triglyceride, cholesterol were higher in older male who are worker 
than in the other demographical categories of patients, and were even higher in patients 
with poor metabolic control. This result is similar with that done by Yusef in Lebanon 
(2000). Since increased serum triglyceride concentrations and a high waist to hip ratio 
were found in the EURODIAB Study to be risk factors for retinopathy (Porta et al., 2001) 
and persistent microalbuminuria (Chaturvedi et al.,2001) we cannot rule out the possibility 
that these patients in this particular study had a greater risk of microvascular 
complications. Yusef in his study conducted at UNRWA primary health care in Lebanon 
found that there is a difference between the means for both sexes was statistically 
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significant for triglycerides but not significant for cholesterol (Yusef, 2000).However, in 
our study significant association for both mean of cholesterol and triglyceride with sex was 
found. 
 
6.7    Diagnosed T1DM complications  
6.7.1  Retinopathy  
There is a paucity of information about the prevalence of retinopathy in TIDM in Palestine. 
Some reports refer to diabetic patients as a whole, not only T1DM (Abu Mousa, 1998). 
The present study has revealed a relatively high prevalence of diabetic retinopathy among 
T1DM in Ramallah district. Our results are similar to those of some studies (Agardh et al., 
1997; Kozek et al., 2003) but much higher than those of others (Blanco et al., 2004; 
Nordwall et al., 2006; Donaghue et al., 2005). This may be due to better diabetic control. 
Patients with retinopathy had higher HbA1c compared to patients without retinopathy.  
The present study has revealed that retinopathy is more frequent in males than female. Our 
results are similar to those of some studies (Pinto-Figueiredo et al., 1992). This different 
may be attributed to that finding by the EURODIAB Study which reported that moderate 
non-proliferative diabetic retinopathy to be significantly less frequent in women than in 
men, but mild nonproliferative and proliferative diabetic retinopathy did not differ between 
the sexes (Sjolie et al., 1997). Our study show that there is a significant relationship 
between age and development of diabetic retinopathy, this is similar to previous finding by 
other studies (Lievre et al., 2005; Klein et al .,1984). The present study has revealed 
significant relationship between retinopathy with marital status. This is not similar as other 
study (El-Shazly et al., 2000; Zhang et al 2001).This finding may be attributed to that most 
people who are married are older in age.  Our study showed that there is a significant 
relationship between smoking habit and development of diabetic retinopathy, these 
findings is consistent with other studies from different part of the world (Muhlhauser et al., 
1996, Chaturvedi et al., 1995; Chase et al., 1991).While this finding is different from other 
studies(Blanco et al., 2004; Ammari, 2004). The diverging results could in part be 
explained by not adjusting for the possible confounding effect of metabolic control in some 
studies. The duration of diabetes is probably the strongest predictor for development and 
progression of retinopathy, long duration of diabetes is shown among patients with 
retinopathy compared to patient without retinopathy in this study. This finding is similar as 
reported in different previous studies (Blanco et al., 2004; Ammari, 2004). The prevalence 
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of retinopathy in our study in patient diagnosed with T1DM post pubertal was significantly 
greater than prepubertal diagnosed subjects. This significant association finding is similar 
as reported in previous studies in which age at diagnosis and puberty play a major role in 
developing retinopathy (Kernell et al., 1997).  
The Diabetes Control and Complications Trial Research Group have shown that intensive 
insulin therapy aiming at glycemia levels as close to the non-diabetic range as possible is 
effective in delaying the onset and slowing the progression of diabetic retinopathy 
(DCCT,1993).Patients with retinopathy had higher HbA1c compared to patients without 
retinopathy. This study further showed a direct association between poor metabolic control 
and retinopathy, as also has been observed in several other previous studies (Blanco et al., 
2004; Ammari, 2004; Danne et al., 1994). We used only the result of determinations of 
HbA1c performed in the objective testing of the study; in that case, the value of the 
analysis of the relationship between glycemic control and the prevalence of complications 
is limited. We think, however, that it probably reflects the metabolic control for a 
particular patient during a longer period. In this sense, Aghard et al., in a 5-year follow-up 
study of 442 adults type 1 diabetic patients under routine care, showed that the individual 
levels of glycemic control and blood pressure can be kept fairly constant.   
Significant relationship between microalbuminuria and diabetic retinopathy was shown in 
previous studies (Danne et al., 1994) .In our study patients with retinopathy show high 
average results of kidney function tests i.e, creatinine and urea. In this study significant 
association was shown between Triglyceride, cholesterol and LDL-cholesterol, as also has 
been observed in several other previous studies (Chaturvedi et al., 2001; Watts et al., 
1996). 
 
6.7.2 Nephropathy 
  
About 7.4% of the patients in this study had nephropathy. This finding is similar to other 
finding by previous studies (Fagulha  et al., 2004; Olsen, 1999). Our prevalence is much 
lower than that reported by some authors (Rahlenbeck & Gebre-Yohannes 1997; Andersen 
et al 1983), which may be due to types of studies used. The low prevalence of nephropathy 
in this study may come from our evaluation since it depends only on creatinine and urea 
measurement which give an indicative for the last stage of nephropathy and not the 
beginning stage. As a consequence of the rather low prevalence of nephropathy and the 
cross sectional nature of the present study, and a rather limited number of patients in the 
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various demographical data, this study does not allow to assess the impact of 
demographical variable on nephropathy any further. However, other series have shown that 
demographical data is associated with an increase in nephropathy (Andersen et al 1983). 
Some studies showed that adult men with T1DM have a higher risk of diabetic 
nephropathy than women (Andersen et al 1983). These studies also showed that the 
relationship between sex and increased microalbuminuria is not straightforward (Canton et 
al., 2004; Ammari, 2004).  In this respect our finding of nephropathy shows that both adult 
male and female have the same percent value to develop nephropathy.  
Rossing and colleagues showed that the duration of diabetes has a role as risk factor in 
developing nephropathy (Rossing et al., 1995). In this respect our finding shows that the 
mean duration of diabetes among patient who develops nephropathy was higher than those 
who did not have nephropathy (18.6±3.5 vs.6.9±0.9).  
Poor long term glycemic control, and poor control during the first years of diabetes in 
particular may later predispose to microalbuminuria (Powrie et al 1994, Rudberg et al., 
1993). In keeping with the previous findings the patients with nephropathy in the present 
series had higher HbA1c than those without nephropathy (9.3±0.6 vs.7.7±0.2). 
The mean average for cholesterol, triglyceride, and LDL was much higher than those with 
out nephropathy (223±20,175±20,158±23 vs.189±5.8,145±14, and 118±4.9). These results 
are consistent with those described previously in the Spainish population (Blanco et al., 
2004) suggesting that patients who develop nephropathy have a worse lipid profile. 
 
6.7.3 Neuropathy 
  
20.6% of the patients in the present study had clinical neuropathy with significant 
difference according to sex.  This finding is similar to other finding by previous studies 
(IDF, 2003; Kokez et al., 2003). This study show lower prevalence of neuropathy than 
previous reports from Denmark and Sweden (Olsen, 1999; Nordwall et al., 2006). The 
discrepancy between the percentages of neuropathy prevalence in our study and these two 
studies is probably due to the slightly higher duration of diabetes, although some other 
factors could be involved, including some methodological issues.  
 
Poor metabolic control is one of the most important prognostic factors on peripheral nerve 
function in children and adolescents with T1DM (Dahl-Jørgensen  et al 1986; Amthor et 
al., 1994), while duration of diabetes may become increasingly important for the 
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progression of nerve dysfunction later in the course of diabetes (Ziegler et al 1991; DCCT, 
1993). In keeping with the previous findings the patients with neuropathy in our study not 
only had higher HbA1c than those without neuropathy but also a longer duration of 
diabetes.  
 
 6.8: Home monitoring and self-care assessment as reported by patients themselves 
 
A: Self assessment 
It was important to know how the diabetic patients deal with their diabetes, and how does 
he/she consider his/her life-long visitor that will live with him for the rest of his life. 
Therefore, self-management of diabetes is the ultimate goal for all patients with diabetes, 
with insulin dosing decisions based on interpretation of blood glucose results. Self-
monitoring of blood glucose (SMBG) allows people with diabetes and their families to 
measure blood glucose levels rapidly and accurately. All basal/bolus diabetes management 
regimens of insulin and all self-management skills rely on frequent SMBG. 
In the present study, the self-monitoring of blood glucose was reported by 68.2% of the 
study sample at home by using glucometers. However, only 24.3% reported to test their 
blood glucose more than one time per a day. The DiaComp study which is a substudy of 
the WHO DiaMond study of type 1 diabetes incidence, it comprised 25 centers world wide 
found different results of daily SMBG as reported by participants. In Puerto Rico, 
Romania, and Sweden the percentage of daily SMBG was 30%, 27.8%, and 23.5% 
respectively. While in Israel, Italy, and U.K the percentage of daily SMBG was 67.3%, 
92.2%, and 79.5% respectively (ADA, 2004). Punnose in his study conducted in United 
Arab emirates found that (57%) had regular blood glucose monitoring (daily fasting and 2–
3 post prandial values) at home (Punnose et al., 2002). 
 
In our study Glucose measurement at home show no significant association with glycemic 
control. This could be explained that most patients lack good interpretation of blood 
glucose monitoring results and how to use these results for insulin dose calculations. The 
low percentage of glucose measurement at home could be due to economic factors (i.e. 
price of strip), and lack of reinforcing and follow up possibilities.  
 
The findings about self-monitoring show that 2.8% of our patients used urine sticks for 
testing glucose and the same percent was seen for ketone test in urine. The result of this 
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study is much lower than that done by Bassili at Egypt in which checking glucosuria at 
home was 45.2% of insured children compared to 34.0% of uninsured children (Bassili et 
al., 2001). This low percent of finding indicate that patients at the risk of establishing 
ketoacidosis, a condition that requires immediate medical attention. 
Home blood pressure monitoring may be useful in the management of many patients with 
hypertension and diabetes. The United Kingdom Prospective Diabetes Study (UKPDS) 
clearly demonstrated the need for tight control of blood pressure in persons with diabetes 
(UKPDS, 1998).   In this study, “tight” blood pressure control reduced the risk of multiple 
diabetes endpoints: 32% decrease in deaths related to diabetes; 44% decreased risk of 
stroke; and 34% decrease in risk of all macrovascular diseases, as well as a significant 
decrease in the development of retinopathy and proteinuria. In this study only 26% of the 
diabetic patients reported that they measure their blood pressure at home. Jilleh in his study 
at Palestine found that 85.5% of diabetic patients check their blood pressure regularly and 
80% check it every month (Jilleh, 2002).   
 
B: Diet regiment  
In the study sample, 60 patients (56%) reported that they had follow diet regiment. Roaeid 
in his study conducted at Libyan Arab Jamahiriya found that among both type 1 and type 2 
only 2.7% of them were on diet control (Roaeid R, and Kablan A.,2007). 
However, no statistical significant found between diet regiment and glycemic control. This 
could be explained by that most patients do not consult with a dietitian to develop/discuss 
their medical nutrition plan. Another reason could be due to incorrect dose of insulin. 
Patients do not consider height, weight, and BMI in diet regimen and this mainly to less 
educated program about management of diabetes.  
 
 
6.9 Patients follow up and treatment by PHC centers 
 
 
It is universally accepted that a number of services are supposed to be provided in the 
diabetes health care facilities. These core services are recognized as the components of 
optimal diabetes care (Hiss, 1996, and ADA, 2006). They include: Consultation with 
general pediatrician (GPs), consultation with dietitian, ophthalmologic examination 
service, neurological examination, provision of health education program, evaluation of the 
previous treatment and the past and present degrees of glycemic control, and having 
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laboratory testing (HbA1c, lipid profile, microalbuminuria, serum creatinine) and heart 
echogram (ECG). 
 
A:  Services in PHC 
Another important determinant for T1DM disorder complications is the provision of 
certain services, as shown in the study conceptual framework. In our study, clinical 
services were identified as the most important services to be offered to the diabetic patients 
in the health care setting. A 62.6% of the study population receives care at MOH, PHC 
centers only, while 30.1% receive their whole treatment from UNRWA, PHC centers only.  
The results of this study differ from that conducted by Abu Mousa (1999) in which 49.3% 
receive care at UNRWA, PHC centers, and only 31.1% from MOH (Abu Mousa, 1999).  
However, place of care showed no significant association with glycemic control. This 
could be explained that both UNRWA and MOH have nearly the same services offered to 
diabetic patients.  
 
B: Availability of health insurance 
 
Another important determinant for services provided for T1Dm patients is having health 
insurance, as shown in the study conceptual framework. Most study populations have 
health insurance. However, no statistical significant relationship between health insurance 
and glycemic control. This could be due to that most these health insurance does not cover 
all treatment of diabetes, and it is just for receiving insulin and cover test available at PHC 
only. El-Shazly in his study that conducted in Egypt found no significant association could 
be detected between being health insured and the development of retinopathy(El-Shazly et 
al ., 2000). 
 
 
C: Management according to insulin therapy type 
 
Insulin therapy of type 1 diabetic patients aims at insuring both a good quality of life, 
especially avoiding severe hypoglycemia, and a good metabolic control in order to prevent 
diabetic complications. The most appropriate insulin scheme comprises the injection of 
short-acting insulin before each meal, to control postprandial hyperglycemia, and one (or 
possibly two) injection of a long-acting insulin, to maintain adequate plasma glucose levels 
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between meals and at time bed (Philips, and Radermecker, 2005).  A 77.6 % of the 
participants reported using insulin mixture in there treatment at time of interview. This 
could be explained that this type of insulin is the most available at both MOH and 
UNRWA. Most of the diabetic participants use two injections daily. Mortensen et al in 
there study found that 60% of the children used two daily insulin injections while 37% 
used three or more. Of those on two or three injections daily, 37% used pre-mixed insulins, 
either alone or in combination with short- and intermediate-acting insulin (Mortensen et 
al., 1998). In United Arab Emirates Punnose in his study found that 68.6% of patients were 
managed with NPH insulin, 17.1% of patients with premixed NPH/regular insulin (70/30) 
and in 14.3% of patients regular insulin was added to NPH insulin. Of these patients 91% 
had two times daily insulin injection ( Punnose et al ., 2002).In this study no significant 
association between glycemic control and insulin therapy type this could be explained to  
Insulin type characteristic and patients' factors, in which both these two factors seem to be 
influence the effectiveness of an insulin regimen (Hirsch, 1999). 
 
D: Management according to screening test 
Screening for the long-term complications of diabetes is a critical component of diabetes 
management; however, evidence in this study demonstrates that screening rates for some 
tests in diabetes populations are not suboptimal. 
The type of screening tests and its frequencies have been described .The association 
between screening test with glycemic control and diabetic complications were also 
investigated. 
 
Reported screening rates in this study were as follows: 24.3% had at least one HbA1c 
measurement per a year, 16.8% had a foot exam, 53.9% had a protein urine test, 11.2% had 
an eye exam, 84.1% had a blood pressure reading and 51.1% received a fasting lipid 
profile. Within this group, 9.4% of subjects reported undergoing all five tests (optimal 
screening).However our result is much lower than found in a study conducted at 
Pittsburgh, Pennsylvania by Dorsey et al (2006) in which rates for screening tests i.e. 
HbA1c, foot exam, spot urine test, eye exam, blood pressure, and fasting lipid profile were 
87.9%, 63%, 73.3%, 81.9%, and 68.7% respectively. 37.7% patients reported undergoing 
all five tests (optimal screening) (Doresy et al., 2006). 
In this study, glycemic control show no significant association with any screening test. 
This finding could be explained that frequencies of tests play a role in glycemic control.  
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6.10        Methodological aspects 
 
A cross-sectional study design was used to collect information from diabetes patients 
themselves about their health care services, diabetes complications, and means of self-
management they practiced in their daily life. The patients described herein are those in 
regular follow-up by PHC as previously stated. Of the patients, 75% were allocated and 
had all medical data needed for the purpose of the study, but others could not be traced 
(18.3%) and data for 6.3% were insufficient to be included in the analysis. These patients 
correspond mainly to subjects followed by private practice, primary health care, or under 
irregular follow-up. However, they were not different in terms of age, sex and age at onset 
in comparison to those who were followed up. However, this non-response rate still might 
cause bias in this study, which is also a bias in any research.  
Only intervention studies can give a definite answer whether associations between risk 
factors are causal. In this type of descriptive study, there is a complex interrelationship 
between different risk factors and it is necessary to use statistical methods such as logistic 
regression models to adjust for confounding factors. However, introduction of several 
variables in the analysis can diminish the possibility to really discover significant 
associations, especially if the population is quite small as in our study in which numbers of 
cases are very small. We can’t exclude that lack of association in some cases could partly 
be explained by too low statistical power. 
The present study was based on examination tests for participant patients, which was one 
of the strengths of the study. These tests include funds examination by ophthalmologist, 
ECG, nerves evaluations by specialist. The relationship between metabolic control, lipid 
profile, kidney function testing and the development of macro and microvascular 
complications in type 1diabetes was based on objective testing for participant patients, 
which gave strengths to the study.   
This study is associated with several limitation that must be consider when interpretation 
our finding.  First, with exception of objective tests and complication evaluation by 
consultation, all data are self reported, which could result in recall bias. Validation studies 
surrounding self-report of diabetes preventive care services, found that patients tend to 
over- report screening test for diabetes complications (Fowles et al., 1999). Thus, it is 
possible for the reported screening tests frequency rates to be higher than actually they are 
.Second, the finding from this study come from cross-sectional design.  
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 Conclusions  
 
This study described, for the first time in Palestine, the situation of patients with type 1 
diabetes mellitus. We evaluated the prevalence of macro and microvascular complications 
and the treatment protocol offered by PHC centers. The conclusion of the study would 
answer the present questions, objectives and hypothesis of this research. 
Diabetes is a growing public health problem in the Palestinian community. This is the 
result of the epidemiological transition experiences in the community with rapid reform 
towards the westernized lifestyle. According to our sample population we could estimate 
the prevalence of T1DM to be 0.05%, with no discrepancy between male and female. 
Positive clinical outcome such as glycemic control is not achieved in a large part of the 
studied population. To a large extent, these studied populations are affected by one ore 
more of the early or late complications associated with diabetes.  Diabetic patient in this 
study reported to have 36.4% retinopathy problems, 3.7% heart diseases symptoms, 7.5% 
nephropathy-associated symptoms, 26.2% neuropathy-associated symptoms, 10.3% 
reported having diabetic foot, and 0.9% amputation. 
After evaluation of diabetic patients through ophthalmologist test and endocrinologist, we 
found that 33.8% have diabetic retinopathy, 7.4% nephropathy and 16.2% clinical 
polyneuropathy. The mean HbA1c was 7.8 (SE±0.16). 
A number of risk factors have been positively associated with the development of diabetes 
complications among the Ramallah district population were identified, these include 
Glycemic control, sex, age, marital status, disease duration, age at diagnosis, 
hyperlipidemia, and smoking. Glycemic control and disease duration were the most 
important factors to develop macro and microvascular complications. There was 
significant association between glycemic control and disease duration with neuropathy and 
retinopathy. Retinopathy and neuropathy were highly prevalent among male, there was 
significant association between sex with retinopathy and neuropathy.  Smoking was highly 
prevalent among males, and there was significant association between smoking and 
retinopathy. 
 
Patients with diabetic complication are older than those without complications; there was 
significant association between age and retinopathy. Patient who had diagnosed with 
diabetes during puberty and post pubertal had higher prevalence of diabetic complication 
compared with those diagnosed with diabetes during prepuberty stage; there was 
significant association between age at diagnosis with retinopathy and neuropathy. 
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Hyperlipidemia is more prevalent in older male who are worker and married than other 
group; there was significant association between high cholesterol and triglyceride with 
retinopathy, while significant association was found between high triglyceride with 
neuropathy.  
Clinical status of the patients is not affected by the services offered to them from either 
MOH or UNRWA or by the self care practice of these patients. Services offered to diabetic 
patients in MOH and UNRWA health care setting are to a large extent biomedical oriented.  
Clinical services offered to diabetic patients were found to have no or minimal effect in 
delay or prevent the development of disease complications in the studied population. 
People with diabetes in Ramallah district are not receiving all what can be offered to them 
of diabetes screening tests. The frequencies of screening tests doing to them are not 
sufficient to meet their needs as diabetics. 
The results indicate that home blood pressure and home blood glucose monitoring is not of 
value in the management of diabetic patients. 
 
6.12  Recommendations 
The major concern in setting any control program is to define plans of action. The goal of 
the program is to be able to have a marked reduction in type 1 diabetes complications 
prevalence and to have an acceptable impact in decreasing morbidity and mortality-related 
diseases. Therefore, the following is recommended: 
 
1- Fundus examination, blood pressure check-up and urine testing should form the 
corner stone of diabetes care. Patients should be provided with glucometers for 
self-monitoring of blood glucose. Laboratory facilities should include estimation of 
HbA1c, lipid profile and urine for micro- and macroproteinurea.                                      
2- Patients should be educated about the nature of the disease, importance of treatment 
compliance, foot care, exercise, symptoms and treatment of hypoglycaemia, and 
dangers of smoking on developing complications. There should be visual 
demonstrations on how to inject insulin, feet check-ups.    
3- Patients should be educated about the important of making good interpretation of 
blood glucose monitoring results and how to use these result for dose calculations 
for achieving good metabolic control.   
4- A dietician, preferably someone knowledgeable about Palestinian food and eating 
habits, should be available daily in the PHC clinics. A chiropodist and full-time 
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ophthalmologist are necessary. Health care providers (doctors, nurses, and other 
medical personnel) should be trained both locally and abroad on diabetes health 
care.       
5- Annual screening for microalbuminuria should be initiated once the child is 10 
years of age and has had diabetes for 5 years; more frequent testing is indicated if 
values are increasing.  
6- Ophthalmological screening evaluations should be reviewed and regular 
examinations scheduled with an eye care professional skilled in the care of children 
and adolescents with diabetes. The first ophthalmologic examination should be 
obtained once the child is 10 years of age and has had diabetes for 3–5 years. After 
the initial examination, annual routine follow-up is generally recommended.                  
7- Behavioral interventions that enhance the ability of youth and families to self-
manage diabetes should be incorporated into routine care. 
8- Routine screening of psychosocial functioning, especially depression and family 
coping should be performed.  
9- Cooperation between the various health care providers to set up a national care 
strategy for T1DM.  
10- To set up professional education programs that are based on research findings this 
will help professional to set up a Palestinian national program for T1DM patients. 
11- From a research point of view, a national survey should be set to have a data bank 
of all these patients.  This will help T1DM to have a follow up program, regardless 
of the implementing body, such as supporting their medication, examination 
programs, education programs, and also for research programs.  
12- Focusing research on the identification of associated risk factors could help us to 
prevent, or at least delay, the incidence of diabetic complications 
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  ( ﻴﻭﻤﻴﺎ)________________________؟ ﻫﻲ ﻋﺩﺩ ﺍﻝﺴﺠﺎﺌﺭﺎﻤ, ﺇﺫﺍ ﻨﻌﻡ  
  
  ﻻ .2  ﻨﻌﻡ .1 ؟                                ﻫل ﻜﻨﺕ ﺘﺩﺨﻥ ﻭﺘﻭﻗﻔﺕ ﻋﻥ ﺍﻝﺘﺩﺨﻴﻥ-02    
  ( ﺴﻨﻭﺍﺕ)________________________؟  ﻤﺘﻰ ﺘﻭﻗﻔﺕ ﻋﻥ ﺍﻝﺘﺩﺨﻴﻥﺫ ﻤﻨ,ﺇﺫﺍ ﻨﻌﻡ       
  ( ﺴﻨﻭﺍﺕ)________________________ﻤﺎ ﻋﺩﺩ ﺍﻝﺴﻨﻭﺍﺕ ﺍﻝﺘﻲ ﺩﺨﻨﺘﻬﺎ؟            
  
   ﺍﻝﺘﺎﺭﻴﺦ ﺍﻝﻤﺭﻀﻲ:ﻡ ﺍﻝﺜﺎﻝﺙﺍﻝﻘﺴ
  
  ( ﺴﻨﻭﺍﺕ)_________________ﻤﺘﻰ ﺘﻡ ﺘﺸﺨﻴﺼﻙ ﺒﻤﺭﺽ ﺍﻝﺴﻜﺭﻱ ؟-12  
  
  ( ﺴﻨﻭﺍﺕ)_________________ ﻜﻡ ﻜﺎﻥ ﻋﻤﺭﻙ ﻋﻨﺩ ﺘﺸﺨﻴﺼﻙ ﺒﺎﻝﻤﺭﺽ ؟-22  
  
  ﻁﺒﻴﺏ ﺃﺨﺼﺎﺌﻲ.2  ﻁﺒﻴﺏ ﻋﺎﻡ                   .1 ﻤﻥ ﻗﺎﻡ ﺒﺘﺸﺨﻴﺼﻙ ﺒﺎﻝﻤﺭﺽ؟                              -32  
  ﻻ ﺃﺫﻜﺭ.4  ﺒﺩﻭﻥ ﻁﺒﻴﺏ      .3    
  
ﻤﻥ ﺨﻼل ﺇﺠﺭﺍﺀ ﻓﺤﻭﺼﺎﺕ ﻁﺒﻴﺔ ﻓﻲ ﺍﻝﻤﺴﺘﺸﻔﻰ                     .1   ﻜﻴﻑ ﺘﻡ ﺘﺸﺨﻴﺼﻙ ﺒﻤﺭﺽ ﺍﻝﺴﻜﺭﻱ ؟  -42  
ﻤﺭﺍﺠﻌﺔ ﻝﻠﻁﺒﻴﺏ ﺒﺴﺒﺏ ﻅﻬﻭﺭ ﺃﻋﺭﺍﺽ ﺍﻝﻤﺭﺽ                .  2    
  ﺨﻼل ﻋﻴﺎﺩﺓ ﺍﻷﻤﻭﻤﺔ ﻭﺍﻝﻁﻔﻭﻝﺔ               . 3    
  ﻤﺭﺽ ﺃﺨﺭﻓﻲ ﺍﻝﻌﻴﺎﺩﺓ ﺒﺴﺒﺏ .  4    
  ﺒﺎﻝﺼﺩﻓﺔ                .  5    
  ﺒﻌﺩ ﻋﻤﻠﻴﺔ ﺠﺭﺍﺤﻴﺔ . 6    
  ﻻ ﺃﺫﻜﺭ .7    
  
  ﺒﺴﺒﺏ ﻀﻐﻁ ﻋﺼﺒﻲ.2ﺒﺴﺒﺏ ﻀﻐﻁ ﻨﻔﺴﻲ             .1ﻤﺎ ﺴﺒﺏ ﻅﻬﻭﺭ ﺍﻝﺴﻜﺭﻱ ﻝﺩﻴﻙ ﺒﺎﻋﺘﻘﺎﺩﻙ؟                             -52  
  ﺒﺴﺒﺏ ﻤﺭﺽ ﺁﺨﺭ،.4  ﺃﺜﻨﺎﺀ ﺍﻝﺤﻤل.3    
  ----ﺤﺩﺩ 
    ﻻ ﺃﻋﻠﻡ.5    
  
  ﻻ.2  ﻨﻌﻡ.1   ﺍﺴﺘﻤﺭ ﺍﻝﺴﻜﺭﻱ ﺒﺎﻝﻅﻬﻭﺭ ﻤﻌﻙ ﺒﻌﺩ ﺍﻨﺘﻬﺎﺀلﻫ, ﺇﺫﺍ ﻜﺎﻥ ﺴﻜﺭﻱ ﺤﻤل-62  
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  (ﻝﻠﺴﻴﺩﺍﺕ)ﻓﺘﺭﺓ ﺍﻝﺤﻤل؟
  
  
  
  ﻻ.2  ﻨﻌﻡ.1  ﻫل ﻝﺩﻯ ﺃﺤﺩ ﺃﻓﺭﺍﺩ ﻋﺎﺌﻠﺘﻙ ﻤﺭﺽ ﺍﻝﺴﻜﺭﻱ؟-72  
  
 ﻤﺼﺎﺒﻭﻥ ﺒﻤﺭﺽ ﻓﻲ ﻨﻔﺱ ﺍﻝﺒﻴﺕﺃﺭﺠﻭ ﺘﻌﺒﺌﺔ ﺍﻝﺠﺩﻭل ﺍﻝﺘﺎﻝﻲ ﻷﻱ ﻓﺭﺩ ﻤﻥ ﺃﻓﺭﺍﺩ ﺍﻷﺴﺭﺓ ﻤﻤﻥ ﻴﻌﻴﺸﻭﻥ ﻤﻌﻜﻡ  -82    
  ﺍﻝﺴﻜﺭﻱ؟
     
ﻨﻭﻉ ﺍﻝﺴﻜﺭﻱ   ﺼﻠﺔ ﺍﻝﻘﺭﺍﺒﺔ  ﺍﻝﺠﻨﺱ  ﺍﻝﻌﻤﺭ  ﺍﻻﺴﻡ  ﺍﻝﺭﻗﻡ
  (ﺍﻷﻭل،ﺍﻝﺜﺎﻨﻲ)
            1.82
            2.82
            3.82
            4.82
            5.82
            6.82
            7.82
            8.82
            9.82
  
   ﺍﻝﻌﻼﺝ ﺍﻝﻤﺴﺘﺨﺩﻡ ﻝﻠﻤﺭﻴﺽ:ﺍﻝﻘﺴﻡ ﺍﻝﺭﺍﺒﻊ
  ﺍﻝﺭﺠﺎﺀ ﻭﻀﻊ ﺭﻗﻡ ﺍﻝﺠﻭﺍﺏ ﺍﻝﺼﺤﻴﺢ ﻓﻲ ﺍﻝﻤﺭﺒﻊ 
  
  
  ﻻ.2  ﻨﻌﻡ.1  ﻡ ﻨﻅﺎﻡ ﺤﻤﻴﺔ ﻤﻌﻴﻨﺔ ﺒﺎﻹﻀﺎﻓﺔ ﻝﻸﻨﺴﻭﻝﻴﻥ ؟ ﻫل ﺘﺴﺘﺨﺩ-92  
  
 ﻤﺎ ﻫﻭ ﻨﻭﻉ ﺍﻷﻨﺴﻭﻝﻴﻥ -03  
  ﺘﺴﺘﺨﺩﻤﻴﻪ ؟/ﻪﻤﺍﻝﺫﻱ   ﺘﺴﺘﺨﺩ
ﻜﻤﻴﺔ ﺍﻝﺠﺭﻋﺔ   (ﺍﻝﺭﺠﺎﺀ ﻀﻊ ﺩﺍﺌﺭﺓ)ﻨﻭﻉ ﺍﻷﻨﺴﻭﻝﻴﻥ 
  ﻓﻲ ﺍﻝﺼﺒﺎﺡ
ﻜﻤﻴﺔ ﺍﻝﺠﺭﻋﺔ 
  ﻓﻲ ﺍﻝﻤﺴﺎﺀ
    
  ______  ______  (ﺍﻷﺼﻔﺭ ﺃﻭ ﺍﻝﺼﺎﻓﻲ)ﺍﻝﺴﺭﻴﻊ1. 
     ﺍﻷﻨﺴﻭﻝﻴﻥ ﺍﻝﻤﺘﻭﺴﻁ         . 2    
  ( ﺍﻝﺒﻁﻲﺀﻭﺍﻷﺨﻀﺭ ﺃ) 
  ______  ______
  ______  ______  (ﺍﻝﺒﻨﻲ) ﺍﻷﻨﺴﻭﻝﻴﻥ ﺍﻝﻤﺨﻠﻭﻁ. 3    
  
  ﻭﻜﺎﻝﺔ ﺍﻝﻐﻭﺙ. 2  ﻭﺯﺍﺭﺓ ﺍﻝﺼﺤﺔ . 1   ﻋﻨﺩ ﺒﺩﺍﻴﺔ ﺍﻝﺴﻜﺭﻱ، ﻤﻥ ﺃﻴﻥ ﻜﻨﺕ ﺘﺤﺼل ﻋﻠﻰ ﺍﻝﺩﻭﺍﺀ ؟-13  
  ﺃﻜﺜﺭ ﻤﻥ ﻤﺼﺩﺭ . 4  ﻗﻁﺎﻉ ﻁﺒﻲ ﺨﺎﺹ. 3    
     ﺭﻻ ﺃﺫﻜ. 5     
  
ﺘﻡ ﺍﻝﺤﺼﻭل ﻋﻠﻰ  ﺍﻝﺫﻱ ﻴﻲ ﻤﺎ ﻫﻭ ﺍﻝﻤﺼﺩﺭ ﺍﻝﺤﺎﻝ-23  
  ﺍﻝﺩﻭﺍﺀ ﻤﻥ ﺨﻼﻝﻪ ؟
  ﻭﻜﺎﻝﺔ ﺍﻝﻐﻭﺙ. 2  ﻭﺯﺍﺭﺓ ﺍﻝﺼﺤﺔ . 1
  ﺃﻜﺜﺭ ﻤﻥ ﻤﺼﺩﺭ . 4  ﻗﻁﺎﻉ ﻁﺒﻲ ﺨﺎﺹ. 3    
  
  ﻻ.2  ﻨﻌﻡ.1   ﻫل ﻝﺩﻴﻙ ﺘﺄﻤﻴﻥ ﺼﺤﻲ ؟-33  
  
  ﺨﺎﺹ. 3  ﻭﻜﺎﻝﺔ. 2  ﺤﻜﻭﻤﺔ. 1   ﺇﺫﺍ ﻜﺎﻥ ﺍﻝﺠﻭﺍﺏ ﻨﻌﻡ ﻓﻤﺎ ﻫﻭ ﻨﻭﻉ ﺍﻝﺘﺎﻤﻴﻥ ؟-43  
  
  ﻻ.2  ﻨﻌﻡ.1   ﻝﻤﺭﺽ ﺍﻝﺴﻜﺭﻱ ؟ﻡ ﺍﻝﻼﺯ ﻫل ﺍﻝﺘﺎﻤﻴﻥ ﺍﻝﺼﺤﻲ ﻴﻘﻭﻡ ﺒﺘﻐﻁﻴﺔ ﺠﻤﻴﻊ ﺍﻝﻌﻼﺝ-53  
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_________        ﻤﺎ ﺃﻨﻭﺍﻉ ﺍﻝﻔﺤﻭﺼﺎﺕ ﺍﻝﺘﻲ ﻴﻐﻁﻴﻬﺎ ﺍﻝﺘﺎﻤﻴﻥ، ﺍﻝﺭﺠﺎﺀ ﺍﻝﺘﺤﺩﻴﺩ؟-63  
  ____________________________________________________________
  
  
  
   ﺍﻝﻤﻀﺎﻋﻔﺎﺕ ﺍﻝﻤﺭﻀﻴﺔ:ﺍﻝﻘﺴﻡ ﺍﻝﺨﺎﻤﺱ
  
ﻴﺔ ﺒﺴﺒﺏ ﻤﺭﺽ ﺍﻝﺴﻜﺭﻱ؟                       ﻫل ﺘﻌﺎﻨﻲ ﺃﻭ ﺃﺼﺒﺕ ﺒﺈﺤﺩﻯ ﺍﻝﻤﺸﺎﻜل ﺍﻝﺼﺤﻴﺔ ﺍﻵﺘ  -73
  ( ﺍﻝﺭﺠﺎﺀ ﻭﻀﻊ ﺍﺸﺎﺭﺓ ﺼﺢ ﻓﻲ ﺍﻝﻤﻜﺎﻥ ﺍﻝﻤﻨﺎﺴﺏ)
  ﻻ ﺃﺫﻜﺭ.3  ﻻ.2  ﻨﻌﻡ.1    
         ﻤﺸﺎﻜل ﻓﻲ ﺍﻝﻌﻴﻨﻴﻥ؟-1.73  
         ﺇﺼﺎﺒﺔ ﺒﻨﻭﺒﺔ ﻗﻠﺒﻴﺔ؟-2.73  
         ﻤﺸﺎﻜل ﻓﻲ ﺍﻝﻜﻠﻰ؟-3.73  
     ﺘﺎﺜﻴﺭﻝﻠﺴﻜﺭﻱ ﻋﻠﻰ ﺍﻷﻋﺼﺎﺏ ﻤﺜل ﺍﻷﻁﺭﺍﻑ؟                  -4.93  
         ﺘﻘﺭﺤﺎﺕ ﻓﻲ ﺍﻝﻘﺩﻤﻴﻥ؟-5.73  
        ﻗﻴﺎﻡ ﺍﻷﻁﺒﺎﺀ ﺒﺒﺘﺭ ﺃﻱ ﺠﺯﺀ ﻤﻥ ﺃﺼﺎﺒﻌﻙ ﺒﺴﺒﺏ ﺍﻝﺴﻜﺭﻱ؟-6.73  
،   ﺔﺍﻝﺘﻌﺭﻕ، ﺍﻝﺭﺠﻔ:   ) ﺍﻹﺼﺎﺒﺔ ﺒﺄﻋﺭﺍﺽ ﻫﺒﻭﻁ ﺍﻝﺴﻜﺭﻱ-7.73  
  ( ﺍﻝﺭﺃﺱﻡ، ﺃﻝﺞﺍﻝﺘﻬﻴ
      
         ﺘﺸﺨﻴﺼﻙ ﺒﺄﻥ ﻀﻐﻁ ﺍﻝﺩﻡ ﻤﺭﺘﻔﻊ-8.73  
  
  ﻻ ﺃﺫﻜﺭ.3  ﻻ.2  ﻨﻌﻡ.1   ﻫل ﺃﺩﺨﻠﺕ ﺍﻝﻤﺴﺘﺸﻔﻰ ﺒﺴﺒﺏ ﺍﻝﺴﻜﺭﻱ؟-83  
  
  ______________________(ﺃﺫﻜﺭ)، ﻓﻜﻡ ﻤﺭﺓﺍﻝﺠﻭﺍﺏ ﻨﻌﻡ ﺇﺫﺍ ﻜﺎﻥ -93  
  
  ﻫﺒﻭﻁ ﺤﺎﺩ ﻓﻲ ﺍﻝﺴﻜﺭ. 2  ﻥﺩﻭﺨﺔ، ﻏﻤﻴﺎ. 1   ﻤﺎﺫﺍ ﻜﺎﻥ ﺍﻝﺴﺒﺏ ﻓﻲ ﺩﺨﻭﻝﻙ ﻝﻠﻤﺴﺘﺸﻔﻰ؟-04  
  ﺨﻠل ﻓﻲ ﺍﻷﻋﺼﺎﺏ.4  ﺠﻠﻁﺔ.3    
  ﺍﺭﺘﻔﺎﻉ ﻓﻲ ﺍﻝﺴﻜﺭ.6  ﺍﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻝﺩﻡ.5    
  ________  __ﺃﺴﺒﺎﺏ ﺃﺨﺭﻯ، ﺤﺩﺩ. 7    
  ﻫل ﻜﻨﺕ ﺘﻌﺎﻨﻲ ﻤﻥ ﺇﺤﺩﻯ ﺍﻷﻤﺭﺍﺽ ﺍﻝﺘﺎﻝﻴﺔ ﻗﺒل ﺘﺸﺨﻴﺼﻙ ﺒﻤﺭﺽ ﺍﻝﺴﻜﺭﻱ؟               -14  
  ( ﺍﻝﺭﺠﺎﺀ ﻭﻀﻊ ﺍﺸﺎﺭﺓ ﺼﺢ ﻓﻲ ﺍﻝﻤﻜﺎﻥ ﺍﻝﻤﻨﺎﺴﺏ   )
  ﻻ ﺃﺫﻜﺭ.3  ﻻ.2  ﻨﻌﻡ.1    
        ﺍﻝﻀﻐﻁ-1.14  
        ﻤﺸﺎﻜل ﻓﻲ ﺍﻝﻘﻠﺏ-2.14  
        ﻤﺸﺎﻜل ﻓﻲ ﺍﻝﻌﻴﻨﻴﻥ-3.14  
        ﻤﺸﺎﻜل ﻓﻲ ﺍﻝﻜﻠﻰ-4.14  
        ( ﻨﻔﺱﻕﺃﺯﻤﺔ، ﻀﻴ)ﺘﻴﻥ ﻤﺸﺎﻜل ﻓﻲ ﺍﻝﺭﺌ-5.14  
         ﻤﺜﻼﺔﺃﻤﺭﺍﺽ ﻨﺘﻴﺠﺔ ﻝﻼﻝﺘﻬﺎﺒﺎﺕ ﺍﻝﻔﻴﺭﻭﺴﻴ-6.14  
        ﺃﻤﺭﺍﺽ ﻓﻲ ﺍﻝﺩﻡ-7.14  
        ﺃﻭﺭﺍﻡ ﺴﺭﻁﺎﻨﻴﺔ-8.14  
        ﻤﺸﺎﻜل ﻓﻲ ﺍﻷﻋﺼﺎﺏ-9.14  
        ﻏﻴﺭ ﺫﻝﻙ، ﺤﺩﺩ-01.14  
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   ﺍﻝﻤﺭﻴﺽ ﻨﻔﺴﻪﻥ ﻓﻲ ﺍﻝﺒﻴﻭﺕ ﻤﺔﺍﻝﻤﺭﺍﻗﺒﺔ ﺍﻝﺫﺍﺘﻴ: ﺍﻝﻘﺴﻡ ﺍﻝﺴﺎﺩﺱ
  (ﺍﻝﺠﻭﺍﺏ ﺍﻝﺼﺤﻴﺢ ﻓﻲ ﺍﻝﻤﺭﺒﻊﺍﻝﺭﺠﺎﺀ ﻭﻀﻊ ﺭﻗﻡ )
  
  
  ﻻ.2  ﻨﻌﻡ.1   ﻫل ﻝﺩﻴﻙ ﺠﻬﺎﺯ ﻓﻲ ﺍﻝﺒﻴﺕ ﻝﻘﻴﺎﺱ ﺍﻝﻀﻐﻁ ؟-24  
  
  ﻻ.2  ﻨﻌﻡ.1     ﻫل ﺘﻘﻭﻡ ﺒﻘﻴﺎﺱ ﻨﺴﺒﺔ ﺍﻝﺴﻜﺭ ﺒﺎﻝﺩﻡ ﻓﻲ ﺍﻝﺒﻴﺕ ؟-34  
  
 ﻓﻤﺎ ﻫﻲ ﻋﺩﺩ ﺍﻝﻤﺭﺍﺕ ﺍﻝﺠﻭﺍﺏ ﻨﻌﻡ ﺇﺫﺍ ﻜﺎﻥ -44  
  ﺍﻝﺘﻲ ﺘﻘﻴﺴﻪ ﻏﺎﻝﺒﺎ ؟
  ﻤﺭﺓ ﻓﻲ ﺍﻝﻴﻭﻡ. 2  ﺃﻜﺜﺭ ﻤﻥ ﻤﺭﺓ ﻓﻲ ﺍﻝﻴﻭﻡ .1
  ﻤﺭﺓ ﻓﻲ ﺍﻝﺸﻬﺭ. 4   ﺍﻷﺴﺒﻭﻉﻤﺭﺓ ﻓﻲ. 3    
  
  ___________ ﻤﺎ ﻨﻭﻉ ﺍﻝﺠﻬﺎﺯ ﺍﻝﺫﻱ ﺘﺴﺘﺨﺩﻤﻪ ﻓﻲ ﻋﻤﻠﻴﺔ ﺍﻝﻘﻴﺎﺱ-54  
  
  ﻻ.2  ﻨﻌﻡ.1     ﺍﻝﺒﻭل ﻓﻲ ﺍﻝﺒﻴﺕ ؟ﻲ ﻫل ﺘﻘﻭﻡ ﺒﻘﻴﺎﺱ ﻨﺴﺒﺔ ﺍﻝﺴﻜﺭ ﻓ-64  
  
  ﻻ.2  ﻨﻌﻡ.1  ﻫل ﺘﻘﻭﻡ ﺒﻔﺤﺹ ﺍﻝﻜﻴﺘﻭﻨﺎﺕ ﻓﻲ ﺍﻝﺒﻭل ﻓﻲ ﺍﻝﺒﻴﺕ؟-74  
  
  ﺔ ﺍﻝﺼﺤﻴﺔ ﻓﻲ ﻤﺭﺍﻜﺯ ﺍﻝﺭﻋﺎﻴﻰﺍﻝﻤﺭﺍﻗﺒﺔ ﻝﻠﻤﺭﻀ:ﺍﻝﻘﺴﻡ ﺍﻝﺴﺎﺒﻊ 
  (ﺍﻝﺭﺠﺎﺀ ﻭﻀﻊ ﺭﻗﻡ ﺍﻝﺠﻭﺍﺏ ﺍﻝﺼﺤﻴﺢ ﻓﻲ ﺍﻝﻤﺭﺒﻊ)
  
  
  ﻋﻠﻰ ﺍﻷﻗل ﻤﺭﺓ ﻓﻲ ﺍﻝﺸﻬﺭ. 2  ﻋﻠﻰ ﺍﻷﻗل ﻤﺭﺓ ﻓﻲ ﺍﻷﺴﺒﻭﻉ   . 1   ﻫل ﺘﻘﻭﻡ ﺒﺎﺴﺘﺸﺎﺭﺓ ﻁﺒﻴﺒﻙ ﺍﻝﻌﺎﻡ؟ -84  
  ﻜل ﺴﺘﺔ ﺃﺸﻬﺭ.4ﺜﻼﺙ ﺸﻬﻭﺭ                   ﻜل.3    
  ﺔﻋﻠﻰ ﺍﻷﻗل ﻤﺭﺓ ﻓﻲ ﺍﻝﺴﻨ.6ﻜل ﺘﺴﻌﺔ ﺃﺸﻬﺭ                  . 5    
    ﻻ ﺃﻗﻭﻡ ﺒﺫﻝﻙ. 7    
  
  ﻭﻜﺎﻝﺔ ﺍﻝﻐﻭﺙ. 2  ﻭﺯﺍﺭﺓ ﺍﻝﺼﺤﺔ . 1  ﻱ ﺒﻤﺭﺍﺠﻌﺔ ﻁﺒﻴﺒﻙ ﺍﻝﺨﺎﺹ؟/ﻓﻲ ﺃﻱ ﺍﻝﻤﺭﺍﻜﺯ ﺘﻘﻭﻡ-94  
  :ﺃﻜﺜﺭ ﻤﻥ ﻤﺼﺩﺭ. 4  ﻗﻁﺎﻉ ﻁﺒﻲ ﺨﺎﺹ. 3    
  _________:ﺤﺩﺩ
  
  ﻻ.2  ﻨﻌﻡ.1  ﻱ ﻝﻠﻌﻼﺝ ﻓﻲ ﻤﺭﺍﻜﺯ ﺍﻝﺭﻋﺎﻴﺔ ﺍﻷﻭﻝﻴﺔ؟/ ﻫل ﻴﻘﻭﻡ ﻁﺒﻴﺒﻙ ﺒﻔﺤﺼﻙ ﻜل ﻤﺭﺓ ﺘﺫﻫﺏ-05  
  
  ﻻ.2  ﻨﻌﻡ.1  ﻝﻁﺒﻴﺏ ﻤﻠﻑ ﺨﺎﺹ ﺒﻙ ﻴﺸﻤل ﻋﻠﻰ ﻤﻌﻠﻭﻤﺎﺕ ﻋﻥ ﺴﻴﺭ ﺍﻝﻤﺭﺽ ﻝﺩﻴﻙ؟  ﻫل ﻴﻭﺠﺩ ﻝﺩﻯ ﺍ-15  
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 ﻫل ﺘﺠﺭﻯ ﻝﻙ ﺍﻝﻔﺤﻭﺼﺎﺕ ﺍﻝﺩﻭﺭﻴﺔ ﺍﻝﺘﺎﻝﻴﺔ ﻓﻲ ﻤﺭﺍﻜﺯ ﺍﻝﺭﻋﺎﻴﺔ ﺍﻻﻭﻝﻴﺔ ﺍﻝﺘﻰ ﺘﺘﻠﻘﻰ ﻓﻴﻬﺎ ﺍﻝﺨﺩﻤﺎﺕ ﺍﻝﺼﺤﻴﺔ؟ -25
  ( ﺍﻝﺭﺠﺎﺀ ﻭﻀﻊ ﺍﺸﺎﺭﺓ ﺼﺢ ﻓﻲ ﺍﻝﻤﻜﺎﻥ ﺍﻝﻤﻨﺎﺴﺏ)
  ﻻ ﺃﺫﻜﺭ.3  ﻻ.2  ﻨﻌﻡ.1    
        ﺭﻱ ﻓﺤﺹ ﺍﻝﺴﻜ-1.25  
        c1A ﻥ ﻓﺤﺹ ﻫﻴﻤﻭﺠﻠﻭﺒﻴ-2.25  
        ﻓﻲ ﺍﻝﺒﻭل( ﺍﻝﺯﻻل) ﻓﺤﺹ ﺍﻝﺒﺭﻭﺘﻴﻨﺎﺕ-3.25  
         ﻓﺤﺹ ﺍﻝﻀﻐﻁ-4.25  
         ﻓﺤﺹ ﺍﻝﻜﻴﺘﻭﻨﺎﺕ ﻓﻲ ﺍﻝﺒﻭل-5.25  
         ﻓﺤﺹ ﺍﻝﺩﻫﻭﻥ ﻭﺍﻝﻜﻭﻝﺴﺘﺭﻭل ﻓﻲ ﺍﻝﺩﻡ-6.25  
         ﻓﺤﺹ ﺍﻝﻁﻭل-7.25  
         ﻓﺤﺹ ﺍﻝﻭﺯﻥ-8.25  
        (GCE) ﻓﺤﺹ ﺘﺨﻁﻴﻁ ﺍﻝﻘﻠﺏ -9.25  
         ﺼﻭﺭﺓ ﺃﺸﻌﺔ ﻝﻠﺼﺩﺭ-01.25  
         ﺨﻼل ﻓﺤﺹ ﺍﻝﻴﻭﺭﻴﺎﻥ ﻓﺤﺹ ﺍﻝﻜﻠﻰ ﻤ-11.25  
         ﺨﻼل ﻓﺤﺹ ﺍﻝﻜﺭﻴﺎﺘﻨﻴﻥﻥ ﻓﺤﺹ ﺍﻝﻜﻠﻰ ﻤ-21.25  
         ﺨﻼل ﻓﺤﺹ ﺤﺎﻤﺽ ﺍﻝﻴﻭﺭﻴﻙﻥ ﻓﺤﺹ ﺍﻝﻜﻠﻰ ﻤ-31.25  
        ﻓﺤﺹ ﺃﻨﺯﻴﻤﺎﺕ ﺍﻝﻜﺒﺩ ﺍﻝﻤﺨﺒﺭﻴﺔ-41.25  
  
 ﻓﻲ ﻤﺭﺍﻜﺯ ﺍﻝﺭﻋﺎﻴﺔ ﺍﻻﻭﻝﻴﺔ ﺍﻝﺘﻰ ﺘﺘﻠﻘﻰ ﻓﻴﻬﺎ  ﻤﺎ ﻫﻲ ﻋﺩﺩ ﺍﻝﻤﺭﺍﺕ ﺍﻝﺘﻲ ﺘﺠﺭﻯ ﻝﻙ ﺍﻝﻔﺤﻭﺼﺎﺕ ﺍﻝﻤﺨﺒﺭﻴﺔ ﺍﻝﺘﺎﻝﻴﺔ-35
  (ﺍﻝﺭﺠﺎﺀ ﻭﻀﻊ ﺍﺸﺎﺭﺓ ﺼﺢ ﻓﻲ ﺍﻝﻤﻜﺎﻥ ﺍﻝﻤﻨﺎﺴﺏ)ﺍﻝﺨﺩﻤﺎﺕ ﺍﻝﺼﺤﻴﺔ؟ 
ﻋﻠﻰ .1    
ﺍﻷﻗل ﻤﺭﺓ 
ﻓﻲ 
  ﺍﻷﺴﺒﻭﻉ 
ﻋﻠﻰ ﺍﻷﻗل .2
ﻤﺭﺓ ﻓﻲ 
  ﺍﻝﺸﻬﺭ
  
 ﻜل.3
ﺜﻼﺙ 
ﺸﻬﻭﺭ                  
ﻜل .4
ﺴﺘﺔ 
  ﺃﺸﻬﺭ
ﻜل .5
ﺘﺴﻌﺔ 
  ﺃﺸﻬﺭ
ﻋﻠﻰ ﺍﻷﻗل .6
  ﻤﺭﺓ ﻓﻲ ﺍﻝﺴﻨﺔ
ﻻ .7
ﺃﻗﻭﻡ     
  ﺒﺫﻝﻙ
                ﻓﺤﺹ ﺍﻝﺴﻜﺭﻱ-1  
                c1A ﻥﻓﺤﺹ ﻫﻴﻤﻭﺠﻠﻭﺒﻴ-2  
                ﻓﺤﺹ ﺍﻝﺒﺭﻭﺘﻴﻨﺎﺕ ﻓﻲ ﺍﻝﺒﻭل-3  
                ﻓﺤﺹ ﺍﻝﻀﻐﻁ-4  
                ﻓﺤﺹ ﺍﻝﻜﻴﺘﻭﻨﺎﺕ ﻓﻲ ﺍﻝﺒﻭل-5  
ﻓﺤﺹ ﺍﻝﺩﻫﻭﻥ -6  
  ﻭﺍﻝﻜﻭﻝﺴﺘﺭﻭل ﻓﻲ ﺍﻝﺩﻡ
              
                ﻓﺤﺹ ﺍﻝﻁﻭل-7  
                ﻓﺤﺹ ﺍﻝﻭﺯﻥ-8  
ﻓﺤﺹ ﺘﺨﻁﻴﻁ ﺍﻝﻘﻠﺏ -9  
   (GCE)
              
                ﺼﻭﺭﺓ ﺃﺸﻌﺔ ﻝﻠﺼﺩﺭ -01  
 ﺨﻼل ﻥﻓﺤﺹ ﺍﻝﻜﻠﻰ ﻤ-11  
  ﻓﺤﺹ ﺍﻝﻴﻭﺭﻴﺎ
              
               ﺨﻼل ﻥﻓﺤﺹ ﺍﻝﻜﻠﻰ ﻤ-21  
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  ﻓﺤﺹ ﺍﻝﻜﺭﻴﺎﺘﻨﻴﻥ
 ﺨﻼل ﻥﻓﺤﺹ ﺍﻝﻜﻠﻰ ﻤ-31  
  ﻓﺤﺹ ﺤﺎﻤﺽ ﺍﻝﻴﻭﺭﻴﻙ 
              
ﻓﺤﺹ ﺃﻨﺯﻴﻤﺎﺕ ﺍﻝﻜﺒﺩ -41  
  ﺍﻝﻤﺨﺒﺭﻴﺔ 
              
 
  
  
  
  
  
  :ﺍﻝﻔﺤﻭﺼﺎﺕ ﺍﻝﺠﺴﻤﻴﺔ ﻝﻤﺭﻀﻰ ﺍﻝﺴﻜﺭﻱ
  
   ( ﺍﻝﺭﺠﺎﺀ ﻭﻀﻊ ﺇﺸﺎﺭﺓ ﺼﺢ ﻓﻲ ﺍﻝﻤﻜﺎﻥ ﺍﻝﻤﻨﺎﺴﺏ) ﻫل ﺘﺠﺭﻯ ﻝﻙ ﺍﻝﻔﺤﻭﺼﺎﺕ ﺍﻝﺘﺎﻝﻴﺔ؟ -45
  
  ﻻ ﺃﻋﻠﻡ.3  ﻻ.2  ﻨﻌﻡ.1    
         ﻓﺤﺹ ﺍﻝﻌﻴﻭﻥ ﻝﺩﻯ ﺃﺨﺼﺎﺌﻲ-1.45  
         ﺍﻝﻔﺤﺹ ﻤﻥ ﻗﺒل ﺃﺨﺼﺎﺌﻲ ﺍﻷﻋﺼﺎﺏ-2.45  
 ﺍﻝﻘﻴﺎﻡ ﺒﺎﻝﻔﺤﺹ ﻝﺩﻯ ﺃﺨﺼﺎﺌﻲ ﺃﻤﺭﺍﺽ -3.45  
  ﺒﺎﻁﻨﻴﺔ
      
         ﺍﻝﻘﻴﺎﻡ ﺒﻔﺤﺹ ﺍﻝﻘﺩﻤﻴﻥ-4.45  
         ﺍﻻﺴﺘﺸﺎﺭﺓ ﻝﺩﻯ ﺃﺨﺼﺎﺌﻲ ﺘﻐﺫﻴﺔ-5.45  
  
 ﻤﺎ ﻫﻲ ﻋﺩﺩ ﺍﻝﻤﺭﺍﺕ ﺍﻝﺘﻲ ﺘﺠﺭﻯ ﻝﻙ ﺍﻝﻔﺤﻭﺼﺎﺕ ﺍﻝﺠﺴﻤﻴﺔ ﺍﻝﺘﺎﻝﻴﺔ ﻓﻲ ﻤﺭﺍﻜﺯ ﺍﻝﺭﻋﺎﻴﺔ ﺍﻷﻭﻝﻴﺔ ﺍﻝﺘﻲ ﺘﺘﻠﻘﻰ ﻓﻴﻬﺎ -55
   ( ﺍﻝﺭﺠﺎﺀ ﻭﻀﻊ ﺍﺸﺎﺭﺓ ﺼﺢ ﻓﻲ ﺍﻝﻤﻜﺎﻥ ﺍﻝﻤﻨﺎﺴﺏ)ﺍﻝﺨﺩﻤﺎﺕ ﺍﻝﺼﺤﻴﺔ؟ 
  
 ﻋﻠﻰ.1    
ﺍﻷﻗل ﻤﺭﺓ 
    ﻓﻲ ﺍﻷﺴﺒﻭﻉ
ﻋﻠﻰ .2
ﺍﻷﻗل ﻤﺭﺓ 
  ﻓﻲ ﺍﻝﺸﻬﺭ
  
 ﻜل.3
ﺜﻼﺙ 
ﺸﻬﻭﺭ                  
ﻜل .4
ﺴﺘﺔ 
  ﺃﺸﻬﺭ
ﻜل .5
ﺘﺴﻌﺔ 
  ﺃﺸﻬﺭ
ﻋﻠﻰ .6
ﺍﻷﻗل ﻤﺭﺓ 
  ﻓﻲ ﺍﻝﺴﻨﺔ
ﻻ .7
ﺃﻗﻭﻡ 
  ﺒﺫﻝﻙ
                ﻓﺤﺹ ﺍﻝﻌﻴﻭﻥ ﻝﺩﻯ ﺃﺨﺼﺎﺌﻲ- 1.55  
ﺍﻝﻔﺤﺹ ﻤﻥ ﻗﺒل ﺃﺨﺼﺎﺌﻲ - 2.55  
  ﺍﻷﻋﺼﺎﺏ
              
ﺍﻝﻘﻴﺎﻡ ﺒﺎﻝﻔﺤﺹ ﻝﺩﻯ ﺃﺨﺼﺎﺌﻲ - 3.55  
  ﺃﻤﺭﺍﺽ ﺒﺎﻁﻨﻴﺔ
              
                ﺍﻝﻘﻴﺎﻡ ﺒﻔﺤﺹ ﺍﻝﻘﺩﻤﻴﻥ- 4.55  
ﺍﻻﺴﺘﺸﺎﺭﺓ ﻝﺩﻯ ﺃﺨﺼﺎﺌﻲ - 5.55  
  ﺘﻐﺫﻴﺔ
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Appendix (2) 
 
Patient name___________                                                       Age______________ 
Address________________                                             Telephone_____________ 
  
Onset of diabetes: --------------------------------------------------------------------------------- 
Past ocular           :---------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------- 
Ocular medication:--------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------- 
Ocular complaint if any---------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------- 
Visual acuity--------------------------------------------------------------------------------------- 
 
Power of Eye glass Aided Unaided   
      
  
Right Eye 
      
  
Left Eye 
  
External ocular exam: ----------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------- 
Extra ocular motility:------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------- 
Pupil reaction:--------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------Anterior 
segment exam :-------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------- 
Intra ocular pressure :-----------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------- 
Findus exam with dilating drops: ---------------------------------------------------------------------
------------------------------------------------------------------------------------------------- 
Left eye Right eye   
    
  
1-Normal 
    
  
2- Simple back diabetic retinopathy 
    
  
3- Diabetic Maculopathy 
    
  
4-Preproliferative diabetic retinopathy 
    
  
5-Proliferative diabetic retinopathy 
    
  
6-Previuos laser therapy 
    
  
7-No of sessions and date 
    8-Does he need laser therapy now 
Date of follow up: --------------------------------------------------------------------------------- 
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 ﺒﺴﻡ ﺍﷲ ﺍﻝﺭﺤﻤﻥ ﺍﻝﺭﺤﻴﻡ
 
 
  ﻜﻠﻴﺔ ﺍﻝﺼﺤﺔ ﺍﻝﻌﺎﻤﺔ/ ﺠﺎﻤﻌﺔ ﺍﻝﻘﺩﺱ
  ﺴﺘﻴﺭ ﺍﻝﺼﺤﺔ ﺍﻝﻌﺎﻤﺔﺒﺤﺙ ﻜﻤﺘﻁﻠﺏ ﻝﻤﺎﺠ
  ﺯﻴﺎﺩ ﺍﻝﺨﻀﻭﺭ: ﺍﺴﻡ ﺍﻝﻁﺎﻝﺏ
 ﺍﻝﺴﻜﺭﻱ ﻤﻥ ﺃﻜﺜﺭ ﺍﻷﻤﺭﺍﺽ ﺍﻝﻤﻨﺘﺸﺭﺓ ﻓﻲ ﻓﻠﺴﻁﻴﻥ،ﺤﻴﺙ ﻴﻘﺴﻡ ﺍﻝﻤﺭﺽ ﺍﻝﻰ ﻨﻭﻋﻴﻥ ،ﻨﻭﻉ ﺽﻴﻌﺘﺒﺭ ﻤﺭ
 ﻋﻠﻴﻪ ﺍﻝﻨﻭﻉ ﺍﻝﺜﺎﻨﻲ، ﻭﻨﻭﻉ ﻴﺼﻴﺏ ﺍﻷﻁﻔﺎل ﻭﺍﻝﺸﺒﺎﺏ ﻭﻫﻭ ﺍﻝﻨﻭﻉ ﺍﻷﻭل ﻤﻥ ﻕﻴﺼﻴﺏ ﺍﻝﻜﺒﺎﺭ ﻭﻴﻁﻠ
 ﻨﺴﺒﺔ ﺍﻝﺴﻜﺭ ﻓﻲ ﺍﻝﺩﻡ ﻤﻤﺎ ﻴﺅﺩﻱ ﺇﻝﻰ ﻅﻬﻭﺭ ﺍﻝﻤﺭﺽ ﻭﻫﻭ ﻨﺎﺘﺞ ﻋﻥ ﺍﻨﻌﺩﺍﻡ ﺇﻓﺭﺍﺯ ﺍﻷﻨﺴﻭﻝﻴﻥ ﺍﻝﺫﻱ ﻴﻨﻅﻡ
  .ﺃﻋﺭﺍﺽ ﻭﻤﻀﺎﻋﻔﺎﺕ ﻫﺫﺍ ﺍﻝﻤﺭﺽ ﻜﻀﻌﻑ ﺍﻝﺒﺼﺭ ﻭﻤﺸﺎﻜل ﻓﻲ ﺍﻝﻜﻠﻰ
ﻤﻥ ﺍﻝﻤﺘﻭﻗﻊ ﺃﻥ ﺘﻜﻭﻥ ﻨﺴﺒﺔ ﺍﻨﺘﺸﺎﺭ ﻤﺭﺽ ﺍﻝﺴﻜﺭﻱ ﻤﻥ ﺍﻝﻨﻭﻉ ﺍﻷﻭل ﻓﻲ ﻓﻠﺴﻁﻴﻥ ﻜﺒﺎﻗﻲ ﺍﻝﺩﻭل 
  ﻫﺫﻩ ﺍﻝﺩﺭﺍﺴﺔ ﻓﻲ ﻤﺤﺎﻓﻅﺔ ﺭﺍﻡ ﺍﷲﻯﻝﺫﻝﻙ ﺴﺘﺠﺭ, %1 ﺍﻝﻰ5.0ﺍﻝﻤﺠﺎﻭﺭﺓ ﺤﻴﺙ ﺘﺘﺭﺍﻭﺡ ﺍﻝﻨﺴﺒﺔ ﻤﺎ ﺒﻴﻥ 
  .   ﻜﻌﻴﻨﺔ ﺃﻭﻝﻴﺔ ﺤﻴﺙ ﻤﻥ ﺍﻝﻤﺘﻭﻗﻊ ﺃﻥ ﻴﻜﻭﻥ ﻋﺩﺩ ﺍﻝﻤﺭﻀﻰ ﻤﺌﺔ ﻭﺨﻤﺴﻭﻥ ﻤﺭﻴﻀﺎ
ﻴﻬﺩﻑ ﻫﺫﺍ ﺍﻝﺒﺤﺙ ﺇﻝﻰ ﻤﻌﺭﻓﺔ ﺍﻝﻭﻀﻊ ﺍﻝﺼﺤﻲ ﻝﺩﻯ ﻤﺭﻀﻰ ﺍﻝﺴﻜﺭﻱ ﻤﻥ ﺍﻝﻨﻭﻉ ﺍﻷﻭل، ﻭﺍﻝﺨﺩﻤﺎﺕ ﺍﻝﺘﻲ 
ﻴﺘﻠﻘﺎﻫﺎ ﺍﻝﻤﺭﻴﺽ ﻤﻥ ﺨﻼل ﻤﺭﺍﻜﺯ ﺍﻝﺭﻋﺎﻴﺔ ﺍﻷﻭﻝﻴﺔ ﺍﻝﺘﺎﺒﻌﺔ ﻝﻭﺯﺍﺭﺓ ﺍﻝﺼﺤﺔ ﻭﻭﻜﺎﻝﺔ ﺍﻝﻐﻭﺙ ﻓﻲ ﻤﺤﺎﻓﻅﺔ 
 ﺍﻝﻤﺭﻀﻰ، ﺀ ﻤﻥ ﺍﻨﺘﺸﺎﺭ ﻤﻀﺎﻋﻔﺎﺕ ﻫﺫﺍ ﺍﻝﻤﺭﺽ ﻋﻨﺩ ﻫﺅﻻﺩﺍﻝﻌﻤل ﻋﻠﻰ ﺍﻝﻭﻗﺎﻴﺔ ﻭﺍﻝﺤﺭﺍﻡ ﺍﷲ ﻤﻥ ﺃﺠل 
ﻝﺫﺍ ﺴﻴﺘﻡ ﻤﻘﺎﺒﻠﺔ ﺠﻤﻴﻊ ﻤﺭﻀﻰ ﺍﻝﺴﻜﺭﻱ ﻤﻥ ﺍﻝﻨﻭﻉ ﺍﻷﻭل .   ﺘﻘﻠﻴل ﻨﺴﺒﺔ ﺍﻝﻭﻓﻴﺎﺕ ﺍﻝﻨﺎﺘﺠﺔ ﻋﻨﻪﻲﻭﺒﺎﻝﺘﺎﻝ
  .ﻓﻲ ﻤﺤﺎﻓﻅﺔ ﺭﺍﻡ ﺍﷲ ﺩﻭﻥ ﺍﺴﺘﺜﻨﺎﺀ
ﺍ ﻨﺭﺠﻭ ﻤﻨﻜﻡ ﺍﻹﺠﺎﺒﺔ ﻋﻠﻰ ﻝﻘﺩ ﻗﻤﻨﺎ ﺒﺘﺠﻬﻴﺯ ﺍﺴﺘﺒﻴﺎﻨﺔ ﺘﺤﺘﻭﻯ ﻋﻠﻰ ﺃﺴﺌﻠﺔ ﺨﺎﺼﺔ ﺒﺄﻫﺩﺍﻑ ﺍﻝﺩﺭﺍﺴﺔ، ﻝﺫ
ﻭﺃﻤﻠﻴﻥ ﻤﻥ ﺤﻀﺭﺘﻜﻡ ﺇﺠﺎﺒﺔ ﻜﺎﻓﺔ ﺍﻷﺴﺌﻠﺔ ﺒﻤﻭﻀﻭﻋﻴـﻪ ﺘﺎﻤﺔ ﺒﻘﺭﺍﺀﺓ ﻜل ﺍﻻﺴﺘﺒﺎﻨﺔ ﻤﻥ ﻗﺒل ﺍﻝﻤﺸﺎﺭﻜﻴﻥ، 
ﻓﻘﺭﻩ ﺒﺘﻤﻌﻥ ﻭﺍﻻﺴﺘﺠﺎﺒﺔ ﻋﻠﻴﻬﺎ ﺤﺴﺏ ﺍﻝﺘﻌﻠﻴﻤﺎﺕ ﺍﻝﻭﺍﺭﺩﺓ ﻗﺒل ﻜل ﻓﻘﺭﻩ، ﻋﻠﻤﺎ ﺃﻥ ﺍﻝﻤﻌﻠﻭﻤﺎﺕ ﺍﻝﻭﺍﺭﺩﺓ ﻓﻲ 
ﺔ ﺍﻝﺘﺎﻤﺔ ﻓﻲ ﺍﻝﻤﻌﻠﻭﻤﺎﺕ ﺍﻝﺘﻲ ﺴﺘﺩﻝﻭﻥ ﻨﻀﻤﻥ ﻝﻜﻡ ﺍﻝﺴﺭﻴﺍﻻﺴﺘﺒﺎﻨﻪ ﺴﺘﺴﺘﻌﻤل ﻷﻏﺭﺍﺽ ﺍﻝﺒﺤﺙ ﻓﻘﻁ، ﻭ
  . ﻝﺫﺍ ﻨﺭﺠﻭ ﻤﻨﻜﻡ ﺍﻝﺘﻭﻗﻴﻊ ﺒﺎﻝﻤﻭﺍﻓﻘﺔ ﻋﻠﻰ ﺍﻝﻤﺸﺎﺭﻜﺔ ﻹﺘﻤﺎﻡ ﺃﻫﺩﺍﻑ ﻫﺫﻩ ﺍﻝﺩﺭﺍﺴﺔ.  ﺒﻬﺎ
  ﺸﺎﻜﺭﻴﻥ ﻝﻜﻡ ﺤﺴﻥ ﺘﻌﺎﻭﻨﻜﻡ
  ﺯﻴﺎﺩ ﺍﻝﺨﻀﻭﺭ:ﺍﻝﺒﺎﺤﺙ
  
 341
 
 ﻗﺭﺭﺕ ﺍﻝﻤﺸﺎﺭﻜﺔ ﻓﻲ ﻫﺫﻩ ﺍﻝﺩﺭﺍﺴﺔ، ﻪﻝﻘﺩ ﻗﻤﺕ ﺒﺩﺭﺍﺴﺔ ﺠﻤﻴﻊ ﺍﻝﺘﻌﻠﻴﻤﺎﺕ ﺍﻝﻭﺍﺭﺩﺓ ﻓﻲ ﻫﺫﺍ ﺍﻻﺴﺘﺒﻴﺎﻥ ﻭﻋﻠﻴ
  .ﺴﻤﻲ ﻭﺘﻭﻗﻴﻌﻲ ﻫﻭ ﺩﻝﻴل ﻋﻠﻰ ﻗﺒﻭﻝﻲ ﻝﻠﻤﺸﺎﺭﻜﺔ ﻓﻲ ﻫﺫﻩ ﺍﻝﺩﺭﺍﺴﺔﻭﺃﻥ ﻭﺠﻭﺩ ﺍ
  
  :ﺦﺍﻝﺘﺎﺭﻴ
  :ﺍﻝﻭﻗﺕ
  ﺍﻝﺘﻭﻗﻴﻊ:                                          ﺍﺴﻡ ﺍﻝﻤﺸﺎﺭﻙ
         ﺍﻝﺘﻭﻗﻴﻊ  ﺯﻴﺎﺩ ﺍﻝﺨﻀﻭﺭ                  :ﺍﺴﻡ ﺍﻝﺒﺎﺤﺙ
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Appendix(5) 
 
Table 5.1 : The distribution of Nephropathy-associated symptoms, Diabetic foot, 
Heart diseases-associated symptoms with the various demographic variables in 
Ramallah district  
 
Variable Nephropathy-
associated symptoms 
 
N=8 
Diabetic foot 
 
 
N=11 
Heart diseases-
associated 
symptoms 
N=4 
Disease duration 
Average ± SE 
12.1±3.7 
range (0.5-31) 
11±2.2 
range (0.1-22) 
12±4.3 
range (2-22) 
Diagnosis age 
Average ± SE 
14±1.1 
range (10-19) 
14.9±1.6 
range (6-25) 
13.8±3.8 
range (5-20) 
Age 
Children (0-16) 
Adult (16-30) 
Older adult (>30) 
 
1(12.5%) 
4(50%) 
3(37.5%) 
 
1(9.1%) 
7(63.7%) 
3(27.3%) 
 
1(25%) 
1(25%) 
2(50%) 
Gender 
Male 
Female 
 
3(37.5%) 
5(62.5%) 
 
5(45.5%) 
6(54.5%) 
 
3(75%) 
1(25%) 
Occupation 
Work 
Not working 
Student 
 
2(25%) 
4(50%) 
2(25%) 
 
3(27.3%) 
7(63.6%) 
1(9.1%) 
 
2(50%) 
 
2(50%) 
Marital status 
Single 
Married 
 
7(87.5%) 
1(12.5%) 
 
7(63.6%) 
4(36.4%) 
 
2(50%) 
2(50%) 
Residency 
City 
Village 
Camp 
 
4(50%) 
3(37.5%) 
1(12.5%) 
 
2(18.2%) 
8(72.7%) 
1(9.1%) 
 
2(50%) 
2(50%) 
Educational level 
0-12 year 
>12 year 
 
7(87.5%) 
1(12.5%) 
 
11(100%) 
----------- 
 
3(75%) 
1(25%) 
 
Note:  all association can not be done since expected value <5  
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Table 5.2: Frequencies and percentage of Diabetic foot-related symptoms, Heart 
diseases-associated symptoms, and nephropathy-related symptoms according to 
possible determinants for diabetes 
Variable Nephropathy-
associated 
symptoms 
N=8 
Diabetic foot 
N=11 
Heart diseases-
associated 
symptoms 
N=4 
Disease duration 
Average ± SE 
 
12.1±3.7 
 
11±2.2 
 
12±4.3 
Diagnosis age 
Average ± SE 
 
14±1.1 
 
14.9±1.6 
 
13.8±3.8 
Diagnosis made by 
GP                         
Specialist         
Without doctor            
Do not remember 
 
 
6(75%) 
2(25%) 
____ 
____ 
 
5(45.5%) 
6(54.5%) 
_____ 
_____ 
 
3(75.0%) 
1(25.0%) 
_____ 
_____ 
Diagnosis method 
During hospitalization   
Repeated diabetic               
complications       
MCH clinic                
At clinic for other 
disease      
Accidentally  
Unknown 
 
 
2(25%) 
4(50%) 
 
____ 
____ 
 
2(25)      
 _____ 
 
3(27.3%) 
7(63.6%) 
 
____ 
____ 
 
1(9.1%) 
____ 
 
1(25%) 
1(25%) 
 
_____ 
1(25%) 
 
1(25%) 
_____ 
Diagnosis cause 
Psychological stress         
Neurological stress             
Cause of other disease 
&Hereditary             
Do not know 
 
 
______ 
3(37.5%) 
1(12.5%) 
 
4(50.0 %) 
 
2(18.2%) 
3(27.3%) 
 
 
6(54.5 %) 
 
 
1(25.0%) 
2(50.0%) 
 
1(25.0 %) 
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5.4.1    Distribution of the objective testing by the various demographic variables 
 
Of the approached patients, 80 patients (69%) have done the objective testing, i.e. HbA1c, 
fasting blood sugar (FBS), lipid profiling, and kidney functions testing, and blood pressure 
testing. Patients were referred to see an ophthalmologist, but only 63.8% did go (n=74 
patients). Also, all these patients (n=107) were referred to consult with a diabetes 
specialist, but only 58.6 % (n=68) attended the consultations.   
The normal ranges for each test in this survey were used according to the ADA values 
(table 5.3). Table 5.4A, 5.4B, and 5.4C summarize the average and standard error (X± SE) 
and range for objective testing (HbA1c, FBS, Urea, Creatinine, Cholesterol, triglyceride, 
LDL, and HDL) and their distribution according to patients demographic variable.  The 
average and standard error (X±SE) of HbA1c was 7.8±0.16. Both male and female show 
higher result of HbA1c than normal value. Older adults show the highest average of 
HbA1c among the rest age group. There was no difference in the average value of HbA1c 
among patients according to the patient's residency place; however, patients who live in 
camp had higher average value of HbA1c than other. Both single and married patients had 
average HbA1c value above the normal range. The mean value for HbA1c still higher 
among patients sample according to their occupations; however patients who are non 
worker had the highest value than other. Both educated and less educated patients had 
average HbA1c value above the normal range. The average and standard error (X±SE) of 
FBS was 203±9. The average value of both male and female of FBS was higher than 
normal range of FBS and much higher than the recommended value for diabetic patients. 
All age group had higher value of FBS: however child had the heist value of FBS. The 
result of FBS was higher than normal range in patients according to the patient's residency 
place; however patients who live in camp had higher result of FBS than other. Single and 
married patient had both high results of FBS with no difference in the result of FBS in both 
group. All occupation and educational level group categories had high average result of 
FBS; however student and less educated patient had the highest result among these 
categories. The average and standard error (X±SE) of Urea was 28.2±1.4, all demography 
categories for patients had an average result for urea in the normal value. The average and 
standard error (X±SE) of creatinine was 0.9±.05. Both male and female had normal 
average value of creatinine, Child and adult had normal average value of creatinine: 
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however old adult show average means of creatinine above the normal range. All 
occupation group, marital status, residency place and educational level categories had 
normal value of creatinine.  The average and standard error (X±SE) of cholesterol was 
191±5.1. Male had an average result of cholesterol in the border line comparing with 
normal value; however female had normal average of cholesterol. Adult and older adult 
had an average result in the border line while child had normal value of cholesterol. All 
residency categories had normal average of cholesterol, while married patients had an 
average result which is at the border line. Worker patients had a average cholesterol in the 
border line while other occupation categories had normal average cholesterol. Educated 
patients show higher cholesterol mean than less educated.  The average and standard error 
(X±SE) of triglyceride was 146±11.1.Older age and male patients had triglyceride above 
the normal range. All residency categories had an average normal triglyceride value. 
Married patients had an average triglyceride result above the normal range, while single 
patients had normal triglyceride result. Worker and student had triglyceride value above 
normal range.  Educated patients had abnormal value of triglyceride.  The average and 
standard error (X±SE) of HDL was 42±0.8. All HDL average results of patients distributed 
according to demographic variable showed normal value. 
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Table 5.3 Normal range and target value for laboratory test done for diabetic patients 
at this study                  
Test Normal range Target value 
HbA1c % 
 
4.5-7 Well control diabetes 
≥8.5    Uncontrolled diabetes 
<7 
Glucose  (mg/dl) 
 
75-115 <140 
Urea  (mg/dl) 
 
6-18       Infant                             
15-33      Children                      
15-45      Adults 
<45
Creatinine 
 (mg/dl) 
 
0.6-1.1     Men                         
0.5-0.9     Women  
<1.4
Cholesterol  
 (mg/dl)  
 
<200         Desirable                   
200-239    Borderline              
240            High 
<200
Triglyceride 
 (mg/dl)  
 
40-150 Men 
35-135       Women 
 
<150 
LDL 
 (mg/dl) 
 
Up to 150 <100 
HDL 
 (mg/dl) 
<40     Low  
≥60     High 
≥40 
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Table 5.4A: Mean and standard error (X± SE) and range of the objective testing by 
the various demographic variables of the 68 patients in Ramallah district  
 Gender Age group  
Testing Male 
X± SE 
Range 
Female 
X± SE 
Range 
Child 
X± SE 
Range 
Adult 
X± SE 
Range 
Older 
adults 
X± SE 
Range 
Total 
X± SE 
HbA1c % 
 
7.5±0.23 
5.7-11 
7.9±0.2 
5.6-11 
7.6±.28 
5.6-11 
7.6±.23 
5.7-11 
8.2±.3 
5.9-11 
7.8±.16 
5.6-11 
FBS  
(mg/dl) 
190±9.5 
70-397 
215±15 
37-510 
222±18.5 
60-406 
192±14.5 
37-510 
201± 13 
79-397 
203±9 
37-510 
Urea  
(mg/dl) 
29.5±1.6 
6-60 
26.9±2.3 
7-88 
21.7±1.4 
6-32 
29±1.3 
16-40 
33.4±4 
9-88 
28.2±1.4 
6-88 
Creatinine 
 (mg/dl) 
1±.06 
.5-3 
0.9±.09 
04-4.1 
0.8±.03 
05-1.1 
0.9±.03 
.4-1.3 
1.2±.17 
0.6-4.1 
.9±.05 
.4-4.1 
Cholesterol  
 (mg/dl)  
207±7.1 
116-306 
175±6.5 
95-273 
158±8.1 
95-243 
202±6.4 
130-273 
208±10 
107-306 
191±5.1 
95-306 
Triglyceride 
 (mg/dl)  
169±16.2 
38-605 
124±14.6 
24-582 
90±10.7 
24-248 
143±10.3 
38-256 
208±29.7 
38-605 
146±11.1 
24-605 
LDL 
 (mg/dl) 
135±7.2 
33-243 
112±5.4 
46-208 
101±8.3 
46-243 
132±6.1 
67-208 
134±9.3 
33-230 
123±4.7 
33-243 
HDL 
 (mg/dl) 
43±1.3 
29-75 
41±1 
32 -64 
42±1.9 
29-75 
42±1.3 
33-65 
41±.93 
32-50 
42±.8 
29-75 
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Table 5.4B: Mean and standard error (X± SE) and range of the objective testing by 
the various demographic variables of the 68 patients in Ramallah district  
 Residency Marital status  
Testing City 
X± SE 
Range 
Village 
X± SE 
Range 
Camp 
X± SE 
Range 
Single 
X± SE 
Range 
Married 
X± SE 
Range 
Total 
X± SE 
HbA1c % 
 
7.9±.3 
5.7-11 
7.5±0..16 
5.6-10 
8.2±0.5 
5.9-11 
7.8±0.19 
5.7-11 
7.6±.27 
5.6-11 
7.8±.16 
5.6-11 
FBS  
(mg/dl) 
190±13.8 
74-406 
197±10.4 
37-386 
235±35.5 
70-510 
205±12.1 
37-510 
198±12.7 
74-397 
203±9 
37-510 
Urea  
(mg/dl) 
29.9±3.5 
7-88 
27.9±1.4 
6-60 
25.5±2.6 
17-48 
27.6±1.9 
6-88 
29.2±1.9 
9-60 
28.2±1.4 
6-88 
Creatinine 
 (mg/dl) 
1±.13 
0.5-4.1 
0.9±.05 
0.5-3 
0.9±.08 
0.5-1.5 
.9±.07 
.4-4.1 
1±.08 
.6-3 
.9±.05 
.4-4.1 
Cholesterol  
 (mg/dl)  
193±7.9 
107-260 
192±6.9 
109-273 
180±17.3 
95-306 
182±6.1 
95-273 
208±8.5 
107-306 
191±5.1 
95-306 
Triglyceride 
 (mg/dl)  
153±19.9 
49-582 
138±11.7 
24-391 
159±54.7 
38-605 
127±12.3 
24-542 
182±20.8 
38-605 
146±11.1 
24-605 
LDL 
 (mg/dl) 
124±5.5 
76-187 
138±11.6 
33-243 
109±14.7 
46-230 
115±5.3 
46-243 
139±8.2 
33-208 
123±4.7 
33-243 
HDL 
 (mg/dl) 
43-1.2 
35-65 
42±1.2 
29-75 
41±2.5 
33 -64 
42±1.1 
29-75 
42±.9 
32-50 
42±.8 
29-75 
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Table 5.4C: Mean and standard error (X± SE) and range of the objective testing by 
the various demographic variables of the 68 patients in Ramallah district  
 Occupation Educational level  
Testing Worker 
X± SE 
Range 
Non 
worker 
X± SE 
Range 
Student 
X± SE 
Range 
≤12yr 
X± SE 
Range 
>12yr 
X± SE 
Range 
Total 
X± SE 
HbA1c % 
 
7.5±.24 
5.6-11 
8.4±.37 
5.9-11 
7.7±.23 
5.7-11 
7.8±0.17 
5.7-11 
7.4±.24 
5.6-11 
7.8±.16 
5.6-11 
FBS  
(mg/dl) 
187±12.5 
70-397 
205±13.8 
150-325 
217±16.8 
37-510 
209±9.9 
37-510 
160±15 
70-201 
203±9 
37-510 
Urea  
(mg/dl) 
30.7±1.6 
16-60 
34.7±6 
9-88 
22.9±1.3 
6-39 
27.9±1.6 
6-88 
29±2.7 
16-40 
28.2±1.4 
6-88 
Creatinine 
 (mg/dl) 
1±.07 
0.4-3 
1.2±.24 
0.6-4.1 
.8±.02 
0.5-.9 
.9±.06 
.5-4.1 
0.9±.06 
0.4-1.1 
.9±.05 
.4-4.1 
Cholesterol  
 (mg/dl)  
212±7.1 
130-306 
184±10.4 
107-260 
173±7.8 
95-273 
188±5.5 
95-306 
209±13.5 
150-260 
191±5.1 
95-306 
Triglyceride 
 (mg/dl)  
212±22.1 
38-605 
142±13.5 
76-241 
208±29.7 
24-256 
140±10.7 
24-605 
186±47 
38-582 
146±11.1 
24-605 
LDL 
 (mg/dl) 
136±7.2 
33-230 
120±8.8 
67-174 
112±7.4 
46-243 
122±5.0 
33-243 
134±13 
80-197 
123±4.7 
33-243 
HDL 
 (mg/dl) 
42±1 
32-64 
43.2±2 
37-65 
41.7±1.4 
29-75 
42±0.8 
29-75 
44±2.6 
37-64 
42±.8 
29-75 
 
 
 
 
 
 
 
 
152 
 
5.4.2 Association between the objective testing and the various demographic variables 
A significant association was seen between sex and lipids testing, i.e. triglyceride and 
cholesterol (P value <0.05, see table 5.5). No significant association was seen between 
metabolic control (HbA1c), FBS, and HDL results by gender. Age categories had 
significant association with metabolic control (HbA1c) and lipids testing (P value <0.05, 
see table 5.6). A significant association was seen between marital status and lipids testing 
(see table 5.7).  No association was found between triglyceride and HDL testing by the 
various educational levels of the patients (P value <0.05).  A significant association was 
seen between patients’ occupation type and lipids testing (P value <0.05see table 5.8). 
Since most of the study populations were Moslems (only 3.7% were Christians), therefore, 
no uni-variate analysis was done.                                                     
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Table 5.5:  The distribution of the various objective testing by gender for the 80 
patients who did the testing in Ramallah district 
Variable Male 
N=39 
No  (%) 
Female 
N=41 
No  (%) 
Total 
N=80 
No  (%) 
P 
value 
HbA1c (%) 
<8.5 
≥8.5 
 
11 (13.8%) 
28 (35%) 
 
7 (8.7%) 
34 (42.5%) 
 
18 (22.5%) 
62 (77.5%) 
 
>0.05 
Sugar (mg/dl) 
<140 
≥140 
 
5 (6.25%) 
34 (42.5%) 
 
5 (6.25%) 
36 (45%) 
 
10 (12.5%) 
70 (87.5%) 
 
 
>0.05 
Urea (mg/dl) 
<45 
≥45 
 
37 (46.3%) 
2 (2.5%) 
 
39 (48.7%) 
2 (2.5%) 
 
76 (95%) 
4 (5%) 
 
* 
Creatinine (mg/dl) 
<1.1 
≥1.1 
 
29 (36.3%) 
10 (12.5%) 
 
39 (48.7%) 
2 (2.5%) 
 
39(48.8%) 
41 (51.2%) 
 
<0.05 
Cholesterol (mg/dl)  
<200 
≥200 
 
14 (17.5%) 
25 (31.2%) 
 
33 (41.3%) 
8 (10%) 
 
47 (58.8%) 
33 (41.2%) 
 
<0.05 
Triglyceride (mg/dl)  
<150 
≥150 
 
13 (16.3%) 
26 (32.5%) 
 
29 (36.2%) 
12 (15%) 
 
42 (52.5%) 
38 (47.5%) 
 
<0.05 
LDL (mg/dl) 
<100 
≥100 
 
11 (13.8%) 
28 (35%) 
 
13 (16.2%) 
28 (35%) 
 
24 (30%) 
56 (70%) 
 
>0.05 
HDL (mg/dl) 
<40 
≥40 
 
20 (25%) 
19 (23.75%) 
 
19 (23.75%) 
22 (27.5%) 
 
39 (48.75%) 
41 (51.15%) 
 
>0.05 
*Chi square not calculated since expected count in one cell less than 5 
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Table 5.6:  The distribution of the various objective testing and age categories fort he 
80 patients who did the testing in Ramallah district 
Variable Child 
N=23 
No  (%) 
Adult 
N=34 
No  (%) 
Older adults 
N=23 
No  (%) 
Total 
N=80 
No  (%) 
P 
value 
HbA1c (%) 
<8.5 
≥8.5 
 
15 (18.8%) 
8 (10%) 
 
28 (35%) 
6(7.5%) 
 
11(13.7%) 
12 (15%) 
 
54 (67.5%) 
26(32.5%) 
 
<0.05 
Sugar (mg/dl) 
<140 
≥140 
 
4 (5%) 
19(23.8%) 
 
5 (6.3%) 
29 (36.2%) 
 
1 (1.2%) 
22 (27.5%) 
 
10 (12.5%) 
70 (87.5%) 
* 
Urea (mg/dl) 
<45   
≥45 
 
23 (28.8%) 
0 (0%) 
 
34 (42.5%) 
0 (0%) 
 
19 (23.7%) 
4 (5 %) 
 
76 (95%) 
4 (5%) 
 
* 
Creatinine (mg/dl) 
<1.1 
≥1.1 
 
23 (28.8%) 
__ 
 
27 (33.75%) 
7 (8.75%) 
 
18(22.5%) 
5 (6.25 %) 
 
68 (85%) 
12 (15%) 
 
* 
Cholesterol  (mg/dl) 
<200 
≥200 
 
20 (25%) 
3 (3.8%) 
 
18 (22.5%) 
16 (20%) 
 
9 (11.2%) 
14 (17.5%) 
 
47 (58.7%) 
33 (41.3%) 
 
<0.05 
Triglyceride (mg/dl) 
<150 
≥150 
 
18 (22.5%) 
5 (6.2%) 
 
16 (20%) 
18 (22.5%) 
 
8 (10%) 
15 (18.8%) 
 
42 (52.5%) 
38 (47.5%) 
 
<0.05 
LDL (mg/dl) 
<100 
≥100 
 
13 (16.2%) 
10 (12.5%) 
 
7 (8.8%) 
27 (33.8%) 
 
4 (5%) 
19 (23.7%) 
 
24 (30%) 
56 (70%) 
 
<0.05 
HDL (mg/dl) 
<40 
≥40 
 
10 (12.5%) 
13 (16.2%) 
 
18 (22.5%) 
16 (20%) 
 
11 (13.8%) 
12 (15%) 
 
39 (48.8%) 
41 (51.2%) 
 
>0.05 
*Chi square not calculated since expected count in one cell less than 5 
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Table 5.7:  The distribution of the various objective testing and marital status for the 
80 patients who did the testing in Ramallah district 
Variable Single 
N=52 
No  (%) 
Married 
N=28 
No  (%) 
Total 
N=80 
No  (%) 
P value 
HbA1c  (%) 
<8.5 
≥8.5 
 
35 (44%) 
17(21%) 
 
19 (23.8%) 
9 (11.2%) 
 
54 (67.8%) 
26 (32.2%) 
 
>0.05 
Sugar (mg/dl) 
<140 
≥140 
 
9 (12.1%) 
43 (52.7%) 
 
1 (1.4%) 
27 (33.8%) 
 
10 (13.5%) 
64 (86.5%) 
* 
Urea (mg/dl) 
<45 
≥45 
 
50 (62.5%) 
2 (2.5%) 
 
26 (32.5%) 
2 (2.5%) 
 
76 (95%) 
4 (5%) 
* 
Creatinine (mg/dl) 
<1.1 
≥1.1 
 
46 (57.5%) 
6 (7.5%) 
 
26 (37.5%) 
6 (7.5%) 
 
68 (85%) 
12 (15%) 
 
* 
 
Cholesterol  (mg/dl) 
<200 
≥200 
 
37 (46.2%) 
15 (18.8%) 
 
 
10 (12.5%) 
18 (22.5%) 
 
 
47 (58.7%) 
33 (41.3%) 
 
 
<0.05 
Triglyceride  (mg/dl) 
<150 
≥150 
 
 
32 (40%) 
20 (25%) 
 
 
10 (12.5%) 
18 (22.5%) 
 
 
42 (52.5%) 
38 (47.5%) 
 
 
<0.05 
LDL (mg/dl) 
<100 
≥100 
 
18 (22.5%) 
34 (42.5%) 
 
6 (7.5%) 
22 (27.5%) 
 
24 (30%) 
56 (70%) 
 
>0.05 
HDL (mg/dl) 
<40 
≥40 
 
 
24 (29.8%) 
28 (33.8%) 
 
 
15 (18.8%) 
13 (17.6%) 
 
 
39 (48.6%) 
41 (51.4%) 
 
 
>0.05 
*Chi square not calculated since expected count in one cell less than 5 
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Table 5.8:   The distribution of the various objective testing and type of occupation 
for the 80 patients in Ramallah district 
Variable Work 
N=33 
No (%) 
Not 
working 
N=14 
No (%) 
Student 
N=33 
No (%) 
Total 
N=80 
No (%) 
P 
value 
HbA1c (%) 
<8.5 
≥8.5 
 
25 (31.25%) 
8(10%) 
 
7 (8.75%) 
7 (8.75%) 
 
22 (27.5%) 
11(13.75%) 
 
54 (67.5%) 
26 (32.5%) 
 
* 
Sugar (mg/dl) 
<140   
≥140 
 
5 (6.2%) 
28 (35%) 
 
0  
14 (17.5%) 
 
5 (6.3%) 
28 (35%) 
 
10 (12.5%) 
70 (87.5%) 
 
* 
 
Urea (mg/dl) 
<45   
≥45 
 
31 (38.7%) 
2 (2.5%) 
 
12(15%) 
2 (2.5%) 
 
33 (41.3%) 
0  
 
76 (95%) 
4 (5%) 
* 
Creatinine (mg/dl) 
<1.1 
≥1.1 
 
23 (28.75%) 
10 (12.5%) 
 
12(15%) 
2 (2.5% 
 
33 (41.3%) 
0 
 
68 (85%) 
12 (15%) 
 
* 
Cholesterol  (mg/dl) 
<200 
≥200 
 
11 (13.7%) 
22 (27.5%) 
 
10 (12.5%) 
4 (5%) 
 
26 (32.5%) 
7 (8.8%) 
 
47 (58.7%) 
33 (41.3%) 
 
<0.05 
Triglyceride (mg/dl) 
<150 
≥150 
 
10 (12.5%) 
23 (28.7%) 
 
9 (11.2%) 
5 (6.3%) 
 
23 (28.8%) 
10 (12.5%) 
 
42 (52.5%) 
38 (47.5%) 
 
<0.05 
HDL (mg/dl) 
<40 
≥40 
 
17 (21.2%) 
16 (20%) 
 
9 (11.3%) 
5 (6.2%) 
 
13 (16.3%) 
20 (25%) 
 
39 (48.8%) 
41 (51.2%) 
 
>0.05 
LDL (mg/dl) 
<100 
≥100 
 
7 (8.7%) 
26 (32.5%) 
 
3 (3.7%) 
11 (13.8%) 
 
14 (17.6%) 
19 (23.7%) 
 
24 (30%) 
56 (70%) 
 
* 
*Chi square not calculated since expected count in one cell less than 5 
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Table 5.9: The distribution of the diagnostic nephropathy with demographic 
variables for the 68 patients in Ramallah district 
 
Risk factor 
Diagnosed 
Nephropathy 
N=5 
No (%) 
No-Nephropathy 
 
N=63 
No (%) 
Total 
 
N=68 
No (%) 
Significance 
Age 
Mean ±SE 
(yrs) 
 
35.8±2.89 
 
21.5±1.34 
  
22.53±1.34 
 
* 
Age      
Child 0 21(30.9%) 21(30.9%) * 
Adults 0 28(41.2%) 28(41.2%)  
Older adults 5(7.4%) 14(20.5%) 19(27.9%)  
Sex     
male 3 (4.4%) 29 (42.6%) 32 (47%)   
female 2 (3%) 34 (50%) 36 (53.0%) * 
Marital status     
Single 2 (3%) 42 (61.8%) 44 (64.8%)   
Married 3 (4.4%) 21 (30.9%) 24 (35.2%) * 
Occupation     
Work 3 (4.4%) 24 (35.3%) 27 (39.7%)  
Not working 2 (3%) 8 (11.7%) 10 (14.7%) * 
Student 0 31 (45.6%) 31 (45.6%)  
Place of residency 
City 2 (3%) 20 (29.4%) 22 (32.4%)  
Village 2 (3%) 33 (48.4%) 35 (51.4%) * 
Camp 1 (1.4%) 10 (14.8%) 11 (16.2%)  
Education level     
0-12 year  5 (7.4%) 54 (79.4%) 59 (86.8%)   
>12 year 0 9 (13.2%) 9 (13.2%) * 
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Table 5.10:  The distribution of the diagnostic neuropathy with demographic 
variables for the 68 patients in Ramallah district 
Risk factor 
Diagnosed 
Neuropathy 
N=11 
No  (%) 
Non Neuropathy 
 
N=57 
No  (%) 
Total 
 
N=68 
No  (%) 
P value 
Age 
Mean±SE  (yrs) 35.91±2.58 19.95±1.26    
Age      
Child 0 21(30.9%) 21(30.9%)  
Adults 3(4.4%) 25(36.8%) 28(41.2%) * 
Older adult 8(11.8%) 11(16.1%) 19(27.9%)  
Sex     
male 11 (16.2%) 21 (30.9%) 32 (47%)   
female 0 36 (53%) 36 (53%) P<0.05 
Marital status     
Single 2 (3%) 43 (63.2%) 45 (66.2%)  * 
Married 9 (13.2%) 14 (20.6%) 23 (33.8%)  
Work 10 (14.7%) Occupation 27 (39.7%)  
Not working 1 (1.5%) 17 (25%) 10 (14.7%) * 
Student 0 (0%) 9 (13.2%) 31 (45.6%)  
Place of residency  31 (45.6%)   
City 3 (4.4%)  22 (32.4%) * 
Village 6 (8.8%) 19 (28%) 35 (51.4%)  
Camp 2 (3%) 29 (42.6%) 11 (16.2%)  
Education level  9 (13.2%)   
0-12 year  10 (14.7%)  59 (86.8%)  * 
>12 year 1 (1.5%) 49 (72.1%) 9 (13.2%)  
  8 (11.7%)   
* Chi square was not calculated since expected count in one cell less than 5 
 
 
 
 
